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Metastatic breast cancer 
Breast cancer is the most common type of cancer among women. A report of the ENCR 
(European Network of Cancer Registries) showed that the Netherlands had a highest 
incidence rate of breast cancer (91.6/105), leading to the third highest mortality (26/105) 
in the year 2000 (www.encr.com.fr/breast-factsheets.pdf). Typically, primary breast cancer 
can be removed by surgery in combination with chemotherapy and radiation therapy. 
However, metastases are very difficult to treat and most breast cancer patients eventually 
die due to drug resistant distant metastasis. Therefore, it is important to understand the 
underlying molecular mechanisms by which metastasis occurs, and design target-specific 
drugs to prevent metastasis formation and overcome the drug resistance of disseminated 
breast cancer. 
 
Metastases are formed by transmission of malignant cells from a primary tumor site to the 
distant target organs throughout the body. The process from primary tumor to metastasis 
occurs in several steps including: 1. transformation of normal cells into cancer (stem) 
cells; 2. proliferation of cancer cells and formation of primary tumor in 
microenvironments; 3. detachment of tumor cells from primary lesion, which generally 
involves an epithelial-mesenchymal transition-like process of tumor cells; 4. invasion of 
tumor cells into the microenvironment and degradation and restructuring of the 
extracellular matrix; 5. intravasation of escaping tumor cells into blood or lymphatic 
vessels; 6. escaping the (innate) immune system surveillance and homing of viable tumor 
cells to target organs; 7. extravasation of tumor cells from the vascular system in distant 
target organs; 8. survival and proliferation of metastasizing tumor cells in distant organs; 
9. development of new blood vessels, i.e. angiogenesis, which supply nutrients to support 
macroscopic  metastatic outgrowth as shown in Figure 1. 
  
Cell adhesion, migration and survival 
Cell adhesion of epithelial cells occurs at cell-cell adherence junctions through E-
cadherin molecules and at cell-extracellular matrix (cell-ECM) adhesions through integrin 
receptors. As mentioned above, typically, epithelial-derived tumors may metastasize when 
cell-cell adhesions are lost during the epithelial-mesenchymal transition (EMT). This 
allows cells to migrate, invade and eventually metastasize. Tumor cells require external 
triggers to initiate EMT and mediate cell migration. In the tumor microenvironment, 
various growth factors, chemokines and cytokines either derived from stromal cells or 
secreted by tumor cells are present. These will stimulate their respective receptors on 
tumor cells and consequently activate the cell migration program described below. 
Although cell migration and invasion may take place by single cell migration and 
collective cell migration strategies [1], here I will only discuss the steps of single cell 
migration, which is the most critical step in the dissemination of tumor cells [2,3]. Cell 
migration requires a sequential set of events, including plasma membrane protrusion and 




adhesion formation at the leading edge of lamellipodia to the substrate, contractile force 




Figure 1. The multiple steps in metastasis formation. A. cellular transformation at primary sites. Growth 
of neoplastic cells must be progressive, with nutrients initially supplied by simple diffusion to expand tumor 
mass. B. tumor cell proliferation and extensive vascularization. The secretion of angiogenetic factors 
establishes a capillary network to supply nutrients from surrounding tissues. Chemokines and receptors are 
essential for cell recruitment in tumor microenvironment. C. tumor cell detachment from primary malignant 
sites, invasion and penetration to circulation. D. survival of disseminated cells in vascular environment. E. 
transportation through the body and arrest in distant organs. In this step, chemokines provide chemotaxis 
clues to target organs. F. cell attachment on the vessel wall and extravasation to nearby tissues. G. 
proliferation of tumor cells and angiogenesis in metastatic niches.  
 
 
Integrin-mediated adhesion is crucial for cell migration process. At the lamellipodia, focal 
complexes (FCs) are formed and mature into larger focal adhesions (FAs). FAs are the 
sites which link adhesion receptors and proteoglycans to the actin cytoskeleton and they 
consist of scaffold molecules, GTPases, and enzymes such as kinases, phosphatases, 
proteases and lipases. FAs are not only anchor sites but also sensors for mechanical and 
biochemical signaling [5,6]. The assembly and disassembly of FAs occur during cell 
migration. The FCs which are regulated by Rac and Cdc42 at the leading edges of 
migrating cells, exert traction force on ECM to relocate cell body. The majority of these 
small FCs undergo fast turnover, while few mature into FAs. The latter are regulated by 





tensile force generation which allows movement of the cell body. FAs either disassemble 
underneath the moving cell body or change in shape and form fibrillar adhesion for ECM 
modification. FAs at the rear of cells maintain cell spreading and ultimately dissociate to 
release the rear of the cells [6]. All these steps are tightly regulated by different 
scaffolding and signaling molecules at the focal adhesion sites, including integrin, focal 
adhesion kinase (FAK), c-Src, paxillin, talin and vinculin [6-10]. Tyrosine, serine and 
threonine phosphorylations of various FA-associated proteins are major signaling events 
at FA sites to control the dynamics of these structures and regulate cell migration. For 
example, tyrosine phosphorylation of FAK creates docking sites for binding of Src-
homology (SH) domain containing proteins, e.g. SH2/SH3-containing proteins and 
thereby regulates the activation of protein kinases, such as Src [7]. Scaffold functions are 
executed by the adaptor proteins, including for example paxillin and p130Cas. Tyrosine 
phosphorylation of these scaffolds allows recruitment of downstream effectors and 
enhances specificity of the signaling.  
 
Integrin-mediated cell migration requires pulling forces generated by cytoskeletal 
contraction of the actin cytoskeleton. This is mediated by the actin/myosin network within 
the cell and the ‘anchors’ derived at FAs through the integrin-ECM interactions. Actin 
filaments are cross-linked by myosin complexes, resulting in bundling as well as 
contraction of these actin fibers [11]. The contractile forces are regulated by myosin light 
chain (MLC) phosphorylation via MLC kinase and Rho-associated kinase (ROCK). 
ROCK controls the phosphorylation of myosin and inhibits myosin phosphatase [12]. 
MLC phosphorylation is a biochemical marker for the status of tension in the cell [13]. 
Given the essential role of the actin cytoskeleton dynamics in cell migration, there is also 
a need for regulation of the actin network. Briefly, this is mediated by Rho GTPases 
family. Activation of Ras-related C3 botulinum toxin substrate 1 (Rac1) stimulates actin 
polymerization via the Arp2/3 complex (a seven-subunit protein regulating actin 
cytoskeleton) at the leading edge, leading to plasma membrane protrusion and extension 
of lamellipodia [14]. RhoA, another small GTPase protein, promotes the formation of 
contractile actin-myosin filaments and this is essential for cell contractility and FA 
assembly and disassembly [4,15]. Besides the Rho GTPases, the actin cytoskeleton 
organization is also regulated by calcium-dependent proteases, i.e. the calpains. Calpains 
are a large family of calcium-dependent cysteine proteases that cleave myofibril or 
cytoskeleton associated proteins to disassemble the FA complexes [7, 8].  
 
Signaling at the cell-ECM contacts not only regulates cell migration processes but also 
controls the survival of cells. In normal epithelial cells, loss of cell-ECM and cell-cell 
interactions causes the onset of apoptosis, also called anoikis. There is increasing 
evidence that the enhanced adhesion signaling in tumor cells at cell-ECM contact sites is 
important for the inhibition of anoikis in metastatic tumor cells [16]. Such an enhanced 
signaling allows the survival of tumor cells in both tumor microenvironment and the 
circulation. Given this paradigm, metastatic tumor cells would be relatively resistant to 
anticancer drugs. Indeed, inhibition of integrin-signaling in different tumor cells makes 




them more susceptible to anticancer drug-induced apoptosis [17]. Drug-induced apoptosis 
is characterized with distinct cellular and biochemical features which include cell 
shrinkage, nuclear fragmentation, chromatin condensation, and chromosomal DNA 
fragmentation. The onset of these apoptotic events is mediated through the release of 
mitochondrial cytochrome c, activation of the apoptosome and generation of active 
caspase-9 and caspase-3. Survival signaling derived from integrin-mediated adhesions 
triggers the activation of survival pathways that inhibit the release of cytochrome c from 
mitochondria and prevent the onset of caspases [18]. These include the activation of 
phosphoinositide-3 kinase (PI3K)/AKT [19] as well as suppression of the pro-apoptotic 
activity of p53 [20]. Although the roles of some FA-associated proteins in the control of 
cell survival have been identified, the exact signaling pathways downstream from cell-
ECM interactions that control apoptosis are not entirely clear, in particular under in vivo 
conditions.  
 
Signaling pathways in cancer progression 
Detrimental cancer progression can not occur without an increase in signal transduction 
that enhances proliferation, survival and metastasis. During cancer progression, many 
prominent molecules and signaling pathways are activated due to either overexpression of 
receptors for example members of the ErbB family, such as EGFR and ErbB2 in breast 
cancer, or loss of tumor suppressor genes such as the lipid phosphatase PTEN to enhance 
the PI3K/AKT pathway. It is beyond the scope of this introduction to discuss all the 
signaling pathways that are involved in cancer. In the context of this thesis, I will only 
detail the following concepts: 1. the roles of growth factors and chemokines (and 
receptors) in breast cancer cell migration and metastasis; 2. mitogen-activated protein 
kinases (MAPKs)-involved cell growth, cytoprotection and motility as well as the role of 
Fra-1, a member of MAPK downstream transcription factor activator protein-1 (AP-1), in 
cancer progression; 3. survival and growth signaling mediated via phosphoinositide 3 
kinase (PI3K)/protein kinase B (PKB, also named AKT). These pathways are mediated by 
FA complexes and we then mainly focus on 4. FAK-related cell migration and survival in 
cancer progression; 5. paxillin-associated migratory and survival signal.  
 
Growth factor and chemokine receptors in cancer 
 
Growth factor receptors 
The ErbB family of protein tyrosine kinase receptors plays an important role in breast 
cancer progression and drug resistance. High expression of EGFR and ErbB2 [21], as 
well as another tyrosine kinase receptor c-Met [22,23] are associated in reduced breast 
cancer patient survival. Increased expression of these receptors promotes survival of 
breast tumor cells. EGFR is activated by epidermal growth factor (EGF) while c-Met by 
hepatocyte growth factor (HGF; also named scatter factor). EGF serves as not only a 
growth factor to facilitate cell survival and proliferation, but also a typical chemotaxic 





gradient, formation of free barbed ends and actin polymerization at the leading edge in 
some cell lines. Condeelis and co-workers have systematically studied EGF-induced 
phenotypic changes and signaling pathways in living rat mammary adenocarcinoma 
MTLn3 cells using various approaches including advanced live cell microscopy [11-14]. 
EGF induces a PI3K-dependent cell protrusion, where Ras is required for PI3K activation 
and lamellipod protrusion while Rac1 for formation of adhesive structures [24]. 
RhoA/ROCK regulates the switching between Cdc42 and Rac1 at the leading edge [25]. 
Moreover, phospholipase C (PLC), LIM-domain kinase (LIMK)-cofillin, and PI3K-
Wiskott Aldrich syndrome protein (N-WASP)-ARP2/3 are implicated in formation of 
barbed ends and lamellipodial protrusion upon EGF stimulation [26, 27]. Importantly, the 
EGFR signaling is essential for enhanced migration and metastasis of MTLn3 cells in 
vivo [28, 29]. HGF, which promotes the EMT process in various epithelial cell lines [30, 
31], binds the tyrosine kinase receptor c-MET, thereby activates similar downstream 
signaling and promotes mitogenesis, cell motility and invasion [32].  
 
Chemokine receptors 
Chemokines (a subfamily of chemoattractive cytokine) and chemokine receptors (a 
subfamily of seven transmembrane G-protein coupled receptors), are implicated in cell 
directional migration and cancer metastasis [33,34]. Many chemokines and receptors are 
expressed by tumor cells and cells in the tumor microenvironment, including stroma cells 
(endothelial cells, fibroblasts) and leukocytes. Chemokines provide chemotaxis signals 
for tumor cells to target specific organs and attract leukocytes to tumor sites [35]. 
Accumulative evidence shows that chemokine receptor activation involves the following 
tumor-related processes [36]: providing the movement direction for migrating cells 
(chemo-attractive effect) via cytoskeleton reorganization; shaping the tumor 
microenvironment by cell recruitment and angiogenesis modulation; providing survival 
and proliferation signaling via downstream effectors, e.g. AKT and ERK1/2 (extracellular 
signal-regulated kinase), and transcription factors such as NF-κB (nuclear factor kappa-
light-chain-enhancer of activated B cells) [37]. The tumorigenic properties and 
implications of diverse chemokine receptors in cancer are listed in Table 1. Malignant 
cells exhibit aberrant expression of particular chemokines and receptors, notably the CXC 
chemokine receptor 4 (CXCR4, also named fusin), the C chemokine (C-C motif) receptor 
7 (CCR7) and C chemokine (C-C motif) receptor 10 (CCR10) [38,39]. Various studies on 
breast, colon and prostate cancers have established that cancer cells express more CXCR4 
than the corresponding normal epithelial tissue [40-44]. Downregulation of CXCR4 by 
microRNA or antagonists prevents tumor invasion and metastases in vitro and in vivo 
[45,46]. Moreover, CXCR4-Chemokine (C-X-C motif) ligand 12 (CXCL12) axis 
potentiates the crosstalk between tumor cells and the microenvironment and activates the 
intracellular activity of MAPKs and AKT [30-33]. However, the molecular mechanisms 
and roles of other chemokine receptors in breast cancer cell migration and tumor 
development remain largely unknown. The chemokine receptor CXCR3 promotes colon 
cancer metastasis to lymph node [47] and melanoma cell metastasis to lymph node [48]. 
Reduction of CXCR3 expression with antisense RNA or special neutralizing antibodies 




against receptors suppresses metastasis [49]. However, so far, relatively little is known 




Table 1. Chemokine receptors in cancer research 
 
 Tumorigenic properties Implication in cancers 
CXCR1/
2 
Angiogenesis, invasion, metastasis, growth, 
proliferation, MMP expression  
Colorectal, lung, melanoma 
CXCR3 Invasion, metastasis, growth, proliferation Colorectal, melanoma 
CXCR4 Angiogenesis, invasion, metastasis, growth, 
proliferation, MMP expression, DC recruitment 
Breast, etc, 23 types 
CXCR5 Invasion, metastasis, growth, proliferation Carcinomas (pancreatic, colon, 
etc) 
CXCR7 Growth survival Breast, lung 
CCR1/2 TAM recruitment, polarization, invasion, 
metastasis, angiogenesis, mmp expression 
Breast, lung, prostate, etc 
CCR3/5 TAM recruitment, invasion, metastasis, 
angiogenesis, MMP-19 expression 
Breast ,cervical, etc 
CCR4 TAM and T-cell recruitment, invasion, metastasis Ovarian, Hodgkin’s lymphoma, etc 
CCR6 DC recruitment, proliferation, invasion, 
metastasis 
Breast, colorectal, etc 
CCR7,9,
10, 
Survival, invasion, metastasis Breast, melanoma, etc 
CX3CR1 Survival, invasion, metastasis Prostate 
 
Chemokines were classified for CXC, CC, C and CX3C, according to the position of cysteine in the N-
terminal. The implications of chemokine receptors in cancers are briefly listed and edited from [39]. MMP, 
matrix metalloproteinase; DC, dentritic cells; TAM, tumor-associated macrophages. 
 
Downstream signaling 
In this thesis, the roles of several signaling pathways downstream of either growth factor 
or chemokine receptors have been studied in relation to breast tumor cell migration, 
metastasis and cell survival. To update all the present knowledge on the diversity of 
signaling pathways that are essential in tumor cell biological programs, I refer to several 
outstanding papers on these subjects [1, 4, 25, 35, 39, 50-55]. Here, I would like to briefly 
discuss the MAPKs, downstream AP-1 transcription factors with the focus on Fra-1, and 
the PI3K/AKT pathway in the link to the rest chapters. Furthermore, I will mainly 
describe the regulations and functions of two essential focal adhesion-associated proteins, 
FAK and paxillin, in more detail.   
 
MAP kinase pathways 
 
ERK, JNK and p38 signaling  
Mitogen-activated protein kinase (MAPK) pathways involve evolutionarily conserved 
kinases that control cell growth, proliferation, differentiation, migration and apoptosis 







The activation of receptor tyrosine kinases triggers guanosine triphosphate (GTP) loading 
of Ras GTPase, which then recruits Raf kinases to the plasma membrane. Activated Raf 
stimulates MEK1 and MEK2 by phosphorylation on serines 218 and 222 in their 
activation loop. ERK1/2 is activated upon phosphorylation by MEK1/2. Consequently, 
active ERKs phosphorylate numerous cytoplasmic and nuclear targets, including kinases, 
phosphatases, transcription factors and cytoskeleton proteins (such as paxillin, see further 
below), thus inducing various cellular biological outcomes. Most cancer-associated 
lesions have elevated Ras/Raf/MEK/ERK activity due to either increased expression of 
(mutant) growth factor receptors such as EGFR, ErbB2 or activated Ras [58-60]. 
Sustained ERK activation promotes phosphorylation and stabilization of early response 
genes, such as Fos, Jun, Myc and Egr-1, and regulates cell-cycle entry by controlling the 
expression of downstream cyclin-related kinases and inhibitors [61]. Although transient 
activation of ERK fails to promote cell differentiation or proliferation, it regulates 
cytoskeletal dynamics and promotes cell movement by myosin light chain kinase (MLCK) 
and Rac1 [62, 63].  
 
Depending on specificity of cell type, JNK is activated by e.g. cytokines, UV radiation, 
growth factor deprivation or DNA-damaging agents [64-67]. There are three isoforms of 
JNK (JNK1, JNK2, JNK3) and the activation requires dual phosphorylation on tyrosine 
and threonine residues at a distinctive Thr-Pro-Tyr (TPY) motif. One major group of JNK 
substrates activated by stress response are apoptosis-related proteins Bcl-xl, Bim, Bmf 
and Bad [65, 68], modulating the mitochondrial and cytochrome c-mediated apoptotic 
pathway. The other group of substrates is transcription factors like c-Jun, Fra-1, ATF, Elk-
1 and NFATc1, which regulate cell cycle arrest and gene expression of cell invasion 
related proteins, such as matrix metalloproteinases (MMPs) [69-71]. JNK activation by 
growth factor alters the transcriptional regulation of MMP9 through transcription factor 
AP-1 [72]. JNK also regulates cell migration via phosphorylation of cytoskeleton-
associated proteins and scaffold protein substrates. For instance, ERK and JNK can 
phosphorylate paxillin [73], which will be further discussed later in this chapter and in the 
following chapters. 
 
Another MAPK is p38, which is activated by stress and inflammatory cytokines. There 
are four isoforms of p38. Once activated, p38 proteins translocate from the cytosol to the 
nucleus where they phosphorylate serine/threonine residues of substrates. p38 pathway 
also plays a role in the regulation of apoptosis, cell cycle progression, growth and 
differentiation in a cell context-dependent manner [74]. 
 
The AP-1 transcription factor Fos-related antigen-1 (Fra-1) 
Activator protein 1 (AP-1) is a transcription factor and this homodimeric or heterodimeric 
protein complex consists of the Jun, Fos and ATF (activating transcription factor) 
families. The Jun family includes c-Jun, JunB and JunD, while the Fos family consists of 
c-Fos, FosB, and fos-like antigen-1 and 2 (Fra-1 and Fra-2) [75]. Both homo- and 




heterodimers of Jun protein can bind DNA directly, while Fos members require the 
interaction with Jun protein. Jun homodimers have little or no DNA binding activity in 
comparison with Jun/Fos heterodimers [76]. AP-1-binding response elements, for 
instance, TRE, CRE and ARF, interact with other proteins like p65 subunit of NK-κB, 
CBP/p300, Smad-3 and -4, thereby controlling gene expression involved in 
proliferation/transformation, pro- and anti-apoptosis, cell cycle, migration and invasion 
[77-82]. AP-1 is activated via MAPK cascades by growth factors, cytokines, stress, UV, 
etc [83-86]. The activity and expression of Fra-1, Fra-2, c-Jun and JunB are particularly 
linked to the sustained activation of ERK1/2 or JNK pathway [83, 87].  
 
Fra-1 expression levels are significantly enhanced in highly invasive cells [88,89] and 
correlate with the mesenchymal characteristics of epithelial tumors. Expression profiles 
of a panel of 27 human mammary cell lines [90] reveal a highly upregulated expression of 
Fra-1 in ‘fibroblast tumor’ cluster compared with ‘epithelial tumor’ cluster. It is the up-
regulation of Fra-1 expression, rather than a mutational activation, that contributes to the 
growth and proliferation of human tumors. Fra-1 is regulated at transcription and post-
translation level via a diversity of promoters, enhancers and signaling pathways, for 
example, AKT [91, 92], β-catenin/Tcf and Raf/MEK/ERK cascades [89-91] (see Figure 2). 
Fra-1 promotes cell survival and growth by the regulation of cell cycle entry. AP-1 
regulates breast cancer cell growth via cyclins (cyclin D) and E2F factors [93]. Fra-1 
controls cyclin A transcription in Ras-transformed thyroid cells [94] and cyclin D1 
expression at G0-G1 cell cycle entry [95]. Fra-1 and JunB may actually antagonize cell 





Figure 2. The regulation of Fra-1 expression. Various mitogens, cytokines, toxicants and carcinogens 
control the induction of Fra-1 via signal transduction pathways and protein interaction of cis-element and 
cognate trans-factors. Fra-1 gene expression is activated by the MAPK pathway. Fra-1 binds to its own 
promoter through trans-activators (Jun, Fos family and ELK1) interaction with cis-element at the TPA 
response element (TRE), serum response element (SRE) and ATF site in the fosl-1 promoter. PI3K-AKT 
regulates fosl-1 expression through the retinoblastoma control element (RCE). Fra-1 is phosphorylated and 
stabilized by ERK signaling. Fra-1 and cJun regulates fosl-1 expression by binding the TRE site in the first 
intron. cJ = c-Jun, JF = JunD or Fra-2, AP-1*= AP-1-like site. Adapted from Young & Colbuin, 2006 [96]. 
 
 





ROCK pathway through most likely indirect modulating the function of β1-integrin. 
Silencing of Fra-1 with siRNA leads to loss of cell polarity, motility and invasiveness, 
formation of stress fiber, and stabilization of focal adhesions [97]. Fra-1 also regulates the 
expression of several cancer progression and tumor cell migration-associated genes 
including for example CD44 and c-Met [98], as well as the expression of MMPs [99,100]. 
Particularly, Fra-1 enhances the motility and invasion of lung epithelial cells by inducing 
the activity of MMPs, in particular, MMP-2 and MMP-9 [100]. Fra-1 is also implicated to 
regulate vimentin during HA-RAS-induced EMT in human colon carcinoma cells [101]. 
Since growth factor signaling regulates Fra-1 expression and Fra-1 regulates cell 
migration, we wondered the relationship between FAK activity and Fra-1 expression in 
the context of breast tumor cell migration and anticancer drug sensitivity. This has not 
been investigated before and will be discussed in this thesis. 
 
The PI3K/AKT signaling pathway  
 
Receptor-mediated activation of Phosphoinositide 3-kinase (PI3K) originates from the 
recruitment of p85 subunit of PI3K via its SH2 domain to phosphorylated tyrosine 
residues in the intracellular domains of growth factor receptors. The p110 catalytic 
subunit of PI3K catalyzes the phosphorylation of the phosphatidylinositol-containing 
lipid PIP2 at its 3-position resulting in increased levels of PIP3 in the plasma membrane. 
AKT is recruited from the cytosol to the plasma membrane through intramolecular 
interaction with PIP3 and PIP2 where AKT undergoes conformational changes and 
becomes activated through phosphorylation on Thr308 and Ser473 by PDK and PKA 
[102]. The lipid phosphatase PTEN dephosphorylates PIP3, thereby antagonizing the 
AKT activation.  
 
AKT signaling is strongly implicated in diverse cancers, and deregulation of AKT 
function promotes cancer progression [103-105]. In addition, AKT regulates cell cycle 
through phosphorylation and cytoplasmic retention of the cell cycle inhibitors p21 and 
p27 as well as enhanced translation and stabilization of cyclin D1 [106]. AKT also 
influences cell survival and prevents apoptosis via enhancing glucose uptake and 
promoting the NF- κB pathway which regulates some pro-survival genes and inhibits pro-
apoptotic Bad and Bax [107]. Activated AKT also promotes MDM2 nuclear translocation, 
increases Bcl-2/Bcl-xl levels, and inhibits cytochrome c release from mitochondria [108]. 
There are three instinct isoforms of AKT (AKT1, AKT2 and AKT3), among which AKT1 
and AKT2 show different functions in cell invasiveness and cancer development [109]. 
Generally, AKT1 regulates cell growth and survival signaling, while AKT2 regulates 
metabolic signaling. In fibroblasts, AKT1 promotes cell migration via phosphorylation of 
an actin-binding protein girdin and therefore forms stress fiber and lamellipodia [110]. In 
fibrosarcoma  cells and mouse mammary epithelia cells, AKT enhances cell invasion via 
increased secretion of MMPs [111,112]. Remarkably, in cells where one AKT isoform 
stimulates motility, the other usually has a limited or even opposite role. AKT1 and AKT2 
have distinct roles in Rac/Pak signaling, cell migration [113] and mammary 




adenocarcinoma development in mouse mammary tumor virus (MMTV)-ErbB2/Neu and 
MMTV-polyoma middle t (PyMT) transgenic mice [109].  
 
The focal adhesion-associated tyrosine kinase focal adhesion kinase (FAK)  
 
FAK domains and interactions 
Integrin clustering and activation of growth factor receptors recruit FAK and c-Src at FA 
sites and transmit adhesion-dependent and growth factor-induced signals into the cell 
interior. FAK is a multidomain non-receptor tyrosine kinase. The structure, 
phosphorylation sites and protein-protein interaction domains of FAK are shown in Figure 
3. The N-terminal region of FAK contains a Band 4.1, ezrin, radixin and moesin 
homology domain (FERM). The FERM domain, particularly a basic surface exposed 
region in subdomain-2, negatively regulates the catalytic activity of FAK through an 
intramolecular interaction with FAK kinase domain. FERM interacts with integrins and 
growth factor receptors [114]. FAK, via its FERM domain, also binds the Arp2/3 complex 
to control actin assembly [115]. Alternatively, the FAK FERM domain binds to FIP200 
(FAK-interacting protein of 200kDa), which confers an inhibitory effect on FAK catalytic 
kinase activity, thus negatively regulates FAK function [116]. On the other hand, in tumor 
progression, FAK enhances survival signals by binding to FIP200, consequently limiting 
FIP200-p53 interaction and suppressing p53 activity. FAK proline-rich regions (PRR1 
and PRR2) bind Src-homology-3 (SH3) domain-containing proteins such as Crk-
associated substrate (p130Cas), GTPase activating protein for Rho associated with FAK 
(GRAF) and the Arf-GTPase-activating protein 1 (ASAP1). The focal adhesion targeting 
(FAT) domain of FAK is c-terminally located and interacts with paxillin and talin, 
resulting in the focal contact localization of FAK [7].  
 
 







Phosphorylation of FAK 
Autophosphorylation of FAK at Y397 upon the engagement of integrins with ECM 
recruits Src at focal adhesion sites. Local Src activation mediates further phosphorylation 
of FAK at Y576 and Y577, therefore a conformation change of FAK enhances the 
catalytic kinase activity of FAK. The Src/FAK protein tyrosine kinase complex mediates 
phosphorylation of other Tyr residues of FAK as well as phosphorylation of other proteins 
(e.g., paxillin, p130Cas) [117,118]. Phosphorylated FAK on Y861 increases the binding 
affinity of p130Cas to the proline-rich regions of FAK c-terminus and is crucial for 
sensing mechanical force [119] and H-ras induced transformation [120]. Phosphorylation 
of Y925 at FAT domain promotes SH2 domain-containing adaptor protein Grb2 (growth 
factor receptor-bound protein 2) binding to FAK, thereby allowing activation of the FAK-
Grb2-Ras-MEK1-ERK2 signaling cascades. Both Y925 phosphorylation and Grb2 
binding seem to be required for FAK function in promoting tumor angiogenesis [121]. 
Phosphorylation of Y925 not only mediates a MAPK-associated angiogenic switch during 
tumor progression, but also provides anti-apoptosis functions of FAK [121,122]. Although 
most tyrosine phosphorylation sites positively affect FAK activity, Y407 has recently 
been reported to negatively regulate FAK kinase activity in cell migration/invasion 
[123,124]. Increasing evidence indicates the importance of tyrosine phosphorylation of 
FAK in cell survival and migration, while the role of serine phosphorylation of FAK still 
remains largely unclear. Phosphorylation of FAK at Ser843 inhibits phosphorylation at 
Y397; Ser843 phosphorylation is increased when FAs disassemble and cells detach from 
the substratum [125]. The effects of phosphorylation at other serine residues, such as 
Ser722, Ser86 and Ser910, are still poorly understood [126,127].  
 
Downstream effectors of FAK in cell migration and survival  
FAK regulates actin cytoskeleton and cell migration by controlling focal complex 
assembly/disassembly at the leading edge of lamellipodia and disassembly at the rear of 
migrating cells [7,8]. As mentioned above, FAK phosphorylates other downstream 
effectors, like paxillin, p130Cas and Raf/MAPK/ERK, and triggers cell migration 
machinery. FAK has indirect and direct effects on Rho-family GTPases Rho, Rac, CDC42 
via GEFs (guanine-nucleotide exchange factors) and GAPs (GTPase activating proteins). 
FAK is involved in actin and microtubule organization via effectors N-WASP and mDia 
[7]. In addition to the roles at FAs and cytoskeleton, FAK also has a scaffolding function 
in cell nuclear compartment under cellular stress conditions. A recent study [128] has 
shown that FAK facilitates p53 degradation and turnover via MDM2, the negative 
regulator of p53. This is not mediated via the FAK kinase activity but by the nuclearly-
localized FERM domain. FERM F1 lobe in FAK N-terminal band 4.1 binds to p53, while 
FERM F2 lobe mediates nuclear accumulation and F3 lobe connects p53 and MDM2 for 
proteasomal degradation [114]. Interestingly, there is also a p53 binding site in the fak 
gene promoter. Overexpression of p53 negatively regulates FAK promoter activity 
[129,130]. This interesting connection between FAK and p53 may be of relevance to 
cancer progression given the defects in p53 in many types of cancers. This FAK-




dependent down regulation of p53 function seems important for the control of apoptosis 
[131]. The studies in our group demonstrate a role of FAK in the control of the AKT pro-
survival pathway. Thus, conditional expression of a inhibitory splice variant of FAK, FAK 
related non-kinase (FRNK), sensitizes breast cancer cells to doxorubicin-induced 
apoptosis by inhibiting doxorubicin-induced AKT activation [132]. Other studies also 
demonstrate a relationship between FAK and AKT activation. Collagen matrix 
contraction-caused mechanical signal induces fibroblast cell apoptosis via disturbing β-
integrin-FAK- PI3K/AKT survival signaling [133]. 
 
FAK in breast cancer development and progression  
FAK regulates cell proliferation, survival and migration in cancer development and 
abnormal FAK expression and activity have been implicated in a panel of cancer types, 
including breast cancer [134-137]. Overexpression of FAK and growth factor receptors 
(EGFR, ErbB, c-MET) is associated with cell invasiveness, angiogenesis and poor patient 
survival [138-140]. Reconstitution of Tyr with Phe at different FAK Tyr residues (Y397, 
Y863, Y925) delays breast cancer cell migration through endothelial monolayer, 
indicating that the phosphorylation of FAK is crucial for breast tumor extravasation [141]. 
FAK also regulates tumor cell invasion and angiogenesis via supporting the expression of 
MMPs and VEGF [121,142]. The FAK inhibition with FRNK in our established 
orthotopic rat breast tumor model inhibits primary tumor formation and early phase of 
tumor metastasis [143]. Dual reduction of FAK and Pyk (another FAK family member) 
inhibits tumor formation and lung metastasis via reduced MAPK activity [144]. 
Mammary epithelial specific disruption of FAK in a transgenic Cre/LoxP mouse model of 
human breast cancer retards tumor formation and metastasis, which might be linked with 
the altered expression of a variety of cell cycle and metastasis-related genes [145]. This 
disruption of FAK also impairs mammary epithelial proliferation and the transition of 
premalignant hyperplasias to carcinoma and metastasis [146]. Moreover, recent data 
obtained with the same strategy of this breast cancer model indicates that FAK also has a 
role in maintaining the mammary cancer stem cell population [147].  
 
Modulation of FAK activity in cancer progression and anticancer therapy 
Given the critical role of FAK in tumor development and implication of FAK in cancer 
progression and treatment, modulation or disturbance of FAK signaling could be a 
potential target in anticancer therapy. Since fak complete knockout results in early 
embryonic lethality, FAK conditional ablation in tumor cells or animal models can be 
used to investigate its role in tumor progression. A few genetic knockout of FAK in 
specific tissue sites have been developed in animal models, such as myosin light chain 2v 
(MLC2v)-Cre/FAKflox [148], Cre-ER (estrogen receptor)/ FAKflox [149,150], and mouse 
mammary tumor virus (MMTV)-Cre/ FAKflox [145-147]. Alternatively, FAK activity can 
be modified by transient, constitutive or conditional expression of inhibitory splice 
variants of FAK, FRNK, or the FAT domain [143,151]. Overexpression of these mutant 
variants either induces tumor cell killing by itself, or enhances the susceptibility to cell 





inactive FAK in breast carcinoma cells induces caspase-8 dependent apoptosis [154]. 
knock down approaches using shRNA or antisense RNA have also demonstrated the role 
of FAK in cell survival [155], and FAK inhibition with antisense RNA enhances cancer 
cell sensitivity to some anticancer drugs, e.g., camptothecins and docetaxel [156,157]. 
Recently, different FAK specific inhibitors (TAE226, PF228 and PF271) have been 
developed to study kinase activity and scaffold function of FAK in cell survival, 
proliferation and migration in vitro as well as tumor progression in vivo [158-161]. Since 
the above modulations of FAK in vivo may affect both tumor cells and stroma cells within 
tumor microenvironment, it has not been possible to precisely define tumor cell- specific 
role of FAK in anticancer drug resistance. Moreover, a more global understanding of 
FAK-mediated cell survival and proliferation remains unavailable. We previously showed 
that conditional expression of FRNK inhibited primary tumor formation and early phase 
of lung metastasis formation in a rat tumor and metastasis model [143]. However, the in 
vivo effect and mechanism of FAK inhibition on tumor formation and metastasis in the 
anticancer treatment still need to be further established. We studied the effect of 
conditional FRNK expression on doxorubicin sensitivity of primary breast tumors and 
lung metastases in vivo in chapter 3. 
 
The focal adhesion scaffold protein paxillin 
 
Paxillin structure and interactions 
Paxillin is another important component of cell adhesion complex at focal adhesions. As a 
central scaffold protein at FA sites, paxillin contains various domains that mediate the 
interactions with other structural and signaling proteins (Figure 4) [162-164]. Paxillin 
contains five conserved leucine-rich (LD) motifs, which interact with actin-binding 
proteins (e.g. vinculin and actopaxin) and signaling proteins such as FAK, integrin linked 
kinase (ILK), and the family members of ADP ribosylation factor/GTPase activating 
proteins (ARF/GAPs), including G-protein-coupled receptor kinase interacting 
protein/paxillin kinase linker (GIT1/PKL) [165,166]. Between LD1 and LD2 there is a 
proline-rich motif, which binds to SH2 domain of Crk and p120 RasGAP [162]. In 
addition, paxillin contains four c-terminal LIM domains, which are highly conserved 
cystine-rich 2-zinc-fingers-contained structures that mediate protein-protein interactions 
[167,168]. In paxillin, LIM2 and LIM3 domains bind to tubulin and regulate microtubule 
dynamics at adhesion sites, while LIM3 and LIM4 bind to protein tyrosine phosphatase 
(PTP)-PEST and regulate cell spreading and motility [169]. Paxillin LD2 and LD4 
interact with FAK and GIT1 via its FAT domain [170,171].  
 
Paxillin phosphorylation 
Paxillin can be phosphorylated on a variety of Tyr and Ser/Thr residues [172]. Depending 
on the phosphorylation status, paxillin plays different roles. Non-phosphorylated paxillin 
is essential for fibrillar adhesion formation and fibronectin fibrillogenesis, while 
phosphorylated paxillin regulates the assembly of nascent adhesions and the distal part of 
late adhesions and induces FA turnover [173]. Phosphorylation at Tyr118 and Tyr31 




regulate cell migration via paxillin-Crk complex. Phosphorylation at Ser178 is triggered 
by growth factor or stress response via MAPK pathway [73,174]. Phosphorylation at 
Ser273 regulates cell adhesion and protrusion dynamics by increasing paxillin-GIT1 
binding and promoting the localization of a GIT1-PIX-PAK signaling module near the 
leading edge [175]. Ser188 or 190 is a target of tyrosin kinase phosphorylation and 
involved in cell adhesion [176]. Ser244 can be phosphorylated by CDK5 and thus reduces 
the interaction of FAK and paxillin in oligodendrocyte precursor cells (OPCs) [177]. 
 
 
Figure 4. Adaptor protein paxillin interacts with other cytoskeleton-related proteins through LD and 
LIM domains. See the text for more details. Adapted from Schmalzigaug et al., 2007 [162] and Deakin et 
al [178]. LD domains mediate adhesion/integrin signaling and lamellipodium formation. LIM domains 
direct the FA targeting. 
 
Paxillin in cell migration and survival 
Assembly of paxillin LD4-PKL-PIX-Pak-Nck complex and sequential activation of 
paxillin (Y31/118)/Crk/p130Cas/DOCK180 cascade are two major ways to regulate cell 
motility via adhesion assembly and Rac activation. Explicatedly, the paxillin LD4 binds a 
complex of proteins containing PAK, Nck and PIX and the binding between paxillin and 
this complex is mediated by PKL [166,179]; PKL is a substrate of PTP-PEST which 
inhibits cell spreading and motility [169]. This complex is also crucial for Rac activation 
and cell polarization. The paxillin-Crk complex is believed to promote cell spreading and 
lamellipodia formation via recruitment of paxillin to focal adhesion [180]. Paxillin is also 
associated with the apoptotic machinery [178]. Paxillin is a substrate of caspase-3 and the 
cleavage of aspartic acid residues of paxillin by caspase-3 inhibits integrin-mediated cell 
survival signaling [181]. Recently, it is reported that Bcl-2 interacts with LD4 motif of 
paxillin to promote cell survival [182]. Also, paxillin shuttling through the nucleus serves 
as a co-activator of transcriptional factors [183], which may modulate gene expression of 
anti-apoptotic routes. Cell stress causes drastic changes in the cytoskeleton and focal 
adhesion organization including paxillin dephosphorylation [184]. However, so far it still 
remains largely unclear if and how paxillin regulates focal adhesion and cytoskeletal 
reorganization under cellular stress conditions caused by for example anticancer drug 





(JNK) to focal adhesion sites. JNK is typically activated under cellular stress conditions 
(see above) and activated JNK has been observed at FAs [185]. JNK is also transiently 
activated after growth factor stimulation and phosphorylate paxillin at Ser178 residue 
[69]. Suppression of paxillin with siRNA decreases the phosphorylation level of c-Jun in 
skin cell transformation, indicating that paxillin may also retroact on the JNK pathway 
[186]. It remains elusive how JNK and paxillin interact in response to cellular stress 
caused by anticancer drugs, and how this relates to the growth factor-stimulated activation 
of JNK and cell migration.  
 
Paxillin in cancer 
Paxillin is potentially involved in several processes of tumor development. So far, most 
studies have focused on paxillin-related FA signaling in cytoskeleton organization, cell 
dynamics and survival [162,187]. Paxillin is a target of many oncoproteins, like Src, 
BCR/ABL [188] and E6 [189]. Moreover, it regulates gene expression via the interaction 
with ERK [190], Poly-A-binding protein [191], Abl and androgen receptors [192]. The 
deficient activation or presence of paxillin might have functions on cell migration, 
proliferation and survival in cancer development. However, relatively little is known 
about the role of paxillin in tumor development. Paxillin expression is higher in 
metastatic human osteosarcoma sub-cell line than less metastatic sublines and knock 
down of paxillin reduces cell motility. This is associated with tyrosine phosphorylation of 
paxillin [193]. Yet, to the best of our knowledge, no research about the role of paxillin and 
other alternative phosphorylation residues in breast tumor cell migration, survival or 
breast cancer progression has been published. In this thesis, we aim to investigate the role 
of paxillin, especially Ser178 residue, in cell proliferation and migration of breast cancer 
cell MTLn3 in tumor progression.   
 
Aims and outline of the thesis 
 
Understanding the molecular mechanisms of survival and migratory pathways in cancer 
cells is essential to better comprehending cancer progression, metastasis formation and 
drug resistance, thereby benefiting the development of novel anticancer treatments. The 
overall goal of the work in this thesis is to better understand the role and mechanism of 
focal adhesion-mediated signaling in the control of anticancer drug-related survival 
signaling of breast tumor cells in vivo as well as the regulation of cell migration of breast 
tumor cells in vitro. Moreover, we would like to identify the pattern of C-X-C 
chemokines and corresponding receptors that mediate the downstream signaling events in 
tumor cell migration and invasion. For these purposes we have used the well-established 
rat metastatic breast carcinoma cell line MTLn3 as a working model. The MTLn3 cell 
line is an amoeboid-like motile breast cancer cell line. The MTLn3 cell system is suitable 
to study anticancer drug responses, since these cells are sensitive to anticancer drugs in 
vitro [194,195]. However, they are insensitive to anticancer drugs under in vivo conditions 
[196], indicating that specific micro-environmental signaling may suppress drug toxicity. 




Moreover, since this cell line demonstrates dynamic cell movement in 2D, it is also an 
excellent model to study growth factor and chemokine-triggered cell migration and 
invasion. Cytoskeleton reorganization in the context of growth factor-induced cell 
migration has been examined in MTLn3 cells [24, 25, 197]. Besides, previous work in our 
lab has established that MTLn3 cells form bigger focal adhesion under DNA-damage 
stress conditions [132], providing a possible link between cellular stress responses and 
focal adhesion organization. Furthermore, these cells can easily be used in xenograft 
models of breast tumor formation and experimental lung metastasis to determine the role 
of particular signaling pathways in metastasis formation as well as drug resistance. 
 
We discuss the autocrine chemokine receptor CXCR3-mediated signaling pathways and 
biological effects in breast cancer cell in chapter 2. We have profiled the transcriptional 
expression of chemokines and receptors in MTLn3 cell line. The gene expression profiles 
have revealed that CXCR3 and CXCR4 are highly expressed. While the respective 
chemokines CXCL9, 10, 11 for CXCR3 are present, the CXCR4 ligand CXCL12 is 
absent. We have demonstrated that CXCR3 and the respective chemokines form an active 
autocrine loop and contribute to cell motility of MTLn3 cells. The MEK/ERK and 
PI3K/AKT pathways have been characterized as CXCR3 downstream signaling pathways 
that are essential for CXCR3-mediated migration. Importantly, the disturbance of CXCR3 
signaling by knock down (KD) of CXCR3 with siRNA decreases cell migration to an 
artificial wound.  
 
FAK has been shown to be involved in cell survival, migration and invasion. We have 
demonstrated that FAK is required for primary tumor formation and early stage of tumor 
metastasis. For this purpose MTLn3 cell lines that conditionally express the dominant-
negative acting splice variant of FAK, FRNK, were used. In chapter 3, we show that 
FAK inhibition with the dominant-negative-acting mutant FRNK improves cell sensitivity 
to the anticancer drug doxorubicin and reduces tumor growth and outgrowth of lung 
metastasis, hence improving tumor sensitivity to doxorubicin. Transcriptomics analysis 
has revealed the differential expression of genes upon FRNK-expression. Fra-1 is 
prominently altered by FRNK expression as well as siRNA-mediated KD of FAK. In 
accordance with the finding that FRNK sensitizes MTLn3 cells to doxorubicin, 
downregulation of Fra-1 using siRNA approaches sensitizes the cells to doxorubicin. 
Interestingly, Fra-1 knock down also causes cytoskeleton reorganization and impairs cell 
migration associated with reduced focal adhesion turnover.  
 
In chapter 4, another focal adhesion-related scaffold protein paxillin and stress activated 
MAPK/JNK pathway have been investigated in the context of cytoskeleton reorganization 
and cell cycle inhibition/apoptosis after treatment with the anticancer drug vincristine, a 
microtubule disrupting agent. Vincristine induces focal adhesion formation, stress fiber 
formation, and cell cycle arrest prior to the onset of MTLn3 cell apoptosis. Vincristine 
selectively activates the MAPK/JNK pathway, but not MAPK/ERK or MAPK/p38 





phosphorylation of paxillin at serine 178 residue and another unknown modification of 
paxillin. Phosphorylation of Ser178 paxillin and the unknown modification are dependent 
on JNK activity. Furthermore, SP600125, A JNK inhibitor, reduces vincrisitne-induced 
cell contractility, in association with the inhibition of F-actin stress fibers and larger focal 
adhesion formation. Finally, paxillin knock down reduces vincristine-induced cell 
contractility and focal adhesion formation. All these phenomena indicate a tight 
interaction between JNK and the focal adhesion-associated adaptor protein paxillin in 
microtubule disruption-induced cytoskeleton reorganization.  
 
Previous researches suggest that paxillin also plays an important role in cell migration 
and proliferation. In chapter 5 we further studied the potential role of JNK-mediated 
paxillin Ser178 phosphorylation in MTLn3 cell migration. The in vitro studies are 
performed with MTLn3 cell lines that stably express either GFP-paxillin or GFP-paxillin 
mutant S178A, which can not be phosphorylated by JNK. The GFP-S178A-paxillin 
reduces cell proliferation, focal adhesion turnover and cell migration process. 
Interestingly, GFP-S178A-paxillin reduces EGF-induced activation of both ERK and 
AKT, suggesting a potential defect in the EGFR signaling pathway. This is not observed 
for HGF-induced cell signaling, and GFP-S178A-paxillin is unable to block HGF-
induced MTLn3 cell migration.  
 
I briefly summarize our studies and discuss the work in related with other literature in 
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Chemokine receptor signaling has a prominent role in breast cancer cell migration 
in the context of metastasis formation, but the roles of many receptor-ligand pairs in 
this process remain unclear. Here we determined the expression profile of chemokine 
receptors and their respective ligands in the metastatic mammary adenocarcinoma 
cell line MTLn3 by microarray gene expression profiling and semi-quantitative RT-
PCR. CXCR3 and its ligands CXCL10 and CXCL11 were prominently expressed in 
MTLn3 cells. CXCR3 activation by CXCL10 and CXCL11 induced transient 
intracellular Ca2+ mobilization. CXCL11 enhanced random cell migration and 
stimulated chemotaxis-driven cell invasion. CXCR3 activation by either CXCL10 or 
CXCL11 caused activation of both ERK and AKT. Pharmacological inhibition of 
MEK with U0126 or phosphoinositide-3 kinase with LY294002 inhibited the 
CXCL11-induced MTLn3 cell invasion. Finally, knock down of CXCR3 in MTLn3 
cells inhibited cell migration into an artificial wound which was associated with 
reduced protrusion formation. Together, these data suggest that autocrine CXCR3 
activation is important for MTLn3 tumor cell migration and invasion and a 
potentially important drug target to inhibit cell biological steps of breast cancer 




Malignant breast cancer is characterized by metastasis to regional lymph node, bone 
marrow, lung and liver. Metastasis is a complex progress including detachment, migration, 
invasion, extravasation, homing to specific organ, and proliferation in sites of metastasis. 
Recent reports demonstrate that chemokines contribute to a number of tumor-related 
processes, such as tumor development, growth and metastasis via providing the 
movement direction for migrating tumor cell through chemo-attractive effect; shaping the 
tumor microenvironment by cell recruitment, including recruitment of leucocytes, tumor-
associated macrophages and dentritic cells and angiogenesis modulation; providing 
survival and proliferation signaling (1-4). 
 
Chemokines are small chemoattractant molecules with either CC or C-X-C motifs 
involving a wide variety of biological and pathological processes (4). Chemokines bind to 
their respective CC or C-X-C chemokine receptors, which belong to the subfamily of 
seven-transmembrane G-protein coupled receptor and are capable to activate intracellular 
downstream signaling (5, 6). Previous attention has been focused on the chemokine-
mediated chemotaxis properties of immune cells. Recent evidence demonstrates an 
essential role for chemokine receptor-signaling in tumor cell survival, proliferation, 
chemotaxis, adhesion and migration, especially in relation to the homing of tumor cells to 
distant target organs (7, 8). The majority of studies on chemokine receptors in cancer 
progression have so far focused on CXCR4 (1, 9-11). CXCL12 (SDF-1alpha) acts as a 
prominent chemoattractant that activates CXCR4 receptors and drives the metastasis of 




various cancers to distant organs such as lung (12, 13). This is related to the activation of 
Ras/MEK/ERK and PI3K/AKT signaling pathways (6, 14).  
 
CXCR3 is primarily characterized for the expression on effector and memory CD4 T cells 
(15), CD8 T cells and Natural Killer cells. And it contributes to the accumulation of 
antibody secreting cells at the sites of inflammation (16). CXCR3 has raised considerable 
interests in the context of cancer because of its discovery in the tumor microenvironment 
(17, 18). Moreover, several studies indicate the expression of CXCR3 on different cancer 
cells including colon cancer and melanoma (19-22). Recent data also demonstrate that  
overexpression of CXCR3 enhances colon cancer metastasis (22) as well as melanoma 
cell metastasis to lymph node (23). So far little information is available on the role of 
CXCR3 in breast cancer. Thus a systematic analysis of the expression of chemokine 
receptors and their ligands in breast tumor cells has not been performed. Besides, the role 
of specific chemokine-chemokine receptor pairs and possible autocrine activation 
mechanisms remain largely unknown. We have investigated these in the context of breast 
cancer cell motility and invasion.   
 
In the present study we show the expression profile of chemokines and chemokine 
receptors on MTLn3 breast cancer cell. These cells express functional CXCR3 and 
CXCR4 as well as CXCL10 and CXCL11 but not CXCL12. CXCL11 not CXCL10 
enhanced cell random migration and directional migration to collagen-coated membrance 
by interaction with its receptor CXCR3. We determined the role of MEK/ERK and 
PI3K/AKT pathway in the chemokine-induced tumor cell invasion. Finally siRNA-
mediated knock down of CXCR3 inhibited MTLn3 cell migration into an artificial wound. 
Collectively, our data support a role of CXCR3 in breast tumor cell migration, and 
suggest a possible autocrine loop by which tumor cell-derived CXCR3 ligands stimulate 
the migration of the tumor cells. 
 
 
MATERIALS AND METHODS 
 
Chemicals and Antibodies- α-modified MEM with ribonucleosides and 
deoxyribonucleosides (α-MEM), fetal bovine serum (FBS), phosphate buffered saline 
(PBS) and trypsin were from Life Technologies. Collagen (type Ι, rat tail) was purchased 
from Upstate Biotechnology and used at a working concentration of 20 µg/ml. Propidium 
iodide (PI) and PI3K inhibitor LY294002 were from Sigma (St.Louis, MO). Fluo-4-
acetoxymethyl (AM) ester was from Invitrogen. MEK inhibitor U0126 was from 
Promega Benelux B.V. Recombinant murine CXCL10, CXCL11, CXCL12 were obtained 
from PeproTech Inc. and used at a working concentration of 100 ng/ml. All primers for 
PCR were ordered from Biolegio B.V., Rabbit anti-p-ERK1/2 (p44/42 MAP Kinase, 
Thr202/Tyr204), rabbit anti-ERK (p44/42 MAP Kinase), rabbit anti-p-AKT (Ser473), and 
rabbit anti-AKT antibodies were from Cell Signaling Technology. All other chemicals 
were of analytic grade.  





Cell Culture- MTLn3 rat mammary adenocarcinoma cells were cultured as described 
previously (24). GFP-MTLn3 was generated by overexpression of eGFP (enhanced GFP) 
followed by clone selection using G418. Selected clone had a similar behavior and 
morphology as parental MTLn3 cells. For experiments, cells were serum starved in α-
MEM medium with 12 mM HEPES and 0.35 % (w/v) bovine serum albumin (starvation 
medium) for 2 hrs before experiment treatment (25). Under these conditions cell signaling 
was shut down as determined by cellular p-ERK levels. To study cell migration, cells 
were seeded on 20 µg/ml collagen-coated transwell chambers or collagen-coated glass 
bottom dishes (Greiner).  
 
Microarray Analysis- Total RNA was isolated from MTLn3 cells according to Qiagen 
RNAeasy manufacturer’s instruction. Concentration and quality of RNA were determined 
using lab-on-a-chip analysis. mRNA was converted to cDNA and subsequently to 
digoxigenin-labeled cRNA with a NanoAmpTM RT-IVT labeling kit from Applied 
Biosystems according to the manufacturer’s instruction. Digoxigenin-labeled cRNA 
samples were hybridized to Rat Genome Survey Microarray (ABI) and detected with a 
chemiluminescent detection kit (ABI) following the manufacture’s instruction. After 
conversion of raw signals on microarrays to expression values by Expression Array 
System Analyzer Software version1.1.1, a filtering step was applied based on a signal-to-
noise ratio of >3 to exclude low expressed genes. 
 
Semi-quantitative Reverse Transcription-PCR and Real Time PCR- cDNA was 
synthesized from 5 µg RNA using Superscript II Reverse Transcriptase (Invitrogen). PCR 
reactions were performed from 50 ng cDNA using BIOTAQ Red DNA polymerase 
(1U/25 µl, GENTAUR). The sequence-specific primer pairs were separately designed by 
online primer design tools (https://www.genscript.com/ssl-bin/app/primer and 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The reactions were amplified 
for 35 cycles of 94°C for 30 s, 60°C for 30s, 72°C for 50s. GAPDH and β-actin were used 
as internal controls. PCR products were analyzed by electrophoresis on 2 % agarose gels.  
 
Quantitative RT-PCR of CXCR3 in siRNA experiments was performed on ABI 7700 
system with the SYBR Green PCR Master Mix kit (Applied Biosystem) adapted 
according to the manufacturer’s instructions. The reactions were set up using 50 ng of 
template per reaction. 200, 100, 50, 25, 12.5, 6.25, 0 ng of mixture templates were run for 
standard curve. Reactions were performed in duplicate for 40 cycles (95°C /1min for 
denaturing step, 60°C /1min for annealing step and 65°C -95°C for melting curve step). 
Monopeak in melting curve showed unique fragments yielded. The mRNA expression 
was normalized to the expression level of β-actin in each sample and relative normalized 
units were compared between samples.  
 
Calcium Mobilization Assay- Cells were detached and loaded with 2 µM Fluo-4-AM, 
0.01% pluronic acid, and 1 mM probenicid in FBS-free medium for 60 min at 37 °C in 




the dark. Cells were washed twice with pre-warmed FBS-free medium. Propidium iodide 
(1µM) was added to exclude dead cells after loading. Flow cytometry analysis was done 
on FACScalibur (BD Biosciences). First 30 seconds were recorded as baseline. 
Chemokine (100 ng/ml) or ionomycin (20 μM) was added at 30 seconds. Fluo-4 and PI 
staining were detected at 530nm (530/30 nm dichroic bandpass filter) and 585nm 
(585/42nm band pass filter). At least 105 cells per sample were analyzed and PI-positive 
cells were excluded from the Fluo-4 intensity analysis.  
 
Random Migration Assay- 1*105 GFP-MTLn3 cells were seeded in collagen-coated 
glass-bottom dishes and incubated overnight. After serum starvation for 2 hour, cells were 
visualized for 1 hour in indicated medium (starvation medium followed by addition of 
either 5 % FBS or 10 nM EGF or 100 ng/ml chemokine) maintained at 37°C in 5% CO2 
in a climate control unit on a Nikon Eclipse TE2000 U-inverted microscope. Migration 
tracks of about 50 cells were recorded framing every 5 minutes with 40x oil objective 
lens (Nikon), zoom 2.0 using Bio-Rad Radiance 2100 confocal system. Image acquisition 
was done using the LaserSharp software (Bio-Rad) with homemade auto-focus system. 
To determine the efficiency of stimulus, cell movement was traced for each lapse interval 
recorded during 1hr period and cell speed was calculated by tracking cell center in each 
frame. Cell surface area change between two sequent frames was calculated to represent 
cell dynamic and motility using ImagePro Plus (version 5.1, Media Cybernetics Inc.). 
 
Transwell Migration Assay- Cell invasion was assayed using 24-well transwell inserts 
containing 6.5 mm-diameter chamber with 8 µm-pore filter (Greiner Bio-one). Inserts 
were coated with collagen. After serum starvation for 1 hr, cells were trypsinized and 
resuspended at 5*105 cells/ml in serum starvation medium. 0.1 ml of cell suspension was 
added to the upper chamber. 0.6 ml serum starvation medium with indicated 
chemoattractant was added to the lower chamber. After incubation for 8 hr, the cells on 
the upper surface of filters were scraped with cotton swabs to remove the non-migrating 
cells and non-attached cells, the filters were washed with PBS and fixed with 4.0% 
formaldehyde for 10 min and stained with crystal violet (0.1% w/v) for 30 min. The 
number of the migrating cells was counted in 3 different random areas. Data were 
normalized as the migration index. For the experiments with inhibitors, U0126 (10 µM) 
or LY294002 (10 µM) was added to medium in the lower chambers. 
 
Immunoblotting- For western blot analysis, cells were starved for 4 hr and stimulated 
with 100 ng/ml chemokine or 10 nM EGF pre-incubated either with or without inhibitor 
U0126 (10 µM) or LY294002 (10µM). At indicated time points, cells were washed with 
ice-cold PBS and TSE (10 mM Tris-HCL, 250 mM sucrose, 1 mM EGTA) and lysed in 
ice-cold TSE with inhibitor cocktail (1 mM dithiothreitol, 10 μg/ml leupeptin, 10 μg/ml 
aprotinin, 1 mM sodium vanadate, 50 mM sodium fluoride, 1 mM 
phenylmethylsulfonylfluoride, pH 7.4). After sonication, protein concentrations of cell 
lysates were determined using Bradford protein assay with IgG as a standard. Equal 
amounts of protein (25 µg) were separated with 7.5-10% SDS-PAGE and transferred to 




PVDF membrane (Millipore). Blots were blocked with 5 % w/v BSA followed by 
incubation with primary antibodies (1:1000) against phospho-ERK, ERK and AKT or 
blocked in 0.2% I-BlockTM (Applied Biosystem) followed by incubation with antibody 
against phospho-AKT (1:1000) and subsequently incubated with horseradish peroxidase-
conjugated secondary antibody (1:2000) for p-ERK, ERK, AKT or alkaline phosphatase-
conjugated secondary antibody for p-AKT (1:2000). Blots were detected with ECL-Plus 
reagent (Amersham Bioscience) on a multilabel Typhoon imager 9400 detection system 
(Amersham, Bioscience) or developed in Tropix reagent (Applied Biosystem) and 
exposed on films. 
 
siRNA-mediated Knock Down of CXCR3- CXCR3 knock down with SMARTpool 
siRNA was performed by normal transfection with DharmaFECT reagent 2 (Dharmacon 
RNAi Technologies). Briefly, 1.5 -2*105 cells were seeded in 6-well plates overnight and 
transfected with 50 nM siRNA or sicontrol. mRNA was collected after 48 hr transfection. 
For would healing assay, cells were detached after 24 hr post-transfection, reseeded on 
collagen coated glass bottom plates and incubated for another 24 hrs. The monolayer of 
cells was scratched to generate a wound with 200 μl plastic tips following with overnight 
movies. The wound edges were visualized with 20x objective lens on Nikon Eclipse 
TE2000-E PFS microscope with differential interference contrast (DIC). Frames were 
obtained every 5 min with NIS-elements AR software (Nikon). The speed of the wound 
closure was calculated with ImagePro Plus software. 
 
Statistical Analysis- Student’s t-test was used to determine significant differences 




Expression of CXC Receptors and Ligands in Metastatic Mammary Adenocarcinoma 
MTLn3 Cells- To study the role of chemokine receptors in cell migration and invasion, 
we used the highly metastatic breast cancer cell line MTLn3 as a model system. We 
focused on the receptors and corresponding ligands of the CXC family. First we designed 
primer sets for RT-PCR reactions to detect the mRNA levels of CXCR 1, 2, 3, 4 and 
CXCL 1, 2, 4, 5, 9, 10, 11, 12. (supplemental data S1 and S2). In addition, we performed 
gene expression profiling of MTLn3 cells on ABI rat full genome microarrays to evaluate 
the relative expression of these CXC-receptors and ligands (Table 1). In MTLn3 cells, 
based on both microarray analysis and RT-PCR, the expression of CXCR3 was most 
abundant. CXCR1 and CXCR4 were also present, but less abundant; CXCR2 was absent. 
For the CXC-receptor ligands, CXCL1, 2, and 5 were most abundant; they bind to 
CXCR2 which is absent in MTLn3 cells, excluding autocrine activation. The CXCR3 
ligands CXCL9, 10 and 11 were all present in MTLn3 cells, possibly mediating an 
autocrine activation of CXCR3. This is not the truth for CXCR4, since no CXCL12 
mRNA could be detected either on the microarray or by RT-PCR.  Given the high 
abundance of CXCR3 as well as the corresponding ligands CXCL9, 10 and 11, we 




decided to further study this interaction in MTLn3 cell migration and invasion. 
 
Table: mRNA expression of CXC chemokines receptors and ligands in MTLn3 cells.  
 
CXC chemokine receptors and 
ligands ABI microarray
1 RT-PCR2 
CXCR1 1.2 ±       0.4 +++ 
CXCR2 0.6 ±       0.1 - 
CXCR3 22.0 ±       2.4 ++++ 
CXCR4 5.6 ±       1.2 +++ 
CXCL1 1542.4 ±   325.0 ++++ 
CXCL2 159.7 ±     18.4 ++++ 
CXCL 4 1.1 ±       0.3 + 
CXCL 5 62.8 ±     31.5 ++++ 
CXCL7 0.7 ±       0.1 - 
CXCL9 2.3 ±       1.5 + 
CXCL10 102.5 ±     10.0 ++++ 
CXCL11 7.1 ±       1.5 +++ 
CXCL12 0.5 ±       0.2 - 
beta-actin 6570.0 ± 1546.3 +++ 
GAPDH 6772.8 ±   772.6 ++++ 
 
1 mRNA expression was determined by ABI microarrays. Shown are data of three independent 
experiments .Values shown are mean intensities of the indicated probe sets (mean ± SD, n=3).  
2 mRNA expression was validated using RT-PCR. Markers indicate the relative band intensities (see 
supplementary data S1 and S2) 
 
CXCL10 and CXCL11 Induce Ca2+ Mobilization in MTLn3 Cells- Next we determined 
the functionality of the CXCR3 receptor. Typical chemokine receptor activation triggers 
the release of intracellular Ca2+ from intracellular free calcium stores (26). Of the three 
CXCR3 ligands that were present in MTLn3 cells, the affinity for CXCR3 is 
CXCL11>CXCL10>>CXCL9 (27). Also CXCL11 has higher potency and efficacy in 
vitro when compared to CXCL9 and 10 in activated T cells or cells transfected with 
CXCR3 (15). Based on the relative expression levels of these CXCR3 ligands in MTLn3 
cells (see above), we decided to use CXCL10 and 11 to activate CXCR3. This effect was 
compared to the activation of CXCR4 by CXCL12. The calcium-ionophore ionomycin 
was used as a positive control. Ca2+ mobilization was measured by loading MTLn3 cells 
with Ca2+ indicator Fluo-4, followed by real time cell population-based analysis of the 
Fluo-4 intensity by flow cytometry. A clear transient increase in fluorescence intensity 
was observed by CXCL11 (100 ng/ml) within 1 min (Fig. 1A). Ionomycin (20 µM) 
caused a sustained increase in the Fluo-4 intensity. An overall slight decrease of intensity 
for both chemokine, ionomycin and control situation was likely due to leakage of Fluo-4 
from cells. We calculated the average population intensity per 15 second time frame and 
plotted this as relative Fluo-4 intensity (Fig. 1B). Both CXCL10 and CXCL11 induced a 
transient Ca2+ increase which was slightly lower than that observed in the activation of 
CXCR4 by CXCL12 (100 ng/ml). These data demonstrate that MTLn3 cells contain 
functional CXCR3 and CXCR4 receptors.  





 Figure 1: Chemokine 
receptors CXCR3 and 
CXCR4 are functional in 
MTLn3 cells. Intracellular 
free Ca2+ was determined by 
Fluo-4 fluorescence intensity 
analysis using flow cytometry 
as described in Materials and 
Methods section. A. 
Representative dotplots for 
Fluo-4 intensity vs. time (sec) 
are shown the treatments with 
CXCL11 (100 ng/ml), 
ionomycin (20 µM) and 
control condition respectively. 
B. Relative average Fluo-4 
intensities of the cell 
population were calculated for 
15 sec time intervals after 
stimulation with CXCL10, 
CXCL11 and CXCL12 (100 
ng/ml, each) or ionomycin (red 
line) and control conditions 
(green line). Data shown are 
results from 3 independent 
experiments (mean ± SD; n=3). 
 
 
CXCR3 Activation Causes MTLn3 Cell Migration- Activation of chemokine receptors 
can induce actin cytoskeletal rearrangement thereby facilitating cell morphology and 
motility. To investigate the effect of CXCR3 ligands on the behavior of MTLn3 cells, we 
performed live cell imaging of GFP-labeled MTLn3 cells to study the migration behavior 
of the cells. Cells were serum starved for 4 hrs followed by addition of either CXCL10 or 
CXCL11. Again we included CXCL12 for comparison, but also growth factor EGF as 
well as normal fetal bovine serum (FBS). Cell motility was visualized for 1 hr, followed 
by cell tracking analysis to calculate both cell speed and cell dynamics. CXCL11 induced 
a clear increase in the random MTLn3 cell migration, which was comparable to that 
observed with EGF (Fig. 2A and C). CXCL10 also stimulated random cell migration. 
Despite the fact that CXCL12 induced a drastic Ca2+ mobilization (see above), it did not 
induce random cell migration (Fig. 2C). Since relative absence of cell speed does not 
necessarily mean that cells remain fully static, we also analyzed the relative movement of 
cells based on their relocation between two time points which was calculated as the 
percentage of average cell surface change to total cell surface area (see Fig. 2B). 
Apparently, control cells are dynamic (i.e. 20 % surface change between time points; Fig. 
2B), but hardly migrate away (Fig. 2A). In contrast, cells exposed to either CXCL11 or 
EGF were more dynamic (i.e. ~30 % average surface change; Fig. 2D) and also had 
longer migration trajectories (Fig. 2A). 
   




Figure 2: CXCR3 
activation induces 
increased random cell 
migration. GFP-MTLn3 
cells were serum starved for 
2 hrs followed by live cell 
imaging of cell migration in 
the absence (control) or 
presence of the indicated 
chemokines (100 ng/ml), 
EGF (10 nM) or 5 % FBS. A. 
Images were analyzed by 
ImagePro-Plus software to 
determine individual cell 
tracks, or B. Relative 
dynamics between different 
time points; green indicates 
the overlapping area between 
two sequential frames, 
yellow indicates the cell area 
in previous frame and blue in 
the present frame. C. 
Average cell speed was 
calculated per hour. D. The 
ratio of surface area change 
to total area was calculated as the average over the 1 hr period. Results shown are from at least 3 
independent experiments (mean ± SD; n=3).  
 
 
Realizing that chemokines presented on the endothelial cell surface typically trigger 
integrin affinity and mediate leukocyte arrest on endothelial wall, we presumed that 
chemokines in tumor cells would also enhance integrin-mediated adherence. Therefore, 
we also examined the capability of CXCR3 ligands to promote cell adhesion and 
spreading on collagen. We discriminated cell phenotypes as adherent (but still rounded), 
half-spread, fully spreading and elongated in shape. CXCL11, and to a lesser extent 
CXCL10, stimulated the spreading of MTLn3 cells on collagen (Fig. 3A). Cells treated 
with EGF and FBS attached and spread even faster. Interestingly, under these conditions 
both EGF and FBS stimulated the rapid formation of focal adhesions as determined by 
staining for phosphorylated-Tyr118-paxillin. This was not observed for CXCL10, 
CXCL11 or CXCL12 (data not shown) indicating differential downstream signaling from 



















Figure 3: CXCL11 and CXCL12 facilitate 
cell adhesion and directional migration. 
Serum starved MTLn3 cells were detached and 
reseeded on collagen coated coverslips in 
starvation medium in the absence or presence 
of chemokines (100 ng/ml), EGF (10 nM) or 
5 % FBS. Cells were fixed and stained with 
Hoechst, pY118-paxillin and F-actin. A. Cell 
phenotype was classified as attached (left top), 
half spreading (left bottom), fully spreading 
(right top) or elongated (right bottom). B. To 
determine directional invasion, 50,000 serum 
starved cells were seeded on collagen-coated 
membrane with 8 μm pore diameter and were 
attracted to lower chamber containing indicated 
chemoattractant at similar concentration as in 
panel A. After 8 hrs the relative numbers of 
invading cells were quantified as indicated in 
Materials and Methods section. Results shown 




Migration and invasion into extracellular surroundings are major features of the 
metastatic capability of tumor cells. This is typically stimulated by chemotactic activities 
of growth factors and chemokines. To investigate the role of CXCR3 and CXCR4 in this 
process, we evaluated the ability of serum-starved MTLn3 cells to invade through 
collagen coated microporous membranes towards a concentration gradient of either 
CXCL10 or CXCL11; again both CXCL12 and EGF were used for comparison. CXCL11 
and CXCL12 facilitated cell directional migration by 64±21% and 87±22% compared to 
control (starvation medium only), while CXCL10 was not effective at all. Both EGF and 
FBS showed stronger potential (315 ± 24 % and 283 ± 49% respectively; Fig 3B). The 
combined data indicate that the activation of CXCR3 can induce cell adhesion, migration 












Figure 4: Chemokines trigger 
cell directional migration via 
ERK and AKT pathways. A. 
Serum starved MTLn3 cells in 6 
cm dishes were exposed to 
CXCL10, CXCL11, CXCL12 
and EGF for 0, 5, 10, 20 or 60 
mins followed by sample 
collection for western blotting. 
Blots were stained for p-ERK, 
ERK, p-AKT and AKT. B. To 
determine the role of the 
MEK/ERK and PI3K/AKT 
pathway in MTLn3 cell 
directional migration, cells were 
exposed to either CXCL11 or 
EGF; U0126 and LY294002 
were added to bottom chambers 
prior to the addition of cells in 
the chambers. C. The effects of 
U0126 and LY294002 on ERK 
and AKT activation by CXCL11 
and EGF were determined by 
western blotting similarly as in 
panel A. Results shown are from 
3 independent experiments 
(mean ± SD). 
 
 
Activation of ERK and AKT Pathways Drives CXCL11-Induced Cell Migration- Next 
we investigated the signaling pathways that mediate CXCL11-induced cell migration. 
Several signaling pathways are downstream of chemokine-induced receptor activation, 
including the phosphoinositide-3 kinase (PI3K)/AKT pathway and the Ras/Raf/ERK 
pathway (28). Therefore, we first examined the activation of these pathways in more 
detail. Serum-starved MTLn3 cells were exposed to CXCL10, CXCL11, CXCL12 or 
EGF for various time periods, followed by the analysis of ERK and AKT activation by 
western blotting. CXCL11 and CXCL12 caused a transient and strong activation of ERK 
and AKT after 10 min of exposure, which reduced thereafter again. The activation of 
ERK and AKT by CXCL10 was less strong, while EGF induced a more sustained 
activation of ERK and AKT which lasted up till 60 min (Fig. 4A). Next we determined 
whether these pathways were involved in MTLn3 cell migration. For this purpose we 
used U0126, a selective inhibitor for MEK1/2, upstream of ERK, and LY294002, which 
inhibits PI3K, upstream of AKT. The transwell migration assay was performed to 
determine the role of both pathways in the directional migration/invasion. Both U0126 
and LY294002 inhibited MTLn3 cell migration through the transwell membranes induced 
by CXCL11 and EGF (Fig. 4B). Importantly, both U0126 and LY294002 also inhibited 
the activation of ERK and AKT induced by either CXCL11 or EGF (Fig. 4C). These data 
indicate a role for both ERK and AKT activity in CXCL11-induced cell migration of 
MTLn3 cells. 
  















Figure 5: CXCR3 knock down impairs cell migration 
into an artificial wound. 70% confluent MTLn3 cells 
were transfected with 50 nM siRNA (Dharmacon 
SMARTpool mix) against CXCR3 or control siRNA. A. 
mRNA was collected 48 hr post-transfection and CXCR3 
mRNA expression was determined by qRT-PCR as 
described in Materials and Methods. B. 48 hr after 
transfection, an artificial wound was generated and cell 
migration into the wound was monitored by live cell 
imaging for 16 hr using DIC microscopy on a Nikon 
TE2000-E PFS microscope. Top panels are individual 
frames from representative movies (see also supplemental movie M1 and M2 for control siRNA and 
siCXCR3, respectively). Cell velocity was defined as wound edge migration per hour (μm/hr). Data shown 
are results from 3 independent experiments (mean ± SD; n=3). 
 
 
CXCR3 is Essential for MTLn3 Cell Migration- The above data indicate that exogenous 
CXCL11 can drive MTLn3 cell migration. Given the fact that MTLn3 cells express 
CXCR3 as well as CXCL9, CXCL10 and CXCL11, we suggest that a possible autocrine 
loop is essential in normal cell migration. To further investigate it, we modulated the 
expression of CXCR3 in MTLn3 cells using siRNA-mediated knock down (KD) with 
Dharmacon SMARTpool siRNA mixes. Non-targeting siRNA SMARTpool mixes were 
used as control. 48 hrs after transfection, CXCR3 mRNA expression was reduced by 
more than 80% as determined by qRT-PCR (Fig. 5A), without affecting cell viability. 
Next we performed live cell imaging of the wound healing assay using differential 
interference contrast (DIC) microscopy. This allowed us not only to determine the 
efficiency of cell migration, but also to monitor the behavior of individual cells (see 
supplemental movies M1 and M2). CXCR3 KD MTLn3 cells were less effective in 
closing the artificial wound and had a slower velocity of 7.1 μm/hr compared to 16.4 
μm/hr for sicontrol cells (Fig. 5B). Interestingly, while sicontrol cells were highly motile 
and showed large protrusions when entering the wound, siCXCR3 cells were more static 
and did not show much protrusion formation. Nevertheless, mitotic events were observed 
under both conditions indicating that CXCR3 KD does not affect cell viability (see 
supplemental movies M1 and M2). These data suggest that CXCR3 is essential for cell 
migration of MTLn3 cells, most likely through autocrine signaling by either CXCL10 or 
CXCL11. 






In the present manuscript we investigated the expression of CXC-receptors and ligands in 
the highly metastatic breast cancer cells MTLn3 and determined the role of the prime 
CXC-receptors in tumor cell migration and invasion. Our data indicate that, firstly 
MTLn3 breast tumor cells have abundant expression of CXCR3 in association with 
expression of corresponding ligands CXCL10 and CXCL11. Secondly, the CXCR3 
receptor in MTLn3 is functional and responds strongly to CXCL11 thereby inducing 
activation of Ca2+ mobilization as well as activation of ERK and AKT. Thirdly, the 
activation of CXCR3 drives cell migration and invasion which is dependent on 
Ras/MEK/ERK and PI3K/AKT signaling pathways. MTLn3 cell migration is dependent 
on CXCR3 since knock down of CXCR3 prevents spontaneous cell migration into a 
wound which is associated with reduced cell protrusion formation. Together, these data 
are suggestive of an autocrine CXCR3 activation loop in MTLn3 cells, whereby 
expression of CXCL10 and CXCL11 induces cell migration and invasion processes. 
These data suggest that targeting CXCR3 in breast cancer can be a suitable way to inhibit 
local tumor cell invasive properties thereby preventing intravasation and tumor cell 
dissemination. 
 
Chemokines have the ability to activate second messenger G- protein, the downstream 
activation of phospholipase Cβ (PLCβ), PI3K/AKT and Ras/MEK/ERK pathways as well 
as c-Src-related non-receptor tyrosine kinases (29). Indeed, activation of CXCR3 
receptors in MTLn3 cells activates Ca2+ mobilization, which is most likely mediated by 
PLC activation, as well as activation of the PI3/AKT and Ras/MEK/ERK pathways. 
CXCL12 can also induce the phosphorylation of the focal adhesion-associated kinase 
FAK at Y397 and Y577 and other focal adhesion-associated adapter proteins such as 
paxillin and Crk (13). These phosphorylation events are likely to modulate the focal 
adhesion dynamics in migrating cells by CXCL12. However, we did not observe a 
significant change in the phosphorylation of pY397-FAK and pY118-paxillin after either 
CXCL11 or CXCL12 treatment (data not shown). Chemotaxis and invasion of tumor cells 
involve not only cytoskeleton reorganization but also the secretion of various hydrolytic 
enzymes like matrix metalloproteinase (MMPs). Using gelatin zymography, we detected 
the activity of MMP2 and MMP9 in MTLn3 serum-free conditioned culture medium but 
did not observe a significant increase in their activity after chemokine addition (data not 
shown). 
 
So far there are three studies by Fulton and co-workers on the role of CXCR3 in breast 
cancer progression (18, 30, 31). High CXCR3 expression was associated with poorer 
overall survival in a clinical study in 75 women diagnosed with early-stage breast cancer. 
The inhibition of CXCR3 by the AMG487 compound or shRNA gene silencing reduced 
spontaneous lung metastasis formation (18, 30). Intriguingly, overexpression of the 
CXCR3 ligand CXCL9 in the same cell line reduced primary tumor growth and almost 
fully inhibited lung metastasis formation. This was associated with enhanced T-cell and 




Natural Killer cell infiltration in tumor tissue (31). Apparently, there is a tight balance 
between the autocrine activation of tumor cell CXCR3 by secreted CXCR3 ligands and 
the chemoattractant activity of these ligands to attract immune cells. Too much secretion 
of CXCR3 ligands may activate the immune response, and inhibiting this secretion may 
not be beneficial to ultimate disease outcome. So far it remains unclear whether CXCL10 
and CXCL11 overexpression have a similar effect as CXCL9 and whether this effect is 
also observed in other breast tumor models. Moreover, it is unclear at which expression 
level of CXCR3 ligands, the breast tumor biology will tip from autocrine activation of 
tumor cells to promote migration and invasion towards enhanced T-cell infiltration to 
compromise tumor growth. In colon cancer and melanoma, high CXCR3 expression is 
associated with reduced patient survival (32, 33), while overexpression of CXCR3 
promotes spontaneous metastases of colon carcinoma cells to lymph nodes (32) and 
knock down of CXCR3 with antisense reduces metastasis to lymph node of B16F10 
melanoma cells (23). Further studies are required to determine the role of CXCR3 in 
breast cancer metastasis formation to lymph node, lung and bone, and whether autocrine 
activation is an essential component of the metastasis formation. Moreover, the relative 
importance of CXCL9, CXCL10 or CXCL11 expression in the metastatic process of 
breast tumor cells as well as other tumor cells including colon and melanoma, needs to be 
determined. Thus, increased levels of these ligands in the primary tumor will promote the 
migratory behavior of tumor cells or promote tumor cell killing by T- and NK cells. 
Alternatively, high levels of these CXCR3 ligands in the dissemination target organs, 
including lymph node, lung, bone and liver, could be crucial to facilitate homing and 
induce adhesion, migration and invasion of the tumor cells, ultimately resulting in local 
metastasis formation.    
 
In this study we have compared the potentials of CXCR3 activation by CXCL11 with 
CXCR4 activation by CXCL12 and EGFR activation by EGF. CXCR4 activation, similar 
to CXCR3, was effective in inducing Ca2+ mobilization, ERK and AKT activation and 
chemoattractant-induced invasion. However, spontaneous cell migration was less affected. 
CXCL12 was not expressed by MTLn3 cells, excluding possible autocrine activation in 
the primary tumor. Indeed, accumulating evidence indicates that local high level of 
CXCL12 drives metastasis formation of breast tumor cells to lung, which is dependent on 
the functionality of CXCR4 receptors. Thus, knock down of CXCR4 with siRNA (10, 11) 
or pharmacological inhibition of CXCR4 impaired breast tumor cell invasion and delayed 
the formation and metastases of breast cancer (1). Given the combined expression of 
CXCR3 and CXCR4 in our breast cancer cells, we could anticipate that these receptors 
synergistically affect tumor metastasis formation by autocrine activation of CXCR3 in the 
local primary tumor microenvironment and by activation of both CXCR3 and CXCR4 at 
distant organs such as lung. Indeed in colon cancer, both CXCR3 and CXCR4 positive 
primary tumors have a worse disease progression (22). Therefore, pharmacological 
intervention of both CXCR3 and CXCR4 may be beneficial in anticancer treatment 
regimens. Here it is noteworthy that the effects of CXCR3 and CXCR4 activation in 
MTLn3 cells were in all respects not as strong as observed from EGFR stimulation. Also, 




in vivo the EGFR signaling is essential for metastasis formation of MTLn3 cells (34). 
Therefore, on the long term the intervention of both CXCR3 and/or CXCR4 together with 
EGFR antagonists may be most effective in preventing metastasis formation. 
 
In conclusion, our current data indicate an important role of CXCR3 in controlling cell 
migration and invasion properties of breast tumor cells. Future work will focus on the role 
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Supplemental data S1: The primer sets used in RT-PCR for mRNA expression of chemokines and 
chemokine receptors. 
 
Name Genebank No. Forward primer  Reverse primer  product
CXCR1 U71089 5'  CTGTCTCTGCCTTTTGCCA  3' 5'  GCTTCACCCAGGACCTCAT  3' 83bp













5'  CGGTACTTGTCTGTCATGCTCC  
3' 66bp
CXCR4* U90610 5'  CGCCCTCCTCCTGACTATCC  3' 5'  ACAGATGTACCTGCCGTCCC  3' 70bp
CXCL1 NM_030845 5'  TAAACCAGCTCCAGCACTCC  3' 
5'  GCGGCATCACCTTCAAACTCT  
3' 212bp
CXCL2 NM_053647 5'  GGAAGCCTGGATCGTACCTG  3' 5'  CCCTCTGACTGCGTCTGTTT  3' 369bp
CXCL4 NM_001007729 5'  GCTGCTTCTTCTGGGTCTGC  3' 5'  AGGCTGGTGATGCGTTTGAG  3' 141bp
CXCL5 U90448 5'  TGGCATTTCTGCTGCTGTTC  3' 5'  AAGTGCATTCCGCTTTGTTT  3' 299bp
CXCL9 NM_145672 5'  ATTCCTCATGGGCATCATCTT  3' 5'  TCTCCGTTCTTCAGTGTAGCG  3' 191kb
CXCL10 BC058444 5'  AGCCAACCTTCCAGAAGCAC  3' 5'  TGCGGACAGGATAGACTTGC  3' 197bp
CXCL11 NM_182952 5'  GCCCTGCAAACATTTCTACGC 3' 5'  TCTTTAGCCCTTTAGACTGCC 3' 103bp
CXCL12 BC078737 5'  CCCTGCCGATTCTTTGAGA  3' 5'  CCTTTGGGCTGTTGTGCTT  3' 197bp













5'  TGACCGAGCGTGGCTACA 3' 71bp
 





Supplemental date S2: PCR products of CXC chemokines and chemokine receptors. The numbers below 
gels are raw data from microarray. 
 
 
Supplemental movies M1 and M2: 70% confluent MTLn3 cells were transfected with 50 nM siRNA 
(Dharmacon SMARTpool mix) against CXCR3 or control siRNA. 48 hrs after transfection, an artificial 
wound was generated and cell migration into the wound was monitored by live cell migration imaging for 
16 hrs using DIC microscopy on a Nikon TE2000-E PFS microscope. Movie M1 is a representative movie 
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Focal adhesion kinase (FAK) is essential for tumor cell survival, migration and 
metastasis formation. The exact role and mechanism of FAK in chemoresistance of 
solid and metastatic tumors remain unclear. Conditional expression of focal 
adhesion kinase-related non-kinase (FRNK) in established MTLn3 mammary fat 
pad tumors prior to doxorubicin treatment reduced tumor progression by more 
than eighty percent. Moreover, in experimental metastasis model doxorubicin 
treatment combined with FRNK significantly reduced lung metastasis outgrowth by 
almost seventy percent without affecting metastasis size. Neither FRNK nor 
doxorubicin alone affected either fat pad tumor or lung metastasis growth compared 
to control conditions. Genome-wide gene expression profiling identified Fra-1, an 
activator protein (AP)-1 family member, as an essential mediator in this process. 
Loss of FAK suppressed Fra-1 expression, while loss of Fra-1 reduced cell adhesion 
and migration in association with increased stable focal adhesion formation. Finally, 
Fra-1 knock down sensitized MTLn3 cells towards doxorubicin, whereas Fra-1 
overexpression suppressed cell death when FAK was absent. A model is proposed 
whereby FAK-mediated signaling is linked to Fra-1 expression and cell survival 
thereby mediating drug resistance.  
 
INTRODUCTION 
Chemoresistance of distant tumor metastases is a major problem in the treatment of 
cancer. This is mainly due to increased and unsuppressed proliferation and survival 
signaling in cancer cells. Increased expression of the non-receptor tyrosine kinase focal 
adhesion kinase (FAK) is implicated in various tumors, including breast tumors (1, 2). 
FAK expression is positively associated with breast cancer development and poor disease 
prognosis (3, 4). The accumulative data indicate a critical role of FAK in tumor cell 
migration, invasion, proliferation and survival processes enhancing the metastatic 
capacity of tumor cells and possibly resulting in a resistant phenotype (5-7).  
 
Once cells adhere to ECM, tyrosine phosphorylation at multiple residue sites of FAK and 
consequent protein interaction signaling result in activation of survival signaling pathway 
(8, 9). Inhibition of FAK by siRNA or expression of FAK deletion mutants, including 
FRNK or FAT, induces the onset of apoptosis itself and/or sensitization to anticancer 
drug treatment in a variety of cancer cell types in vitro including breast cancer cells (10-
12). Furthermore, systemic RNA interference-based FAK knock down inhibits ovarian 
tumor growth and sensitivity towards docetaxel and cisplatin (13-16). However, this has 
not been investigated in breast cancer. Given the non-directed targeting of the siRNAs, it 
remains unclear whether this is related to direct effects on tumor, stromal or vascular 
endothelial cells. So far a direct relationship between specific inhibition of FAK function 
in tumor cells in vivo and sensitization towards anticancer drugs needs to be established. 
Besides, it remains unclear whether such a role of FAK would be similar in primary 
tumors as well as in distant metastases.  





Fra-1 (Fos-like antigen 1, also named Fosl-1), is a component of activator protein (AP)-1 
transcription factor. The AP-1 transcription factor complex comprises of Fos, Jun and 
ATF family members (17). It plays an important role in regulating tumor cell proliferation, 
survival, migration and invasion through modulation of genes expression, for example 
cyclin dependent kinases, cyclins, metalloproteinases and adhesion molecules. Recent 
studies show that Fra-1 expression is associated with breast cancer (18-20) regarding 
lower or no expression in ER-positive luminal-like breast cancer cells and higher 
expression in migratory mesenchymal-like breast cancer cells (19, 20). Overexpression of 
Fra-1 in epithelial-like breast cancer cells promotes cell proliferation (19). Moreover, Fra-
1 is crucial for the migratory and invasive behavior of different cancer cells (19, 21). This 
in colon carcinoma cells is related to the suppression of beta1-integrin activation, thereby 
preventing the initiation of RhoA/ROCK-dependent contractility and focal adhesion 
stabilization (21). In addition, Fra-1 expression is linked to the control of cell survival in 
different cell types (22, 23). So far the relationship between FAK and Fra-1 signaling in 
susceptibility towards anticancer drugs remains unclear.  
 
To investigate sensitization towards anticancer drugs as a consequence of selective tumor 
cell-related FAK inhibition in the in vivo situation, conditional inhibition of FAK in 
tumor cells is required. The rat mammary adenocarcinoma MTLn3 cell line is a good 
model to study the role of FAK in drug sensitivity, since MTLn3 cells are susceptible 
towards a range of anticancer reagents in vitro including cisplatin, etoposide and 
doxorubicin (24, 25), but resistant in vivo ((26) and the present work). Importantly, we 
have recently established a conditional MTLn3 stable cell line, MTLn3-tetFRNK cells 
which allows to conditionally express FRNK in a doxycylin-dependent manner in vivo (7). 
This strategy can conditionally modulate FAK function at any given moment without 
affecting the initial tumor formation and metastasis formation.  
 
Our data indicate for the first time that conditional expression of FRNK in metastatic 
MTLn3 breast tumor cells sensitizes both primary tumors in the mammary fat pad and 
experimental lung metastases towards doxorubicin treatment. Gene expression profiling 
of MTLn3-tetFRNK cells indentified Fra-1 as a target in FAK-mediated signaling. While 
RNAi-mediated FAK knock down suppressed Fra-1 expression, knock down of Fra-1 did 
not affect FAK expression but sensitized cells to doxorubicin-induced apoptosis. 
Moreover, overexpression of Fra-1 inhibited the sensitization to doxorubicin when FAK 
was suppressed. Our data support a model whereby FAK signaling drives Fra-1 
expression and modulates the sensitivity towards anticancer drugs.  
 
EXPERIMENTAL PROCEDURES  
Chemicals and antibodies- Alpha modified minimal essential medium without 
ribonucleosides and deoxyribonucleosides (α-MEM), fetal bovine serum (FBS), 
phosphate buffered saline (PBS), trypsin, Lipofectamine-Plus and geneticin (G418 
sulphate) were from Life Technologies. Doxorubicin (doxo) and doxycycline were from 




Sigma. Hoechst 33258 and the Alexa-488 protein labeling kit were from Molecular 
Probes. Hygromycin was from Roche. Primary antibodies were anti-HA (clone 3F10) and 
anti-HA (clone 12CA5) (Roche), anti-FAK (Upstate, Lake Placid, NY), rabbit anti-Fra-1 
antibody (Santa Cruz Biotechnology), mouse anti-myc (Roche), rabbit anti-p-ERK (Cell 
Signalling), mouse anti-paxillin (Transduction), rabbit anti-paxillin-PY118 and anti-FAK-
PY397(Biosource). All other chemicals were of analytic grade. 
 
Cell culture, stable cell lines and transient knock down- MTLn3 rat mammary 
adenocarcinoma cells and MTLn3-tetFRNK cells were cultured as previously described 
(7). To establish retroviral transduced stable cell lines, the construct p-BABE-puro-Fra-1 
tagged with 8x myc (27) was used. p-BABE-puro empty vector was used as a control. 
MTLn3 cells were infected by retrovirus in the presence of polybrene (10 μg/ml) 
overnight. Stable transfectants were obtained by selection in 2 μg/ml puromycin for 1 
week. Cells were transfected with smartpool Dharmacon siRNA mixes against FAK or 
Fra-1 (50 nM) using Dharmafect reagent 2. siRNA against GFP was a negative control. 
All experiments were performed 48-72 hr post-transfection.  
 
In vitro doxorubicin exposure and cytotoxicity assays- For cell death analysis, after 24 hr 
of pre-incubation with doxycycline to express HA-FRNK, cells were exposed to 2 μM 
doxorubicin in α-MEM for 8hrs. Cell death was determined by staining the pooled 
attached and detached cells for Annexin-V-Alexa488/Propidium Iodide (AV/PI) as 
previously described (24). For apoptosis analysis, cells were exposed to 2 μM 
doxorubicin (or DMSO as a control) for 1hr in Hanks’ balanced salt solution/HEPES, 
followed by recovery of the cells in α-MEM containing 2.5% (v/v) FBS for an additional 
7 hrs. Apoptosis was determined with cell cycle analysis as previously described (28) on 
FACS-Calibur (BD Biosciences) and expressed as the percentage of sub (G0) positive 
cells. For soft agar colony growth assays, MTLn3-tetFRNK cells were cultured for 24 hrs 
in the absence or presence of doxycycline and exposed for 1 hr in Hank’s/HEPES buffer 
with different concentrations of doxorubicin (0, 0.01, 0.05, 0.1, 0.5, 1 and 5 μM). Cells 
were recovered in α-MEM (2.5% (v/v) FBS). After 24 hr, 12,500 viable cells 
(resuspended in 1 mL α-MEM containing 0.33% (w/v) agar, 5% (v/v) FBS and PSA) 
were plated on top of a bottom agar layer (2.5 mL of α-MEM containing 0.66 % agar, 5% 
(v/v) FBS and PSA). After two weeks cells were stained with MTT and the number of 
colonies was quantitated with Image J as previously described (29).  
 
In vivo tumor growth, metastasis formation and doxorubicin treatment- Primary tumors 
and experimental metastases were induced as described previously (5). Briefly, 1x105 
viable cells in 0.2 mL PBS were injected into the lateral tail vein or 1x106 cells in 0.5 mL 
PBS were injected into the fat pad of female Fischer 344 rats. Nine days after injection, 
doxycycline (400 mg/mL in 2.5% (w/v) sucrose) was added to the drinking water; control 
animals received 1.5 % (w/v) sucrose in their drinking water which resulted in equal 
drinking volumes. Three days later animals were treated either with 6 mg/kg doxorubicin 
or with PBS (intraperitoneal injection). After 33 (primary tumor) or 28 days 




(experimental lung metastases), animals were anesthetized with pentobarbital and the 
primary tumor or the lungs were excised. The weight was determined and tumors and 
lungs were fixated (5). After ink injection in the lungs, the number of lung surface 
metastases was counted. Lung metastasis size was determined by classification of the 
metastases size in HE-stained lung sections in five groups: ranging from 1 (small) to 5 
(large).  
 
Gene expression profiling- Cells were pretreated with doxycycline for 24 hr to induce 
FRNK expression. Total RNA was isolated with the Qiagen RNAeasy mini kit and 
digested with RNase-free DNase (Sigma). Eluted RNA was controlled by lab-on-a-chip 
analysis. mRNA was converted to cDNA and subsequently to digoxigenin-labeled cRNA 
with a NanoAmpTM RT-IVT labeling kit (Applied Biosystems). Digoxigenin-labeled 
cRNA samples were hybridized to the microarrays (Applied Biosystems Rat Genome 
Survey Microarrays) and detected with a chemiluminescent detection kit (Applied 
Biosystems). After conversion of the raw signals of the microarrays to expression values 
by Expression Array System Analyzer Software Version 1.1.1, a filtering step based on a 
signal-to-noise ration of >3 was applied. Out of all 26,848 genes on the array, 13,206 
(49.1%) passed this step and were regarded as expressed in the MTLn3 cells. The probe-
to-gene annotation release version 12_05 was used for gene annotation. Subsequently, a 
median-normalization step was performed by computing a gene-by-gene difference 
between individual array and the reference array (the array whose overall log-intensity is 
the median of all array overall log-intensities), and subtracting the median difference from 
the log-intensities on that array, so that the gene-by-gene difference between the 
normalized array and the reference array is 0. BRB-array software tools 
(http://linus.nci.nih.gov/BRB-ArrayTools.html) were applied to identify genes that were 
differentially expressed among classes by using a multivariate permutation test and 
random variance F-statistics. Global-test gene ontology (GO) analyses with GoMiner tool 
(http://discover.nci.nih.gov/gominer/) were carried out to analysis group genes of which 
the expressions were differentially regulated among different treatments.  
 
Quantitative RT-PCR- cDNA was synthesized from RNA using oligo(dT)12-18 primers 
and Superscrip reverse transcriptase (Invitrogen Life Technologies). The sequence-
specific primer pairs were separately designed by online primer design tools 
(https://www.genscript.com/ssl-bin/app/primer and http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and ordered from Biolegio (Nijmegen). Primer sets were: 
Fra-1(NM_012953), left: 5’-AGAGCTGCAGAAGCAGAAGG-3’, right: 5’-
CAAGTACGGGTCCTGGAGAA-3’, length: 182bp. JunB (NM_021836), left: 5’-
ATCACGACGACTCATACGCA-3’, right: 5’-CGATAAGGATCTGCCAGGTT-3’ 
length: 248bp. β-actin ((NM-031144), left: 5’-CAGCTTCTCTTTAATGTCACGCA -3’, 
right: 5’- TGACCGAGCGTGGCTACA- 3’, length: 71bp ) was used as internal standard. 
Quantitative RT-PCR was performed on ABI7700 system with the SYBR Green PCR 
Master Mix kit (Applied Biosystem).  
 




Fluorescence recovery after photobleaching (FRAP) and random migration- To 
determine cytoplasmic mobility of GFP-paxillin, a 1.8 μm-wide strip spanning 
approximately the width of the cytoplasm (without any focal adhesion) was 
photobleached by a short bleach pulse (100 ms) at 100% laser intensity (120 to 160 μW; 
argon laser at 488 nm). Fluorescence recovery within the strip was monitored using 100- 
ms intervals and low laser intensity (450 to 750 nW) to avoid photobleaching by the 
probe beam. Approximately 10 cells were averaged to generate one FRAP curve in a 
single experiment. To determine the turn over of individual focal adhesions, 
photobleaching was applied to a small area covering a single focal adhesion for 1 s with 
laser intensity of 50 μW. Redistribution of fluorescence was monitored with 100 ms time 
intervals at 7.5 μW starting directly after the bleach pulse. Approximately 20 focal 
adhesions (each in distinct cells) were averaged to generate one FRAP curve in a single 
experiment. All measurements were performed at 37 °C using a heating stage with 
temperature control and the experiments were performed on at least three different days. 
Images were analyzed with Image software Zeiss. The relative fluorescence intensity of 
individual focal adhesion was calculated at each time interval as follows: Irel(t) = (FA t/ 
FA0), where FA t is the intensity of the focal adhesion at time point t after bleaching, FA0 
is the average intensity of the focal adhesion before bleaching. The fluorescent curves 
were analyzed with non-linear regression analysis with GraphPad Prism 5 (34).  
 
For live cell random migration, GFP-MTLn3 cells were knocked down with siRNA 
against Fra-1 for 24 hrs and seeded on collagen-coated glass bottom plates. Live cell 
imaging were captured on the second day in a climate control chamber. Cell random 
migration were recorded on a Nikon TIRF microscope system (Eclipse TE2000-E, Nikon 
with automated stage) with framing every 5 minutes for 4 hrs using NIS-elements AR 
software (Nikon).  
 
Immunoblotting and immunofluorescence- Doxorubicin-exposed cells or frozen lung/ 
tumor tissue were prepared and separated by 7.5% SDS-PAGE and transferred to PVDF 
membranes (Millipore) as described before (5). Blots were blocked and probed with 
primary antibody (overnight, 4°C) followed by incubation with secondary HRP-coupled 
antibody and visualized with ECLplus reagent (Amersham Biosciences, Uppsala, Sweden) 
by scanning on a Typhoon imager 9400 (Amersham Biosciences). Immunostaining of 
tissue sections and cells was done as described before (5) and visualized using a Bio-Rad 
Radiance 2100 MP confocal laser scanning system equipped with a Nikon Eclipse 
TE2000-U inverted fluorescence microscope and a 60X Nikon objective.  
 
Statistical analysis-Student’s t test was used to determine significant differences between 
two means (p<0.05).  
 





HA-FRNK Expression Sensitizes MTLn3 Breast Tumors to Doxorubicin. To test 
whether inhibition of FAK sensitizes MTLn3 cells towards doxorubicin treatment under 
in vivo conditions, two models were used: a primary tumor model, in which the tumor 
cells were injected into the fat pad of the rats and an experimental metastasis model, in 
which the cells were injected into the lateral tail vein of the rats. To modulate FAK 
function, we used our previously characterized MTLn3-tetFRNK cell line that 
conditionally expresses the HA-tagged dominant negative acting splice variant of FAK, 
focal adhesion kinase-related non-kinase (FRNK). In both experimental set-ups, HA-
FRNK in the tumor cells in vivo was induced after nine days by addition of doxycycline 
to the drinking water until the end of the experiment (Fig. 1A and 1B). Three days later 
animals were treated either with saline or a sub-lethal dose of doxorubicin (6 mg/kg) (see 
for experimental setup Fig.1A). While all animals survived after the doxorubicin 
treatment, doxorubicin caused a temporal and small loss of weight (data not shown) 
indicative of medium sub-lethal toxicity. Expression of HA-FRNK starting at day nine till 
the end of the experiment did not affect the growth rate of the tumor (Fig. 1C). Also, 
treatment with 6 mg/kg doxorubicin at day twelve alone was not effective in reduction of 
tumor growth. In contrast, exposure to doxorubicin accompanied by the expression of 
HA-FRNK caused a significant decrease of tumor growth. In agreement with tumor 
volumes, neither HA-FRNK nor doxorubicin exposure alone altered the total tumor 
weight. In contrast, the combination of HA-FRNK and doxorubicin strikingly prevented 
tumor growth (Fig. 1D). This indicates that FAK-dependent signaling mediates a resistant 
phenotype against doxorubicin treatment.  
 
 






Figure 1: HA-FRNK alleviates doxorubicin resistance of primary MTLn3 tumors. In vivo 
experimental set-ups for primary tumor and experimental metastatic models as described in experimental 
procedures (A). Primary tumors were isolated, fixated, sectioned and expression of HA-FRNK was 
determined by fluorescence microscopy and immunoblotting stained with antibodies against C-terminal 
FAK and HA. Hoechst staining showed cell populations (B). During the primary tumor experiment, tumor 
growth was followed by measuring tumor size as described in experimental procedures (C). The weight of 
the primary tumors was determined (D). 
 
 







Figure 2: HA-FRNK sensitizes lung metastases to doxorubicin treatment. Animals were injected with 
MTLn3-tetFRNK cells and after 9 days rats were exposed to doxycycline or left untreated followed by a 
single treatment with doxorubicin on day 12. At day 28, animals were sacrificed and lungs were evaluated 
for HA-FRNK expression (A). Lung metastases formation was evaluated in a macro level on ink injected 
lungs (top panel) and microscopical level in HE-stained lung tissue sections (bottom panel) (B). The 
number of surface lung metastasis was quantified (C). Size of the individual remaining metastases and the 
percentage of HA-FRNK positive cells in these metastases were determined in lung sections stained for 
HA-FRNK of animals from the FRNK and FRNK/DOXO groups (D).  
 
 
HA-FRNK Sensitizes Experimental Lung Metastases Towards Doxorubicin Treatment. 
Chemotherapy is the first line treatment for metastastic breast cancer. The difference in 
tissue microenvironment between lung metastases and primary tumor may have an 
alternative effect on survival signaling programs and drug resistance. Therefore, we also 
investigated whether FAK is involved in resistance of MTLn3 lung metastasis. For this 
purpose MTLn3-tetFRNK cells were injected in the tail vein, and after nine days when 
micro-metastases were formed, animals were treated with doxycycline and challenged 
with doxorubicin treatment on day twelve (6 mg/kg). The total number of lung metastasis 
was evaluated at the end of the experiment. Doxycycline treatment resulted in conditional 
expression of HA-FRNK in the majority of lung metastases (Fig. 2A). Neither inhibition 




of FAK nor doxorubicin exposure alone reduced the number of lung metastases. In 
contrast, expression of HA-FRNK followed by doxorubicin treatment three days later did 
induce a dramatic reduction of the lung tumor burden (Fig. 2B and C). The number of 
surface metastases was in agreement with the overall lung tumor burden as determined by 
histopathology (Fig. 2B). Despite the fact that HA-FRNK expression caused a decrease in 
the number of lung metastases by more than 70 % (Fig. 2C), the size of the remaining 
metastases, irrespective of HA-FRNK expression, was minimally reduced. Hardly any 
remaining micro-metastases were observed in any of the experimental conditions. 
Importantly, around 90 % of these remaining metastases contained HA-FRNK positive 
cells, accounting for an average of about 50-70% of all cells (Fig. 2D). These data 
indicate that the combined effect of HA-FRNK expression and doxorubicin treatment 
eliminated large numbers of micro-metastases, but did not affect further outgrowth of the 
remaining metastatic lesions.  
 
FAK Signaling Regulates Fra-1 Expression. Next, we performed a systematic analysis 
of HA-FRNK-associated signaling that could explain the sensitization to doxorubicin. 
Thus, genome-wide expression profiling was carried out in MTLn3-tetFRNK cells; 
MTLn3 tet-on cells were used as a control to exclude potential effects by doxycycline. 
Out of 13,206 genes expressed in the MTLn3 cells, 494 annotated genes (p<0.05, FC>1.5 
or <0.67) were differentially expressed upon HA-FRNK expression (individual genes are 
listed in Supplemental Table 2). Since false discovery rate (FDR) for all genes was larger 
than 0.05, we also performed gene ontology (GO) pathway analysis to define alternatively 
affected biological and molecular pathways and gene sets. 23 GO-groups were identified 
to be differentially expressed (Table 1). Fra-1 and JunB, both activator protein-1 (AP-1) 
family members, were identified as prominently down regulated genes after HA-FRNK 
expression and parts of the GO-group regulation of transcription (Table 1 and Fig. 3A, 
Supplemental Table 2); other AP-1 family members such as c-Jun and c-Fos were not 
affected by HA-FRNK expression (supplemental Fig. 1). Verification of Fra-1 and JunB 
expression by qRT-PCR showed a 37 % decrease of Fra-1 by HA-FRNK expression 
compared to control (Fig. 3B). No significant decrease was observed for JunB. To further 
validate the effect of HA-FRNK, we performed a FAK knock down with Dharmacon 
Smartpool siRNA. FAK knock down in MTLn3 cells significantly reduced Fra-1 mRNA 
expression by more than 50% as determined by qRT-PCR (Fig. 3C). This was in 
agreement with a reduction of Fra-1 protein levels to around 50 %. Fra-1 knock down did 
not affect the levels of FAK expression (Fig. 3D).  






Table 1: FRNK-induced differential alteration in gene ontologies as determined GO-miner.  
 
Gene Ontology  
p 
value1 





epidermal cell differentiation    0.01 KA17 
B cell differentiation  0.04 CLC, TPD52   
cell cycle  0.03 
CDC25B, CDK2, HRASLS3, 
MAPRE3   
mitosis  0 CDC25B, CDK2, MAPRE3   
regulation of transcription, 
mitotic  0 FOSL1, JUNB   
regulation of cell growth  0.02 WISP1   
negative regulation of cell 
growth  0.05 NPPB, OKL38   
cell motility    0.05 TPBG 
regulation of cell shape  0.05 GNA12, MYH9   
GPI anchor biosynthesis  0.01 GPAA1, PIGM   
protein myristoylation  0.03 NMT2   
protein modification  0 GGCX, PPT2   
protein aminoa acid acylation  0.07 PPARGC1A   
protein sumoylation    0.02 PIAS3 
ubiquitin cycle  0.03 RNF40, STAMBP, UBE2D3   
receptor recycling  0.05 RAB40C   
respiraroty chain complex IV    0.02 COX6C
mitochondrial outer membrane  0.04 AKAP1, HK2   
endoplasmic reticulum  0.01 
CYP3A13, DDOST, NPL4, 
NUCB2, TPD53   
endoplasmic reticulum 
membrane  0 PIGM   
integral to endoplasmic 
reticulum membrane  0 DHRS9, ELOVL6, SLC35D1   
GPI-anchor transamidase 
complexes  0.05 GPAA1    
nucleus  0.02 
ACTN4, ANKRD1, ANXA7, 
CDK2, DCK, ETV4, FOSL1, 
HAVCR1, HNRPR, KPTN, MAF, 
MEF2D, NPL4, NR1H2, NUCB2, 
PHLDA1, PIM1, PKD1, POU2F2, 
PPARGC1A, PRKACA, RNF40, 
STAMBP, TCFE2A, TLE4, 
TNPO2, WDR3   
 
    
1P < 0.05, P-value is either up or down in individual gene ontologies 








Figure 3: Fra-1 expression is dependent on FAK signaling. Microarray profiling was performed and 
analyzed as mentioned in experimental procedures. Shown are the expression levels of fra-1 and junB in 
MTLn3-tet-on (open bars) and MTLn3-tetFRNK cells (closed bars) after O/N treatment with or without 
doxycycline (A). fra-1 and junB levels were determined by qRT-PCR in MTLn3-tetFRNK cells with or 
without O/N treatment with doxycycline (n=3, mean ± SEM; asterisk indicates P=0.017) (B). After 
transfection of normal MTLn3 cells with siFAK and siFra1, fra-1 levels were determined by qRT-PCR 
(n=3; mean ± SEM; P = 0.016) (C) and protein levels of Fra-1 and FAK were determined by 
immunoblotting; Fra-1 expression levels were quantified by densitometry (D).  
 
 
Fra-1 Provides Cell Survival Against Doxorubicin-Induced Apoptosis. Fra-1 has been 
implicated in cancer progression, cell survival and cell migration. Therefore, next we 
studied the relationship between FAK and Fra-1 in the context of focal adhesion 
organization and control of apoptosis. Intriguingly, while Fra-1 knock down in MTLn3 




cells did not affect FAK expression, immunofluorescence with phosphorylated paxillin 
indicated the presence of larger focal adhesions and increased actin filaments after Fra-1 
knock down (Fig. 4A). This was associated with delayed cell spreading on collagen when 
the cells were replated (Fig. 4B). Moreover, FRAP experiments with GFP-paxillin 
MTLn3 cells demonstrated a stabilization of focal adhesion turnover after Fra-1 knock 
down (Fig. 4C). Thus, the diffusion of GFP-paxillin in the cytoplasm shows no difference 
in Fra-1 knock down compared to control condition (The reduced mobile fraction (Rf ) in 
control condition is 0.8851 and half-life τ is 0.5498s and Rf in Fra-1 knock down is 
0.8891 and τ is 0.5015s). The turnover rate of GFP-paxillin at FAs significantly decreased 
when Fra-1 was knocked down (Rf in control condition is 0.7560 and τ is 1.239s and Rf  in 
Fra-1 knock down is 0.7385 and τ is 1.846s). This effect of Fra-1 knock down on focal 
adhesion dynamics was linked with reduced cell motility, as determined by random cell 
migration of MTLn3 cells (Fig. 4D). Together, these data indicate that Fra-1 activity 
directly links to both focal adhesion dynamics, size and cell migration properties. This 










Figure 4: Fra-1 KD affects focal 
adhesion organization, dynamic 
and cell migration. MTLn3 cells 
were treated with siFra-1 or 
siGFP for 48hrs and cells were 
fixed and stained for pY118-
paxillin and F-actin. Following 
image acquisition by CLSM, the 
average size of focal adhesion 
(FA) as well as the percentage of 
large FAs (# pixels > 50) was 
determined with ImagePro Plus 
software (A). siFra-1 knocked 
down cells were detached and re-
seeded on collagen-coated 
coverslips for 4 hrs and cell 
morphology were observed with 
phase contrast light microscope 
and cell attachment were 
determined by the percentage of 
spreading cells (B). GFP-MTLn3 
cells were treated with siFra-1 or 
sicontrol (siGFP) followed by 
FRAP analysis on a Zeiss 
confocal microscope as described 
in experimental procedures. 
Shown are representative FRAP 
curves of GFP-paxillin in the 
cytosol and at focal adhesions (C). 
For random cell migration, Fra-1 
was knocked down as described 
above in GFP-MTLn3 cells. 
Random cell migration was 
performed 24 hrs after plating and analyzed as described in experimental procedures. Data shown are 
representative individual cell movements for three independent experiments. The top panels indicate the 
cell tracks of individual cells in sicontrol (left) and siFra-1 (right) conditions (D).  
 
 
Next we determined the sensitivity of MTLn3 cells towards doxorubicin when both FAK 
and Fra-1 were affected. Conditional expression of HA-FRNK sensitized MTLn3 cells 
towards doxorubicin-induced apoptosis (Fig. 5A). Since loss of FAK function decreases 
Fra-1 expression (Fig 3C and 3D), we hypothesized that loss of Fra-1 would also sensitize 
cells to doxorubicin-induced apoptosis. Similar to HA-FRNK expression, Fra-1 knock 
down indeed rendered cells more susceptible to doxorubicin (Fig. 5B). We anticipated 
that increased expression of Fra-1 would protect cells against loss of FAK. Therefore we 
generated a stable MTLn3 cell line with increased Fra-1 expression with retroviral vector 
pBABE-Fra-1 (Fig. 5C). Importantly, although Fra-1 overexpression did not affect FAK 
and paxillin levels in MTLn3 cells, it inhibited the onset of apoptosis under conditions 
when cells were depleted from FAK by siRNA pretreatment (Fig. 5D). All together these 
data indicate a role of FAK in controlling Fra-1 expression, while Fra-1 expression is 
essential for cytoprotection against doxorubicin-induced cell killing in breast tumor cells.  








Figure 5: Fra-1 determines sensitivity towards doxorubicin-induced apoptosis. MTLn3-tetFRNK cells 
were treated overnight with doxycycline to induce HA-FRNK expression and then exposed to doxorubicin 
(2 μM) for 8 hrs. Cell apoptosis was determined by Annexin/PI staining and flow cytometric analysis (A) 
(n=3; mean ± SEM; asterisk indicates P < 0.05). MTLn3 cells were treated with siFra-1 or sicontrol for 
48hrs and exposed with doxorubicin (2 μM) for 8 hrs and followed with subsequent apoptosis analysis (B). 
(n=3; mean ± SEM; asterisk indicates P < 0.05). MTLn3 cell lines expressing Myc-tagged Fra-1 were 
generated as described and characterized for Myc-Fra-1 expression using western blotting and 
immunofluorescence; Myc-Fra-1-MTLn3 cells were also examined for FAK and paxillin expression (C). 
MTLn3-pFra-1 and MTLn3-pBABE control cells were treated with siFAK or sicontrol and followed by 
doxorubicin treatment (2 μM) for 8 hrs and apoptosis was determined as in B (n=3; mean ± SEM; asterisk 





Using an orthotopic breast tumor model and an experimental lung metastasis model in 
combination with conditional doxycyclin-dependent expression of a FAK deletion mutant, 
FRNK, we investigated the role and mechanism of FAK signaling in the regulation of 
chemosensitivity of breast tumor cells towards doxorubicin. We demonstrate that 1) 
tumor cell specific inhibition of FAK in both primary tumor and lung metastases re-
sensitizes breast tumor cells towards doxorubicin; 2) induction of FRNK expression 
selectively affects the expression of a panel of target genes, of which the AP-1 
transcription factors Fra-1 and JunB are prominent; and 3) Fra-1 expression in breast 




tumor cells determines their susceptibility towards doxorubicin. Collectively, these data 
provide a model whereby FAK-dependent signaling supports the expression of the AP-1 
transcription factor Fra-1 and provides survival advantages that protect against 
therapeutic relevant doxorubicin concentrations, thus appearing a drug-resistant 
phenotype. These data support the notion that pharmacological intervention of FAK 
function will provide opportunities for combined therapy in cancer types with increased 
levels of FAK and chemo-resistance.  
 
Both the orthotopic breast tumor model and the experimental metastasis model indicate 
that HA-FRNK expression ameliorates in vivo resistance against doxorubicin. To our 
knowledge, this is the first time to show that tumor cell-specific inhibition of FAK 
enhances drug sensitivity. Although our orthotopic tumor model could not substantiate 
whether the combined treatment resulted in a complete eradication of subsets of tumor 
cells or solely a delay in tumor cell proliferation, our experimental lung metastasis model 
supports that the combined treatment kills off small micro-metastases completely. Thus, 
the total number of lung metastases decreased, and this was not associated with a clear 
decrease in the size of the remaining metastases. Importantly, these remaining metastases 
were in most cases still partly positive for HA-FRNK, indicating that there was not a 
selection of outgrowth of HA-FRNK negative cells. By microscopic analysis of HA-
FRNK stained paraffin sections, no remaining micro-metastases were observed. This 
suggested that FRNK expression rather supported killing of metastatic cells by 
doxorubicin, than induced a dormant phenotype of metastasis that formed up till day 12 
after injection. Moreover, our in vitro data suggest that conditional HA-FRNK expression 
facilitates the killing of MTLn3 cells by doxorubicin-induced apoptosis and prevents long 
term colony formation in soft agar assay (data not shown).  
 
We identified Fra-1 as an important regulator downstream of FAK-mediated survival 
signaling. Thus, both HA-FRNK expression and FAK knock down suppressed fra-1 
mRNA expression as well as protein levels. On its turn Fra-1 knock down sensitized 
MTLn3 cells towards doxorubicin but did not affect FAK expression. Moreover, Fra-1 
overexpression inhibited the onset of apoptosis when FAK was knocked down, but no 
protection was observed when FAK was expressed. Fra-1 encodes a leucine zipper 
protein that can dimerize with proteins of the Jun family and form the transcription factor 
complex AP-1. Interestingly, JunB was also downregulated after FRNK expression (Fig. 
3 and Supplemental Table 2), although this was not significant by qRT-PCR. Based on 
our microarray data, other Fos and Jun family members have relatively low mRNA 
expression levels in MTLn3 cells. Therefore, we hypothesize that Fra-1/JunB dimer is an 
important AP-1 transcription factor complex in these cells. Our previous collaborative 
work indicates that Fra-1 is the most significant differentially expressed gene among a 
large panel of human breast tumor cells with either a epithelial or a mesenchymal 
phenotype, and has an over 600-fold higher average expression level in these 
mesenchymal-like breast tumor cells (20). MTLn3 cells also have mesenchymal 
characteristics. Given the fact that mesenchymal-like breast tumor cells typically have a 




higher metastatic potential (30), we anticipate that such a metastatic and often drug-
resistant phenotype may have a FAK-Fra-1 signaling axis background.  
 
AP-1 is thought to play an important role in the balance between cell proliferation and 
apoptosis, the response to genotoxic stress and cell transformation. In colon cancer cells, 
the classical mitogen activated protein kinase pathway through MEK and ERK is 
essential in the regulation of Fra-1 levels (31). Also stress responses such as DNA-
damage by UV and cisplatin, induce an ERK-mediated Fra-1 phosphoration and 
stabilization by preventing proteasomal degradation (23, 31). Possibly, the FAK-mediated 
regulation of Fra-1 in MTLn3 cells is dependent on ERK signaling, although we have not 
been able to identify a differential activity of ERK upon HA-FRNK expression (data not 
shown). Fra-1 expression seems crucial in tumor cell invasion and motility. This is related 
to the inactivation of beta1- integrin in an unknown way (21). The integrin inactivation 
suppresses the activation of RhoA/ROCK pathway (21). ROCK-mediated contractility is 
also enhanced upon Fra-1 knock down in MTLn3 cells, without affecting the expression 
of FAK itself. This is associated with larger and less dynamic focal adhesions. 
Interestingly, doxorubicin itself increases the contractility of MTLn3 cells in a ROCK 
dependent manner; however ROCK inhibition does not affect the doxorubicin-induced 
apoptosis (data not shown). Since Fra-1 knock down decreases the dynamics of focal 
adhesion and most likely also focal adhesion derived (survival) signaling, we anticipate 
that focal adhesion stabilization may be the driven force for sensitization towards 
doxorubicin. Indeed, FAK-mediated signaling via the PI-3K/AKT pathway seems 
important to control doxorubicin-induced apoptosis in MTLn3 cells (7). However, we can 
not exclude other possible mechanisms by which Fra-1 in concert with focal adhesion 
signaling converges to modulate drug-resistant phenotype. Further research will be 
essential to unravel the exact mechanism of Fra-1-mediated cell survival in breast cancer 
cells.  
 
Although we could functionally link modulation of Fra-1 by FAK to drug sensitivity, 
there are other alternative pathways by which FAK signaling modulates drug resistance 
and tumor development. Indeed, recently, Halder et al. showed that the strategy with FAK 
siRNA and docetaxel reduces tumor growth (13). This effect attributed to decreased 
vascularization with low VEGF levels. In accordance with this, Mitra et al. showed that 
inhibition of FAK resulted in reduced VEGF expression and smaller tumors in mice (32). 
However, our microarray analysis did not reveal any HA-FRNK-induced downregulation 
of VEGF/VEGFR pathway components. Additionally, no difference in the 
vascularization of primary tumors upon expression of HA-FRNK was observed in the 
absence and presence of doxorubicin treatment (unpublished results). Also the small size 
of the micro-metastases at the time point of doxorubicin exposure in our experimental 
metastasis model in combination with the extensive vascularization of lung tissue makes a 
relationship between VEGF, angiogenesis and drug sensitization unlikely. Our GO-
miner-based gene ontology analysis revealed a clear identification of biological programs 
that are significantly affected by HA-FRNK expression including regulation of mitosis, 




mitotic regulation of transcription, regulation of cell growth as well as cell motility 
(Table 1). Defects in such programs are likely to sensitize cells to doxorubicin. It is still 
questionable whether the gene expression changes are directly affected by HA-FRNK 
expression or rather indirect consequences of the altered transcription activity of 
transcription factors such as Fra-1. In addition, some of the most significantly altered 
genes after HA-FRNK expression (supplemental Table 2) are not included in the gene 
ontologies. In this respect, it is worthwhile to mention that AKT1 was significantly 
downregulated by HA-FRNK expression (supplemental Table 2). FAK is involved in the 
generation of second messengers phosphatidylinositol phosphates (PIP3/PIP2), via 
recruitment of PI-3 kinase to its phosphorylated tyrosine residue (Y397). This eventually 
results in the activation of AKT (8, 9). Interestingly, we have previously shown that 
doxorubicin-induced phosphorylation of AKT1 (PKB) is inhibited by expression of 
FRNK in vitro (7). Therefore, HA-FRNK expression, by disturbing the PI3-kinase 
pathway, could interfere in an alternative mechanism with tumor cell resistance towards 
doxorubicin. Further systematic research should be carried out to test all individually 
downstream candidate effectors of FAK signaling that we have identified.  
 
In conclusion, our data indicate that modulation of FAK in vivo can sensitize breast tumor 
cells towards classical anticancer drugs. Therefore, targeted pharmacological intervention 
with FAK inhibitors (33) may become an attractive way to combat resistant metastatic 
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Supplemental Table 1: Experimental set-up for MTLn3-tetFRNK microarrays. 
 
Annotation Cell line doxycycline # of arrays 
Tet-on MTLn3-tet-on - 3 
Tet-on-doxy MTLn3-tet-on + 3 
Control MTLn3-tetFRNK - 3 
FRNK MTLn3-tetFRNK + 3 
 
 




value1 FC Probe_ID Gene_Symbol 
p-
value1 FC 
21856159 Cd3d 0.0010 0.320 22403212 Slc1a7 0.0003 2.703 
21936000 Ehhadh 0.0013 0.205 22324795 Ch25h_predicted 0.0008 3.521 
22393188 Maf 0.0020 0.536 20943419 Cck 0.0011 3.003 
20780557 Havcr1 0.0030 0.452 21321652 DOXL1 0.0015 1.946 
21031326 Slc17a1 0.0032 0.453 22327267 Bcl2l12_predicted 0.0015 2.591 
21201447 Erbb3 0.0045 0.490 21726405 Csf3r_predicted 0.0017 2.358 
20762938 Egfl9_predicted 0.0052 0.548 21267977 Igsf4b_predicted 0.0023 3.663 
21336348 Dhrs9 0.0053 0.493 21927201 Olr1468 0.0027 3.226 
21784618 Il16 0.0054 0.377 20763458 Crebl2_predicted 0.0030 2.114 
21849152 F2r 0.0059 0.597 20752903 Cd7_predicted 0.0034 2.079 
21748787 Tnks_predicted 0.0060 0.450 21979282 Ndr4 0.0034 2.000 
21743859 Eif2c2 0.0064 0.605 21770029 Slc34a3 0.0038 2.532 
21788095 Prkaca 0.0065 0.564 21476914 Cldn23_predicted 0.0042 1.931 
21282318 Olr859_predicted 0.0078 0.342 20879943 Pgam2 0.0047 1.890 
20788184 Pigm 0.0079 0.566 22014663 Sirt1_predicted 0.0053 1.761 
21940318 Wisp1 0.0094 0.611 20777806 Tcf15_predicted 0.0055 2.155 
21231240 Gmps_predicted 0.0094 0.591 21631081 Cyp2a2 0.0064 3.571 
21565791 LOC361237 0.0098 0.573 21215224 Pias3 0.0081 2.849 
21876989 Vat1_predicted 0.0101 0.601 20930584 Ubtf 0.0084 2.375 
22227921 Kptn_predicted 0.0103 0.507 22391474 Selenbp1 0.0086 1.953 
21105219 Cdc25b 0.0105 0.500 20991663 Pfas_predicted 0.0092 1.642 
21998913 Dapk2_predicted 0.0105 0.586 21276979 Sftpd 0.0138 1.761 
20779692 Zfp238 0.0106 0.450 22395853 Sox18_predicted 0.0144 1.859 
22381611 Dlc2 0.0116 0.585 21569506 Palmd_predicted 0.0155 1.880 
21574843 Slk 0.0127 0.614 21848369 Cacna1a 0.0157 2.381 
21944508 Axl_predicted 0.0133 0.569 21507225 Ka40 0.0160 2.020 
21503808 Fbxl12_predicted 0.0133 0.614 20990619 Olr567_predicted 0.0161 1.845 
21200143 Slc35d1_predicted 0.0141 0.619 21960505 Ghr 0.0161 1.742 
20880470 Mapre3 0.0142 0.561 21761328 C1qb 0.0167 1.672 
21600070 Mrps10_predicted 0.0146 0.660 20700469 Pnrc1 0.0169 1.721 
21270267 Akap1 0.0151 0.649 21136726 Guca2a 0.0172 1.661 
20910301 Slc25a14 0.0152 0.597 20846089 Thea_predicted 0.0177 1.639 
22262479 Tle4 0.0153 0.556 21997485 Rtn3 0.0180 2.899 
21944206 Pik3c2b_predicted 0.0154 0.613 20905752 Cplx1 0.0183 2.183 
21075257 Cask 0.0159 0.518 21847074 MGC72957 0.0190 1.953 
22120455 AKT1 0.0159 0.472 22126943 Aqp6 0.0209 1.558 
21545404 Ppt2 0.0167 0.587 21142883 Dhrs3_predicted 0.0212 1.667 
21310129 Okl38 0.0168 0.633 21255269 Pygm 0.0221 2.183 
22135944 Gna12 0.0174 0.556 22287230 Lin10 0.0224 2.273 
21742615 Rrm1 0.0178 0.154 20997792 Tagln3 0.0231 1.799 
21548145 Slc16a2 0.0180 0.447 21902211 Hbp1 0.0237 1.661 




22289377 Ptpn12 0.0185 0.555 20794054 Mfap3 0.0254 2.336 
21661580 Hk2 0.0188 0.623 21137211 Wfdc1 0.0255 1.558 
20828341 Acsl1 0.0188 0.621 21325545 Mmp15_predicted 0.0266 1.739 
21978152 Cln5_predicted 0.0189 0.652 22267496 RGD1306702_predicted 0.0267 1.773 
21833350 LOC286990 0.0190 0.533 20859138 Aldh3a1 0.0276 1.613 
21400107 Rab40c 0.0193 0.550 21379704 Knsl8_predicted 0.0282 1.603 
21851217 Card10_predicted 0.0193 0.608 21003922 Cabc1_predicted 0.0289 1.560 
21959286 Taf1a_predicted 0.0208 0.615 22117376 Usp30_predicted 0.0292 1.639 
21159331 Oit3 0.0209 0.639 22373953 LOC60665 0.0299 1.792 
22407543 Ggcx 0.0213 0.521 21315820 RGD1308955_predicted 0.0304 1.736 
21155260 Nucb2 0.0216 0.445 22351471 RGD1309459_predicted 0.0321 1.721 
21010472 Usp38_predicted 0.0221 0.657 20743259 Cda08 0.0325 2.083 
20821908 Myh9 0.0222 0.637 22120457 RGD1311107_predicted 0.0326 1.912 
21372799 Il17f_predicted 0.0225 0.529 22372665 Exo1_predicted 0.0327 1.786 
22243043 RGD1310520_predicted 0.0231 0.602 21035433 Ccl20 0.0329 1.795 
21281328 Cav2 0.0234 0.648 20904552 Cldn15_predicted 0.0345 2.463 
20824132 Ankrd1 0.0241 0.625 20888760 Olr1337_predicted 0.0347 1.718 
21603659 Slc17a6 0.0242 0.562 21220396 Ttc16_predicted 0.0347 1.618 
21535209 Cyp3a13 0.0243 0.644 21570101 Cbll1_predicted 0.0349 1.592 
21622250 Thap6_predicted 0.0244 0.483 20737316 Gpr124_predicted 0.0355 2.268 
21876288 Lrp8_predicted 0.0249 0.624 21306709 RGD1306952_predicted 0.0361 1.957 
22139518 Etsrp71_predicted 0.0249 0.581 21954151 Ccng2_predicted 0.0374 1.686 
22336310 Junb 0.0251 0.639 22097357 MGC94550 0.0375 1.520 
22136467 Phf15_predicted 0.0273 0.458 22358977 Hapln4_predicted 0.0410 1.876 
21314484 Lgals9 0.0276 0.630 21849031 Cox6c 0.0422 1.730 
21160091 Slc4a11_predicted 0.0279 0.631 20876655 Nr1h4 0.0441 1.901 
22282806 Lrrc15 0.0282 0.323 21417467 Cacna1b 0.0446 1.538 
21305806 Fosl1 0.0284 0.564 22175193 Wt1 0.0447 1.901 
21219586 Pou2f2 0.0287 0.656 21176640 Tpbg 0.0465 1.536 
21897732 Stambp 0.0291 0.658 20854804 Ka17 0.0470 1.499 
20876299 Rnf40 0.0293 0.644 20868496 Sod2 0.0475 1.667 
21006903 Exoc8 0.0301 0.639 20737825 Notch4 0.0476 1.577 
21588690 Nefh 0.0307 0.576 20752295 Tep1 0.0479 1.555 
21968384 Fcnb 0.0308 0.540 21584298 Dpp8_predicted 0.0482 1.504 
22207768 Mdh1b_predicted 0.0313 0.400 21549591 Siah1a 0.0495 1.580 
21110267 Madh3 0.0313 0.456     
21890138 Znf629_predicted 0.0323 0.559     
22288872 Gk-rs1_predicted 0.0324 0.571     
21404310 Hnrpr 0.0332 0.656     
21875776 Nmt2 0.0337 0.665     
21137506 Fkbp14_predicted 0.0341 0.612     
21233599 Tcfe2a 0.0347 0.473     
20875200 Np 0.0353 0.574     
20826517 Meox1_predicted 0.0361 0.353     
20780470 Pim1 0.0367 0.641     
21952268 Klre1 0.0371 0.574     
20989100 Ppargc1a 0.0373 0.590     
21929390 Lgals5 0.0381 0.629     
21113865 Il24 0.0382 0.556     
21985561 Lcn7 0.0385 0.655     
20862355 Rufy1_predicted 0.0388 0.574     
21396873 Ctrl 0.0389 0.650     
21620770 Nppb 0.0389 0.495     
22067183 Epn2 0.0392 0.656     




21591414 RGD1305424_predicted 0.0402 0.404     
21132402 Phospho1_predicted 0.0405 0.667     
21154733 Npl4 0.0406 0.635     
22035995 Fgd3_predicted 0.0407 0.642     
21481266 Dnaja2 0.0415 0.626     
22066307 Actn4 0.0422 0.661     
21239072 Fbxl14_predicted 0.0423 0.667     
21288312 Upb1 0.0431 0.575     
21549672 Hrasls3 0.0431 0.568     
21289633 Dbt 0.0432 0.477     
21466445 Synj2 0.0434 0.644     
21271425 Tufm_predicted 0.0441 0.647     
21995038 Phlda1 0.0443 0.662     
21497995 Procr_predicted 0.0446 0.666     
21388641 Hmmr 0.0453 0.667     
20884920 LOC493574 0.0458 0.623     
21378546 Tnpo2_predicted 0.0459 0.604     
21535218 Car7_predicted 0.0467 0.518     
21418355 Mgat5 0.0473 0.611     
22413236 Pdrp 0.0478 0.656     
21033847 Rap2b 0.0479 0.617     
21513568 Loxl2_predicted 0.0480 0.640     
21921832 Clc 0.0482 0.648     
22104079 Abhd2_predicted 0.0482 0.631     
21700036 Tagln 0.0485 0.407     
21204716 Slc4a2 0.0491 0.648     
21918636 Pdlim7 0.0493 0.510     
21667412 Mef2d 0.0493 0.614     
21153498 MGC94736 0.0497 0.639     
 
1Selection of annotated genes is based on the following criteria: P<0.05 and Fold Change (FC) > 1.5 or 




Supplemental Figure 1: HA-FRNK-dependent gene expression of Fos and Jun family members. 
Shown are the expression values of other Fos and Jun family members in MTLn3 Tet-on and MTLn3-
tetFRNK cells treated with or without doxycycline, as determined in the microarray experiments.  
 
Supplemental Figure 2: Validation of siRNA-mediated Fra-1 knock down. MTLn3 cells were 
transfected with siFra-1 and fra-1 mRNA was evaluated after 24 and 48 hr by qRT-PCR using actin as an 
internal control (upper panel). Fra-1 protein expression was estimated with immunoblotting after 48 and 72 
hr by western blot (lower panel).  
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Microtubule disrupting agents cause cell cycle arrest at G2/M transition as well as 
actin cytoskeleton reorganization, focal adhesion stabilization, cellular contraction 
and cell rounding prior to apoptosis. Here we used MTLn3 mammary 
adenocarcinoma cells to study the role of the c-jun N-terminal kinase (JNK) 
signaling pathway and its substrate paxillin on vincristine-induced actin network 
and focal adhesion reorganization. Vincristine caused G2/M arrest in association 
with actin stress fiber formation and focal adhesion stabilization later followed by 
apoptosis. This was accompanied with an early activation of JNK at focal adhesions. 
Inhibition of JNK with SP600125 inhibited actin stress fiber, focal adhesion 
formation and cell rounding but not cell cycle arrest. Vincristine caused JNK 
dependent phosphorylation of paxillin on serine residue 178 as well as another 
posttranslational modification of paxillin, which was independent on serine178 
phosphorylation. While the inhibition of Rho-kinase prevented vincristine-induced 
myosin light chain phosphorylation and actin stress fiber formation, it did not affect 
JNK activation, paxillin modification or cell cycle arrest. Paxillin knock down 
inhibited vincristine induced c-Jun activation, myosin light chain phosphorylation, 
actin stress fiber formation and focal adhesion stabilization but not JNK activation. 
Altogether our data indicate an important role of the JNK-paxillin axis in 
vincristine-induced actin stress fiber formation and cell contractility, independent 





Cell adhesion is required for diverse cellular processes in both physiological and 
pathological conditions such as tissue regeneration, tumor cell invasion and metastasis 
formation as well as cellular responses to cell injury directly linked to the control of 
apoptosis. The dynamics of cell adhesions involve a continuous remodeling of F-actin 
cytoskeletal network, which must be coordinated both spatially and temporally to 
generate the correct biological outcome. Diverse cellular stress conditions, such as ATP 
depletion (1, 2), oxidative stress (3), mechanical stress and exposure to different 
chemicals and anticancer drugs, cause the disorganization of actin cytoskeleton, which is 
often associated with cell death (4). The exact molecular mechanisms of reorganization of 
F-actin network and its relationship to apoptosis upon cellular stress are largely unknown.  
 
Microtubule disrupting agents (MDAs) including vinca-alkaloids are an important class 
of anticancer drugs in the treatment of a variety of cancers (5-7). Vinca-alkaloids, such as 
vincristine and vinblastine, cause complete microtubule depolymerization. Besides the 
induction of cell cycle arrest and apoptosis in a variety of cell types (8-10), microtubule 
destabilization has the unique feature to induce an increased formation of F-actin 
cytoskeleton network and focal adhesions, which is in accordance with increased cellular 




contraction, a phenomenon observed during apoptosis due to caspase-dependent 
activation of Rho kinases (11, 12). So far the relationship between actin organization, cell 
cycle arrest and/or apoptosis caused by microtubule disruption has not been investigated. 
Moreover, it remains largely unclear what signaling events initiate cellular contractility 
upon microtubule depletion.  
 
Focal adhesions are dynamic multiprotein complexes that form the closest contacts 
between cells and extracellular matrix. They consist of a variety of signaling, adaptor and 
cytoskeletal proteins that mediate downstream signaling for cell survival, proliferation 
and migration. Apoptosis induced by a range of agents is associated with the 
dephosphorylation, phosphorylation and/or degradation/cleavage, of various focal 
adhesion-associated proteins, such as focal adhesion kinase (FAK) and the cytoskeletal 
scaffold protein paxillin. This is often preceded by the formation of stress fibers and focal 
adhesions (11, 13, 14). Also, vinblastine causes increased F-actin stress fiber formation in 
endothelial cells, which is associated with ROCK dependent myosin light chain (MLC) 
phosphorylation (15). Activation of the RhoA/ROCK pathway causes increased 
actin/myosin driven bundling of F-actin filaments and focal adhesion formation (16). 
 
Diverse MDAs, including vincristine and taxol, cause the drastic activation of c-Jun N 
terminal kinase (JNK) through ASK1- and Ras mediated signaling (17), or other MAPK 
family members like ERK and p38 (18). Activation of JNK is involved in the early 
apoptosis caused by microtubule disrupters (18, 19) and seems independent on 
microtubule disruption-related phosphorylation of Bcl-2 and Bcl-XL (20, 21). Recent data 
indicate that active phosphorylated form of JNK accumulates at focal adhesions in several 
cell types, especially under cellular stress conditions (22, 23). This may be via the binding 
of JNK adaptor protein JSAP1 to FAK at focal adhesions (24-26), or an upstream kinase 
of JNK, MEKK1 downstream of FAK (27). Besides, JNK can phosphorylate the focal 
adhesion adaptor protein paxillin at serine residue 178 after epidermal growth factor 
signaling (28). These combined observations suggest a potential relationship between 
microtubule disruption-induced JNK activation, modification of focal adhesion-associated 
proteins and cell contraction possibly in direct relation to the onset of cell cycle arrest 
and/or apoptosis.  
 
In this paper, we have used mammary adenocarcinoma cell line MTLn3 to determine the 
relationship between F-actin reorganization, JNK activation and actin/myosin-based cell 
contraction caused by the anticancer vinca alkaloid drug vincristine. We show that 
vincristine causes early cell cycle arrest in association with a rapid appearance of 
actin/myosin-based cell contraction and focal adhesion formation, which is followed by 
cell rounding. The actin stress fiber formation is accompanied by two modifications of 
paxillin which are dependent on JNK activation: serine178 phosphorylation and a yet 
undefined modification that causes an electric mobility shift. SiRNA mediated knock 
down of paxillin inhibits vincristine-induced JNK pathway, stress fiber formation and cell 
contractility. Moreover, the inhibition of JNK retards cell contraction, and focal adhesion 




formation. These events are dissociated from vincristine-induced cell cycle arrest. Our 
data support a model whereby the JNK-paxillin axis plays a crucial role in microtubule 




Materials - Alpha-modified minimal essential medium with ribonucleosides and 
deoxyribonucleosides (α-MEM) and fetal bovine serum (FBS) were from Invitrogen. 
Bovine serum albumine (BSA), p38 inhibitor SB203580, phosphoinositide-3 kinase 
inhibitor wortmannin, bisindolylmaleimide I, propidium iodide (PI), protein G-Sepharose, 
vincristine, 7-amino-4-methylcoumarin (AMC) and RNase A were from Sigma. 
SP600125 was from Biomol International. Y27632 was from Tocris Bioscience. Rat tail 
collagen type I was from Upstate. MEK inhibitor U0126 was from Promega and H89 was 
from Calbiochem. All other chemicals were of analytical grade. 
 
Cell culture and stable cell lines - MTLn3 rat mammary carcinoma cells were cultured as 
described (13). For experiments, cells were plated on dishes or collagen-coated (20 μg/ml) 
coverslips and grew in complete medium for three days. Cells were exposed to vincristine 
in α-MEM supplemented with 2.5% FBS for the indicated periods; in some experiments 
cells were pretreated with pharmacological inhibitors for 30 min. 
 
To generate stable cell lines, MTLn3 cells were transfected with GFP-paxillin or GFP-
paxillinS178A in vector (0.72 μg) along with empty vector pcDNA3 (0.08 μg) using 
LipofectAMINE Plus reagent according to manufacturer’s procedures. Stable 
transfectants were selected using geneticin (G418, 600 μg/ml; Invitrogen). Individual 
clones were picked and maintained in complete medium containing 100 μg/ml G418. 
Clones were analyzed for the expression of the GFP constructs by flow cytometry 
analysis, western blotting and immunofluorescence. 
 
Transient transfection - GST-wt-SEK1 and GST-DN-SEK1 (kindly provided by John 
Kyriakis) were transiently cotransfected together with GFP-paxillin with LipofectAMINE 
Plus (Invitrogen) for 48 hr. For knock down experiments, cells were transfected with 
SmartpoolTM  siRNA against rat paxillin (5-50 nM) using Dharmacon reagent 2. siRNA 
against GFP was used as a control. All experiments after siRNA transfection were 
performed between 48-72 hr after transfection. 
 
Cell cycle and apoptosis analysis - Cell cycle distribution and apoptosis were determined 
with cell cycle analysis as described before (29) using flow cytometry (FACS-Calibur, 
Becton Dickenson). The percentages of cells in sub-G0/G1, G-, S- and M-phase were 
determined with Cellquest software (Becton Dickenson). SubG0/G1 represents the 
apoptotic fraction (30). Caspase activity assay was performed with Ac-DEVD-AMC as 
described before (29, 30), the release of AMC was measured on a fluorescence plate 




reader (HTS 7000 Bio assay reader, Perkin Elmer Life Sciences). Caspase activity was 
calculated as pmol AMC/ (min*mg protein) using free AMC as a standard. 
 
Gel electrophoresis and immunoblotting - Western blot analyses were done as before 
(29). Briefly, equal amounts of total cellular protein were separated on a 7.5% SDS-
PAGE and transferred to polyvinylidene difluoride membrane (Millipore). Membranes 
were blocked for 1 hr at room temperature using I-Block (0.2% casein in Tris-buffered 
saline with 0.05 % Tween 20 (TBS-T)) for phospho-state specific antibodies or 5% BSA 
in TBS-T for other primary antibodies. The following primary antibodies were used: anti-
tubulin (Sigma), anti-pT180/pY182-p38, anti-pT202/pY204-p44/42 ERK (New England 
Biolabs), anti-FAK, anti-pY118-paxillin, anti-pY397-FAK, anti-paxillin (Transduction 
Laboratories), anti-pS178-paxillin (Abcam), anti-pT183/pY185-JNK (Promega), anti-
pS63-cjun and anti-pS19-MLC (Cell Signaling Technologies). Incubation with primary 
antibodies diluted in I-Block or 1% BSA in TBS-T were carried out overnight at 4 °C. 
Following washing steps, secondary antibodies diluted in either I-Block (GαRb-AP, 
1:2500) or TBS-T (GαM-HRP, 1:2000, GαRb-HRP, 1:2000, or GαM-CY5, 1:2500; all 
antibodies from Jackson) were added for 1 hr at room temperature. After sufficient 
washes, membranes blocked in I-Block were processed according to the Tropix kit 
protocol (Applied Biosystems). Membranes blocked in BSA were either developed with 
ECLplus reagent (Amersham Biosciences) before detection or directly imaged (CY5 
staining) on the Typhoon Imager 9400 (Amersham Biosciences). 
 
Immunofluorescence - Immunofluorescence studies were performed as before (31). The 
following primary antibodies were used: anti-vinculin (Sigma) and anti-tubulin, anti-
pY118- paxillin and anti-pY397-FAK, anti-paxillin and anti-pT183/pY185-JNK and anti-
pSer19-MLC (Cell Signaling). After three washes in 0.05% Triton/0.5% BSA in PBS 
(TBP), coverslips were incubated with fluorescent labeled secondary antibodies 
(Molecular Probes) diluted in TBP for 1 hr at room temperature or overnight at 4°C, 
followed by two washes in TBP, and one in PBS. Post-fixation was then carried out using 
3.7% formaldehyde for 5 min at room temperature. After a final washing step with PBS, 
coverslips were mounted on glass slides with Aqua Poly/Mount (Polysciences). Cells 
were visualized on a Nikon E600 fluorescence microscope and a BioRad Radiance 2100 
confocal laser scanning system. 
 
TIRF microscopy - Total internal reflection fluorescence (TIRF) microscopy was 
performed on non-treated or treated GFP-paxillin MTLn3 cells (50 nM vincristine, 8hr) in 
a climate control chamber. TIRF movies were captured on a Nikon TIRF microscope 
system (Eclipse TE2000-E, Nikon with automated stage) with framing every 5 minutes 
for 4 hours using NIS-elements AR software (Nikon). 
 
Statistical analysis - Student's T test was used to determine significant differences 
between two means (p<0.05). 
 







Vincristine-induced apoptosis of MTLn3 cells is preceded by focal adhesion formation 
and cell contractility - To investigate the molecular mechanism of microtubule 
disruption-induced cytoskeleton reorganization and cell contractility, we used the 
anticancer drug vincristine. Since MDAs also typically induce cell cycle arrest and 
apoptosis in tumor cells, we first examined the dose-dependent effects of vincristine on 
cell cycle progression and apoptosis onset. Cells were exposed to increasing 
concentrations (0-100 nM) of vincristine for 24 hr. The amount of apoptotic cells 
increased in a dose-dependent manner, and reached a plateau at 50 nM (Fig. 1A, left 
panel). Vincristine-induced apoptosis (50 nM) was already observed after 8 hr, which 
further reached a level of 56 % after 16 and 24 hr (Fig. 1A, right panel). The onset of 
apoptosis was confirmed by a time-dependent (Fig. 1B) and concentration-dependent 
(data not shown) caspase-3 activation as well as the subsequent cleavage of a caspase 3 
substrate, polyADP-ribose polymerase (PARP) (data not shown). The onset of apoptosis 
at 8 hr was preceded by cell cycle arrest in G2/M phase, which was already initiated 4 hr 
after exposure (Fig. 1C). For further studies MTLn3 cells were exposed to 50 nM 
vincristine. 
 
Disruption of microtubule network by the MDA nocodazole induces F-actin stress fiber 
formation and focal adhesion organization in serum-starved Swiss 3T3 cells (32). 
Therefore, we determined whether microtubule disruption by vincristine caused similar 
changes in MTLn3 breast tumor cells. Polymerization of microtubules was completely 
inhibited by 50 nM vincristine and the microtubule network had virtually collapsed after 
4 hours; this was associated with an increase of F-actin stress fiber formation 
(supplemental data Fig. S1). Vincristine-treated MTLn3 cells appeared to have a more 
contractile phenotype culminating in cell rounding (Fig. 1D). We reasoned that this 
vincristine-induced contractile phenotype was associated with enhanced focal adhesion 
formation. We stained cells for tyrosine phosphorylated paxillin (PY118-paxillin), which 
specifically localizes at focal adhesions. Untreated cells mainly possessed small focal 
complexes while occasionally cells with more mature focal adhesions were observed. 
Vincristine induced the formation of clear focal adhesions that colocalized at the edge of 
stress fibers at cell periphery (Fig. 1E). Similar observations were obtained after 
immunofluorescent staining for PY397-FAK and vinculin (supplemental data Fig. S2). 
Next we visualized vincristine-induced focal adhesion formation in GFP-paxillin MTLn3 
cells with TIRF microscopy. In untreated cells the relatively small focal adhesions were 
highly dynamic. However, in vincristine-treated MTLn3 cells, paxillin accumulated at 
focal adhesion sites and peripheral ruffles, while focal adhesions became larger in size 
and less dynamic, followed by cell rounding and apoptosis (supplemental data and movie 
Fig. S3). Thus, vincristine-induced F-actin stress fiber and focal adhesion formation is an 
early response that occurs well before the onset of apoptosis. 
 







Figure 1: Vincristine causes cell cycle arrest and focal adhesion formation and cell contractility. 
MTLn3 cells were treated with indicated concentrations of vincristine for 24 hr or exposed to 50 nM 
vincristine for indicated time periods. Apoptosis was determined by cell cycle analysis and expressed as % 
subG0/G1 (A). Cells were treated with 50 nM vincristine for indicated time points and caspase activity was 
measured with Ac-DEVD-AMC. Fluoresencent density was visualized on a Fluostar platereader (B). Cell 
cycle arrest was determined by cell cycle flow cytometric analysis (C). Phase contrast pictures were taken 
after 8 hr exposure to vincristine (50 nM) (D). Cells were treated with vincristine for 8 hr and fixed and 
stained with pY118-paxillin and F-actin. The images were acquired on CLSM (E). Data shown are from (A, 
B and C; mean ± SEM) or representative for (D and E) three independent experiments. 














Figure 2: Vincristine induces JNK 
activation and accumulation at FA sites 
and reduced mobility shift of the focal 
adhesion scaffold protein paxillin. 
MTLn3 cells were treated with 50 nM 
vincristine for indicated time points and 
collected for immunoblotting with 
antibodies to active forms of MAPKs 
pERK, pp38, pJNK (A) and FA-associated 
proteins pY118paxillin, paxillin, 
pY397FAK, FAK (C). Vincristine-treated 
cells were fixed and stained for pJNK and 
F-actin. The images were acquired on 
CLSM as mentioned in experimental 
procedures (B). Data shown are 









Vincristine causes activation of JNK and its localization at focal adhesions in 
association with a paxillin modification - MDAs cause the activation of stress-activated 
MAPKs, including JNK and p38, in different cell types (18, 23, 33-36). In order to 
determine the effect of vincristine on activation of different MAPKs in MTLn3 cells, cells 
were exposed to vincristine for various time periods followed by western blot analysis of 
the phosphorylated forms of JNK, p38 and ERK. A clear increase in the phosphorylation 
of JNK was already evident after 2 hr and reached maximal activation after 8 hr (Fig. 2A). 
Increased JNK phosphorylation was associated with the phosphorylation of one of its 
targets, c-Jun (Fig. 3A). No significant increase in ERK phosphorylation occurred after 
vincristine treatment, while hardly any phosphorylated form of p38 was detectable at any 
time point (Fig. 2A). In contrast, incubation of MTLn3 cells with hydrogen peroxide did 
cause a large increase in p38 phosphorylation (data not shown), indicating the 
functionality of this stress kinase in these cells. 
 
Next, we evaluated the potential relationship between JNK activation and focal adhesion 
organization in vincristine-induced stress response. The JNK-binding adaptor protein 
SJAP1 is localized at focal adhesions through an interaction with FAK (25). This results 
in the localization of the active phosphorylated form of JNK at these sites in different cell 
types (25, 29). MEKK1, another upstream kinase of JNK, can also bind to FAK (27). 
Upon vincristine treatment, the active phosphorylated JNK clearly localized at focal 




adhesion-like structures at the end of F-actin stress fibers (Fig. 2B). In contrast, in control 
cells hardly any phosphorylated JNK was associated with focal adhesions, which fits the 
vincristine-dependent activation of JNK (Fig. 2A). Given the localization of JNK at focal 
adhesions upon vincristine treatment, we next investigated whether the phosphorylation 
of two candidate focal adhesion associated proteins, FAK and paxillin, was affected. The 
expression levels of FAK and paxillin as well as the phosphorylation of FAK at tyrosine 
residue 397 and paxillin at tyrosine residue 118 were not affected by early phase of 
vincristine treatment (0-4hr, Fig. 2C). When apoptosis was initiated (see Fig. 1 for 
comparison), FAK phosphorylation had decreased, which was in agreement with our 
previous observations in the doxorubicin-induced apoptosis of MTLn3 cells (13). 
Interestingly, treatment of MTLn3 cells with vincristine caused a clear mobility shift of 
paxillin already after 4-8 hr (Fig. 2C and see also Fig. 3). Similar observations were 
obtained at other vincristine concentrations in the range of 10-100 nM. This mobility shift 
of paxillin suggests a post-translational modification of paxillin in the vincristine-induced 
stress response. 
 
Vincristine causes JNK-dependent modification of the focal adhesion scaffold protein 
paxillin - The data described above suggest a possible relationship between paxillin 
modification and the activation and localization of JNK at focal adhesions. Recent studies 
indicate that both growth factor and adenoviral E4orf4 protein-induced JNK activation 
can mediate the phosphorylation of paxillin at serine residue 178 (37). Moreover, the 
MDA nocodazole causes an increased phosphorylation of paxillin at serine residues in 
mitotic NIH3T3 cells (38). Therefore, next we evaluated the possible role of JNK in the 
mobility shift of paxillin by exposing MTLn3 cells to vincristine in combination with a 
specific inhibitor of JNK, SP600125. Pharmacological inhibition of JNK with SP600125 
(0-30 μM) abolished the mobility shift of paxillin but did not affect the tyrosine 
phosphorylation of paxillin at tyrosine 118 (Fig. 3A) or FAK at Y397 (data not shown). 
This effect was also associated with the inhibition of vincristine-induced phosphorylation 
of the JNK substrate c-Jun. To evaluate the specificity of this effect, we also determined 
the effect of other protein kinases inhibitors, including U0126 (MEK inhibitor, 10 μM), 
SB203580 (p38 inhibitor, 20 μM), H89 (PKA/ROCK inhibitor, 5 μM), Y27632 (ROCK 
inhibitor, 10 μM), bisindolmaleimide I (PKC inhibitor, 1 μM) and wortmannin (PI-3 
kinase inhibitor, 50 nM). While SP600125 again inhibited paxillin modification, none of 
the other inhibitors could prevent the reduced mobility of paxillin (Fig. 3B). To further 
confirm the indispensable role of JNK activation in vincristine-induced modification of 
paxillin, we transiently co-transfected cells with a dominant negative upstream activator 
of JNK, DN-SEK1 (GST tagged), together with GFP-paxillin. Vincristine also caused the 
mobility shift of GFP-paxillin, which was inhibited in cells that co-expressed DN-SEK1 
(Fig. 3C). Together, these data indicate that the modification of paxillin is selectively 
mediated by JNK. 
 







 Figure 3: Vincristine causes a selectively JNK-dependent modification of paxillin. MTLn3 cells were 
exposed to vincristine (50 nM) and JNK inhibitor SP600125 (conc. 0, 5, 10, 20 and 30 μM) for 8 hr. Cell 
lysates were collected for immunoblotting with antibodies against pJNK, pc-Jun, pY118paxillin and 
paxillin (A). Cells were treated with vincristine and various specific inhibitors for individual signal 
components (JNK, p38, MEK, PKA, ROCK, PKC, and PI3K) and immunoblotted with anti-paxillin (B). 
Cells were transiently co-transfected with different ratios of GST-tagged DN-SEK1 and GFP-paxillin, 
followed by immunoblotting for paxillin (left C) and the percentage of shifted paxillin was quantified by 
densitometry (right C). MTLn3 cells were treated with or without vincristine (50 nM) in the absence or 
presence of SP600125 (20 μM) for 8 hr and immunoblotted for pSer178paxillin, paxillin or tubulin (D). 
GFP-wt-paxillin (WT) and GFP-S178A-paxillin (SA) MTLn3 cells were treated with or without vincristine 
(50 nM) for 8 hr and immunoblotted for pSer178paxillin, paxillin and tubulin (E). Data shown are 
representative for three independent experiments (n=3). 
 
 
Since JNK can phosphorylate paxillin directly at serine residue 178 under certain 
conditions (39), we next explored the possible modification at this residue after 
vincristine induced JNK activation. Vincristine caused a drastic phosphorylation of 
paxillin at Ser178, which was present in the mobility-shifted form of paxillin. Importantly, 
Ser178 phosphorylation was inhibited by SP600125 (Fig. 3D). Since pSer178-paxillin co-
migrated with the mobility-shifted paxillin, we next investigated whether the 
phosphorylation itself was responsible for the mobility shift. For this purpose we used 
MTLn3 cell lines stably expressing either GFP-wt-paxillin or GFP-S178A-paxillin 
mutant. Vincristine caused a mobility shift in both GFP-paxillin and GFP-S178A-paxillin, 
comparable to endogenous paxillin. However, while phosphorylation of Ser178 was 




observed in both GFP-paxillin and endogenous paxillin upon vincristine treatment, no 
phosphorylation was observed for the GFP-S178A-paxillin mutant (Fig. 3E). This 
indicates that the JNK-dependent mobility shift of paxillin is not due to phosphorylation 
at Ser178 site itself, but most likely due to an alternative post-translational modification 
of paxillin. 
 
Together, these data suggest a model whereby the vincristine-induced activation of JNK 
and its subsequent localization at focal adhesions mediate the modification of paxillin at 
phosphorylation site serine 178 as well as another post-translational modification of 
paxillin which is independent on serine residue 178. 
 
JNK activity is required for vincristine-induced focal adhesion formation and cell 
rounding in early apoptosis - Given the localization of JNK at focal adhesions and the 
vincristine-induced modification of paxillin through active JNK, we reasoned that focal 
adhesion formation, cell contractility and cell rounding were directly related to JNK 
activity. To evaluate this, MTLn3 cells were treated with vincristine in the absence or 
presence of SP600125 followed by analysis of focal adhesion and F-actin cytoskeletal 
organization. SP600125 alone did not alter focal adhesion formation. However, while 
vincristine caused the presence of bigger focal adhesions at cell periphery, SP600125 
inhibited this and still many small focal adhesions were present throughout the cells (Fig.  
4A). In addition, overexpression of DN-SEK1, which inhibits JNK activation and paxillin 
modification (see Fig. 3C), resulted in a decrease in the number of bigger focal adhesions 
after vincristine treatment (supplemental data Fig. S4). While vincristine-induced stress 
fiber formation was associated with cell rounding, this was clearly inhibited by SP600125 
(Fig. 4C and D). Since focal adhesion formation and stability is essential in cell cycle 
progression (33, 40), we next determined whether JNK-mediated focal adhesion 
formation was directly related to vincristine-induced cell cycle arrest. While inhibition of 
JNK with SP600125 inhibited vincristine-induced cell rounding, it did not affect the onset 
of vincristine-induced cell cycle arrest at 8 hr prior to apoptosis. Rather, inhibition of JNK 
with SP600125 itself induced cell cycle arrest in MTLn3 cells (Fig. 4E). Thus, these data 
indicate that the JNK-mediated paxillin modification, focal adhesion stabilization and cell 
rounding occur independently from vincristine induced cell cycle arrest. Since SP600125 
caused apoptosis of MTLn3 cells at later time points, possibly due to cell cycle arrest, we 
could not determine the role of JNK in vincristine-induced apoptosis. 
 






Figure 4: JNK mediates vincristine-induced contractile phenotype but not cell cycle arrest. MTLn3 
cells were treated with or without vincristine (50 nM) in the absence or presence of SP600125 (20 μM) 
from 2 up till 16 hr as indicated. After 8 hr cells were stained for pY118paxillin (A; green) or pS19-MLC 
(B; green) together with F-actin (A and B; red). Phase contrast pictures were taken at 8 hr (C). Cells 
rounding was followed in time and the percentage of cells with rounded morphology was calculated (D; 
mean ± SEM; n=3). Cell cycle distribution was determined at the indicated time points by flow cytometry 
(E; mean ± SEM; n=3). Images shown are representative for three independent experiments. 
 
 
Vincristine-induced cell contractility, but not cell cycle arrest and apoptosis, is 
dependent on ROCK - The data described above suggest a relationship between JNK-
mediated stress fiber formation, focal adhesion stability, cellular contractility and 
vincristine-induced cell rounding. Cell contractility is mediated by the activation of the 
actin/myosin-based cytoskeletal network through RhoA/ROCK-mediated 
phosphorylation of the MLC signaling pathway. Therefore we hypothesized that the 
inhibition of ROCK would prevent vincristine-induced cell contractility. As mentioned 
above, vincristine caused the association of pS19-MLC with thick F-actin bundles while 
there was hardly any appearance of p-MLC bundles in non-treated cells. ROCK inhibition 
with Y27632 prevented the formation of focal adhesions at cell periphery and the 
formation of the F-actin cytoskeletal network (Fig. 5A). This was associated with the 
protection against vincristine-induced cell rounding and contractility (Fig. 5B). Next we 
determined the relationship between JNK activation and ROCK-mediated contractility. 
Importantly, ROCK inhibition with Y27632 did not affect vincristine-induced activation 
of JNK and the modification of paxillin (Fig. 5C). Since JNK is involved in F-actin stress 
fiber formation and focal adhesion stabilization, we hypothesized that JNK activation acts 




upstream of ROCK/RhoA pathway. Indeed, the inhibition of JNK with SP600125 
inhibited vincristine-induced accumulation of p-MLC at stress fibers (Fig. 4B). Finally, 
we tested whether ROCK-mediated contractility and cell rounding was not related to 
vincristine induced cell cycle arrest. Y27632 did not affect cell cycle arrest (Fig. 5E), 
supporting the dissociation between cell contractility, rounding and cell cycle inhibition. 




Figure 5: ROCK inhibition prevents vincristine-induced cell rounding and contractility but not cell 
cycle arrest or JNK activation. MTLn3 cells were treated with or without vincristine (50 nM) in the 
presence or absence of Y27632 (10 μM) for 8 hr. pSer19-MLC and F-actin were stained to visualize 
actin/myosin cytoskeleton (A). Phase contrast pictures were taken for cell morphology (B). 8 hr after 
exposure, cell lysates were collected and immunoblotted with the antibodies against pY118paxillin, paxillin, 
pJNK and JNK (C). Cell cycle distribution was determined at indicated time points by flow cytometry (D; 
mean ± SEM; n=3; controls were within the same experiments as for SP600125, see figure 4). Images and 
Western blots shown are representative for three independent experiments.  
 
 
Paxillin is essential for vincristine-induced focal adhesion formation and cell 
contractility - The data described above indicate that JNK acts upstream of ROCK to 
mediate focal adhesion formation and cell contractility after vincristine treatment. Given 
the fact that paxillin is also modified by JNK in this process, we further investigated the 
role of paxillin in focal adhesion formation after vincristine treatment. Knock down (KD) 
of paxillin was achieved by transient transfection with Dharmacon Smartpool siRNA 




against rat paxillin (5, 10, 50 nM). Loss of paxillin was already evident at 5 nM siPax; 
cells with clear paxillin knock down were easily discriminated from non effected cells 
(Fig. 6A). Maximum KD in ~95 % cells was observed at 50 nM siPax. Paxillin KD did 
not affect cell survival and cell spreading under normal culturing condition (data not 
shown). Interestingly, most of the remaining paxillin bound with high affinity at focal 
adhesion sites (Fig. 6A). Paxillin KD did not affect JNK activation (Fig. 6B). Paxillin KD 
itself caused some increased staining of pS19-MLC in cells. Nevertheless, while in 
siGFP-treated cells vincristine clearly increased the percentage of cells with strong pS19-
MLC staining, this was not evident in siPax-treated cells (Fig. 6C). Furthermore, to 
determine whether the paxillin KD inhibited the increased focal adhesion formation by 
vincristine, we quantified the percentage of cells with enhanced vinculin positive focal 
adhesions. Indeed, paxillin KD reduced vincristine-induced focal adhesion formation in 
association with reduced stress fiber formation (Fig. 7). Altogether these data indicate that 
paxillin is essential for JNK activation after vincristine treatment, whereas JNK mediates 
downstream phosphorylation and modification of paxillin as well as ROCK-mediated 




Figure 6: Paxillin knock down inhibits myosin light chain phosphorylation. MTLn3 cells were 
transfected with 5, 10, 50 nM siRNA smartpool against rat paxillin or GFP (Dharmacon) for 48 hr and 
followed by immunofluorescent staining against paxillin (top A, red is paxillin; green is pSer19-MLC) and 
immunoblotting against paxillin (bottom A). MTLn3 cells with paxillin KD (50 nM siRNA) for 48 hr were 
treated with vincristine (50 nM) for 8 hr and cell lysates were immunoblotted with antibodies against 
pS178-paxillin, paxillin, pJNK, pc-Jun and tubulin (B), or cells were fixed and stained for pS19-MLC 
(green) and vinculin (red) (top C). The percentage of cells with strong pS19-MLC along stress fibers were 
quantified (bottom C; mean ± SEM; n=3; asterisk indicates p < 0.05 by Student’s T-test). 








In the present manuscript we investigated the mechanism by which MDAs affect cell 
contractility and how this relates to both MDA-induced cell cycle arrest and apoptosis. 
For this purpose we used mammary adenocarcinoma MTLn3 cell line and the MDA 
vincristine as a model compound. Our key findings indicate that, firstly, vincristine 
induced JNK activation is essential in vincristine-induced focal adhesion formation and 
cell contraction. Secondly, this effect is related to a JNK-dependent modification of the 
focal adhesion-associated scaffold protein paxillin on two sites, of which one is Ser178 
phosphorylation and the other is a Ser178-independent high molecular weight 
modification. Thirdly, paxillin is not required for vincristine-induced JNK activation but 
is essential for the enhanced focal adhesion and stress fiber formation in association with 
the phosphorylation of MLC. Our combined data suggest a model in which vincristine 
induces JNK activation and its localization at focal adhesions, thereby mediating a post-
translational modification of paxillin; the JNK-paxillin activation is essential for the 
downstream activation of ROCK-dependent MLC which drives the actin stress fiber 
formation and enhanced focal adhesion formation. This pathway seems independent on 






Figure 7: Paxillin knock down inhibits 
vincristine-induced focal adhesion and stress 
fiber formation. MTLn3 cells with paxillin KD 
(50 nM; 48 hr) were treated with vincristine (50 
 nM) for 8 hr and followed by fixation and a 
triple immunostaining for pY118paxillin (left), F-
actin (middle) and vinculin (right). The 
percentage of cells that possess bigger focal 
adhesions was determined as intense staining of 
vinculin-positive focal adhesions (mean ± SEM; 





Our data suggest that vincristine-induced JNK activation directly affects a central focal 
adhesion-associated adaptor protein paxillin. We observed two different modifications of 




paxillin after vincristine treatment: a phosphorylation at Ser178 and a yet unidentified 
modification. Both modifications were dependent on JNK, since SP600125 inhibited both 
these modifications. This fits with the co-localization of active JNK and paxillin at focal 
adhesions after vincristine treatment. Interestingly, Ser178 seems not to be critical for the 
unidentified modification of paxillin, since GFP-Ser178Ala paxillin could still be 
modified in a similar JNK-dependent manner. Yet, pSer178-paxillin was primarily 
present in the shifted form of paxillin, suggesting that Ser178 phosphorylation and the 
other modification are related. At present we have excluded that this modification is 
directly due to poly-phosphorylation, ubiquitination or sumoylation (data not shown). 
Possibly this modification is related to neddylation or glycosylation, which at least is 
dependent on JNK activity. Importantly, hydrogen peroxide-induced stress response in 
MTLn3 cells, which induced a drastic but transient JNK activation, was also associated 
with the same paxillin mobility shift (data not shown), excluding the notion that this 
would only be observed in the treatment with MDAs. It is noteworthy that another lower 
migration paxillin family member, possibly paxillin-delta or leupaxin (Mw is ~40kDa), 
which is recognized by paxillin and pS178paxillin antibodies and also targeted by paxillin 
siRNAs, responds to vincristine exposure in an exactly similar JNK-dependent pattern in 
MTLn3 cells (data not shown). Leupaxin shares a large homology with paxillin and forms 
a complex with the FAK familiy PYK2, c-Src, PTP-PEST, thereby regulating cell 
migration, adhesion and invasion (41, 42). It is reasonable to deduce that this paxillin-like 
protein has a similar role in cytoskeleton reorganization and focal adhesion assembly 
induced by vincristine. Our data on JNK-mediated phosphorylation of paxillin at Ser178 
adds to the lists of both growth factor and xenobiotic-induced JNK-dependent 
phosphorylation of paxillin (21, 28, 36, 43). Regardless of the actual type of post 
translational modification of paxillin in our model, the data support the general perception 
that JNK activation has many different downstream effectors which may be involved in 
specific biological responses related to either cell stress or other physiological conditions. 
In this respect we also observed that EGF and HGF induce a JNK-dependent 
phosphorylation of paxillin, although this is not the same mobility shift of paxillin by 
vincristine (Le Devedec et al, manuscript in preparation). 
 
The modulation of paxillin in focal adhesion turnover is not only due to phosphorylation 
at Ser178, but also other sites, such as Ser273 via p21-activated kinase activity. Ser273 is 
important to localize paxillin in a GIT1-PIX-PAK complex and regulate adhesion and 
protrusion dynamics (44, 45). Other serine residues like Ser126 and 130 of paxillin can be 
phosphorylated in an ERK-dependent manner and this is also involved in cytoskeleton 
reorganization (46). In our hands ERK was not activated by vincristine, and U0126 did 
not affect the mobility shift of paxillin, excluding the likelihood of enhanced 
phosphorylation of these sites after vincristine treatment. 
 
Our data provide a link between JNK-mediated paxillin modification and increased focal 
adhesion formation in association with activation of actin/myosin-based cell contractility. 
All these data indicate that the inhibition of JNK with SP600125 inhibits focal adhesion 




formation, pSer19-MLC positive stress fibers and cell rounding. Similarly, knock down 
of paxillin inhibits these vincristine-induced events. Since paxillin does not affect 
vincristine-induced JNK activation, we anticipate that JNK acts upstream of paxillin. At 
this moment we do not know whether paxillin Ser178 phosphorylation and/or the 
alternative modification of paxillin, both of which are mediated by JNK activation, are 
central in vincristine-induced focal adhesion formation and cell contractility. We 
expressed Ser178Ala-paxillin mutant in MTLn3 cells; these cells show decreased focal 
adhesion dynamics, are rounded up and have difficulties to fully spread upon stimulation 
with EGF (Le Devedec et al. in preparation). These results would argue that Ser178 
phosphorylation is involved in cell spreading process rather than promoting cell 
contractility process, and would leave the other modification of paxillin as the major 
mediator of cell contractility. Identification of this modification will be an important step 
to further understand the role of paxillin in cellular stress response. 
 
Our data suggest that JNK and paxillin act upstream of ROCK-dependent actin/myosin-
mediated cell contractility. As indicated above, irrespective of the actual type of paxillin 
modification, paxillin KD resulted in a similar inhibition of vincristine-induced 
phenotype as did SP600125. Both JNK inhibition and paxillin knock down prevented 
vincristine-induced MLC phosphorylation. This was also inhibited by an inhibitor of 
ROCK, Y27632, but ROCK inhibition did not affect JNK activation and paxillin 
modification. A JNK/paxillin/ROCK relationship has also been indirectly shown in 
another recent manuscript, indicating that JNK and pSer178-paxillin are essential in the 
recruitment of paxillin to FAs from an internal pool in a ROCK dependent manner (37). 
How could the JNK-paxillin linkage lead to enhanced ROCK-mediated pSer19-MLC and 
cell contraction? It is known that other MDAs lead to the activation of RhoA or a shift in 
the balance between pro-motile Rac activity and pro-contractile RhoA activity (47). 
Possibly this is related to the disrupted targeting of active Rac1 molecules to focal 
adhesions through the microtubular tips, since vincristine disrupts this process. In our 
hands the expression of active Rac mutants prevented vincristine induced contractility 
(data not shown). The association of paxillin with the GIT1-PIX-PAK complex is 
important for the regulation of cell adhesion and protrusion dynamics through Rac 
activation (44). Possibly, the JNK-dependent paxillin modifications affect the formation 
of this complex and the localized Rac activation that would otherwise promote 
lamellipodia formation and antagonize cell contractility. 
 
The JNK-mediated contractility seems not to affect vincristine-induced cell cycle arrest, 
as neither SP600125 nor Y27632 inhibited cell cycle arrest. Cell cycle arrest is most 
likely due to disrupted microtubule and spindle formation. Also the onset of apoptosis 
was not affected by preventing cell contractility (data not shown). Therefore, we propose 
that, at least in our in vitro model, vincristine-induced cell cycle arrest and apoptosis are 
distinct from cytoskeletal reorganization. Since the cytoskeletal events occur at equimolar 
concentration as the microtubule-disrupting activity of vincristine (47), one could 
anticipate that under conditions of in vivo vincristine treatment regimens, vincristine may 




not only prevent cell cycle progression, but also limit the efficiency of tumor cells to 
migrate and intravasate due to decreased focal adhesion dynamics. This would prevent 
the dissemination of metastatic tumor cells, and would be an additional advantage of 
MDA therapy. 
 
In conclusion, we demonstrate the role of JNK-paxillin axis in the regulation of ROCK- 
dependent actin/myosin-related tumor cell contractility after vincristine treatment. 
Although the modulation of JNK-paxillin axis in tumor cells might be relevant to target 
cancer progression, further research is required to identify the exact paxillin modifications 
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Figure. S1: Vincristine induces microtubule disruption and actin stress fiber formation. MTLn3 cells 
were treated with 50 nM vincristine for 8 hr. After fixation, cells were immunostained with the antibodies 
against tubulin (green) and actin (red).  
 
Figure. S2: Vincristine induces focal adhesion formation. MTLn3 cells were treated with 50 nM 
vincristine for 8 hr. After fixation, cells were immunostained with the antibodies against pY397 FAK 









Movie S3: Vincristine reduces the dynamics of focal adhesions. GFP-paxillin MTLn3 cells were treated 
with 50 nM vincristine for 8 hr and cells were visualized with total interference reflection fluorescence 
(TIRF) microscopy for 4 hr with 5 min/frame intervals. Movie S3A and S3B are representative movies 
(S3A for control cells (left DIC and right TIRF) and S3B for vincristine treated cells (left DIC and right 
TIRF)).  
 
Figure. S4: JNK inhibition with DN-SEK rescues vincristine-induced focal adhesion formation. 
MTLn3 cells were transiently transfected overnight with GST-DN-SEK1 and GFP-Histon2B (ratio 20:1) 
and treated with vincristine (50 nM, 8 hr). Cells were fixed and stained with the antibodies against 
pY118paxillin (left top, red) and vinculin (left bottom, blue). Top right panel indicates the transfected cells 
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The focal adhesion-associated scaffold protein paxillin plays a prominent role in cell 
migration. Recent data indicate JNK-mediated phosphorylation of paxillin at 
serine178. Here we investigated the role and mechanism of paxillin-Ser178 in the 
control of EGF-induced cell migration of the highly metastatic rat mammary 
carcinoma MTLn3 cells. EGF induced transient activation of JNK in MTLn3 cells, 
which was associated with JNK-dependent Ser178-paxillin phosphorylation. MTLn3 
cells expressing a GFP-tagged Ser178Ala (S178A)-paxillin mutant had a phenotype 
with reduced proliferation, slower attachment and wound healing rate, compared to 
GFP-wt-paxillin expressing cells. Furthermore, the mutant cells did not undergo 
EGF-induced random cell migration sufficiently. EGF treatment resulted in limited 
phosphorylation at Ser178 of endogenous paxillin in S178A-paxillin MTLn3 cells. 
Moreover, EGF was unable to efficiently activate the PI3K/AKT and ERK pathways 
in these cells, compared to wt-paxillin cells. This suggests that Ser178-paxillin is 
important to control the EGF-induced signaling. Since paxillin phosphorylation at 
Ser178 is important to control cell migration of breast tumor cells, this 
phosphorylation event may also be important for breast tumor progression and 




Breast cancer represents the most common worldwide type of cancer among women. The 
occurrence of distant metastases, or secondary tumors, is related to a very poor disease 
prognosis. The formation of secondary tumors involves distinct steps at the cellular level, 
including detachment, migration, invasion, extravasation and proliferation (1). To combat 
breast cancer metastasis more efficiently, improved insights into biological mechanisms 
in metastasis formation are of great importance. Focal adhesions, the closest contacts 
between cells and ECM, are important sites for signaling events (2-4). At focal adhesions, 
structural and enzymatic molecules act together to facilitate growth factor-stimulated and 
cell adhesion-dependent signaling, which are crucial in the different steps of the 
metastatic process (5,6). 
 
Paxillin, a 68 kD multidomain adaptor protein, is associated with focal adhesions, where 
it functions as a scaffold to integrate multiple signaling pathways (4). At the N-terminus 
paxillin contains five leucine-rich LD domains (consensus LDXLLXXL) and several SH2 
and SH3-binding domains; at the C-terminus paxillin contains four double zinc-finger 
LIM domains. LD domains facilitate the binding of a large array of binding partners, 
including integrin-linked kinase (ILK), actopaxin, G-protein coupled receptor kinase-
interacting protein (GIT), focal adhesion kinase (FAK) and vinculin (7-10). The LIM 
domains of paxillin mediate the interaction with PTP-PEST and tubulin (11). LIM3, 
together with LIM2, targets paxillin to focal adhesions (11).   
 




Throughout the paxillin molecule are many potential phosphorylation sites, including 
tyrosine, serine and threonine, which have all been mapped by mass spectrometry (12-
14). Growth factor and integrin-mediated phosphorylation of paxillin at Tyr31 and 
Tyr118 induces the formation of a paxillin-Crk complex at focal adhesions and is 
essential for cell migration (15-17). Subsequently Crk-DOCK180 mediates the activation 
of Rac to enhance migration through lamellipodial extension (18-20). In NBT-II bladder 
tumor cells, induction of paxillin Tyr 31/118 phosphorylation and its association with 
CrkII are involved in cell adhesion, spreading and motility (20). Also Ephrin B1-
stimulated cell migration requires phosphorylation of paxillin Tyr31/118 as well as the 
LD4 domain in a variety of cell types (21).  
 
Serine/threonine phosphorylation of paxillin is observed by growth factor-mediated 
signaling, cellular stress and during mitosis (22-25). For example, adhesion stimulates the 
phosphorylation at Ser188/190 by an unknown kinase, as well as serine and threonine 
residues within LIM domains 2 and 3 (26). In addition, phosphorylation of paxilin at 
Ser273 has also been reported to regulate cell adhesion and protrusion dynamics via 
enhancing paxillin-GIT1 binding and promoting localization of a GIT1-PIX-PAK 
signaling module near the leading edge (12). Furthermore, p38 MAP kinase targets serine 
85 in the process of neurite outgrowth (23). Finally, phosphorylation of paxillin at serine 
178 is involved in EGF-stimulated cell migration via JNK (26,27) as well as in 
microtubule disruption condition which is also in association with JNK activation (see 
chapter 4). Many cell processes in tumor development depend on growth factor-mediated 
signaling, including EGF and HGF, which involves the activation of different MAPK 
family members. Therefore, it is important to further explore and understand the exact 
role of Ser178-paxillin phosphorylation by growth factors in cell migration and 
proliferation. Here we studied the role of Ser178-paxillin in the highly metastastic breast 
tumor cell line MTLn3. 
 
We generated MTLn3 cell lines stably expressing either wt paxillin or Ser178Ala 
(S178A) mutant paxillin. S178A-paxillin significantly decreased cell proliferation and 
adhesion. Cell migration under control conditions (serum starvation) or after EGF 
stimulation was inhibited. S178A-paxillin suppressed JNK-mediated phosphorylation of 
endogenous paxillin under control and EGF conditions. The data indicate that Ser178 
phosphorylation of paxillin after growth factor stimulation is essential to control cell 
migration and efficient activation of downstream signaling events including the 
PI3K/AKT and MEK/ERK signaling pathways. Altogether we conclude that the serine 
178 residue of paxillin is an important player in cell proliferation and migration of 
metastatic breast tumor cells, and may be important for in vivo metastasis formation.  




MATERIALS AND METHODS 
Chemicals and Antibodies- Alpha modified minimal essential medium without 
ribonucleosides and deoxyribonucleosides (α-MEM), fetal bovine serum (FBS), 
phosphate buffered saline (PBS), trypsin and geneticin (G418 sulphate) were from Life 
Technologies. Rat tail collagen type I was from Upstate Biotechnology. LipofectAMINE 
Plus transfection reagents were from Invitrogen. Bradford protein assay was obtained 
from Bio-Rad and polyvinylidene difluoride (PVDF) membranes were from Millipore. 
Primary antibodies were anti-paxillin (BD), anti-tubulin, anti-GFP (Sigma, St. Louis, 
MO), anti-pT183/pY185-JNK (Promega), anti-Phospho-Thr202/Tyr204 ERK1/2, anti-
pSer473-AKT (Cell signaling), anti-pSer178-paxillin (Abcam, Cambridge, UK). All 
secondary antibodies were from Jackson (GαRb-AP, GαM-HRP, GαRb-HRP or GαM-
CY5). The Western-Star immunodetection system (Tropix kit) was from Applied 
Biosystems and ECL Plus reagent was from Amersham. Hoechst 33258 and rhodamine-
phalloidin were from Molecular Probes and Aqua Poly/Mount was from Polysciences. All 
other chemicals were of analytical grade.  
Cell Culture- MTLn3 cells were cultured as before (28). To generate stable cell lines, 
MTLn3 rat mammary carcinoma cells were transfected with GFP-paxillin or GFP-
paxillinS178A along with empty vector pcDNA3 using LipofectAMINE plus reagents 
according to manufacturer’s procedures. Stable transfectants were selected using G418 at 
a concentration of 500 μg/ml. Individual clones were picked and maintained in α-MEM 
supplemented with 5% (v/v) FBS containing 100 μg/ml G418 (complete medium). Clones 
were regularly analyzed for the expression of GFP constructs by flow cytometry analysis, 
western blotting and immunofluorescence. Cells were used for up to 8 passages and 
expression levels of GFP tagged proteins remained stable during experiment period. For 
stimuli experiments, 80-90% confluent cells were starved for 4hr and stimulated with 
EGF (10 nM) or HGF (5 ng/ml) for indicated time periods. 
Proliferation, Attachment and Wound Healing Assay- For proliferation assay, cells were 
seeded in complete medium on 6 well-plates for 24, 48, 72 or 96 hrs. Cells were detached 
and the amount of cells was determined by counting. For cell attachment assay, cells were 
starved for 1 hr in serum-free medium and detached. Equal amounts of cells were plated 
in complete medium on collagen-coated 6-well plates. After 30, 60, 90 and 120 minutes, 
attached cells were trypsinized and counted. For wound healing assay, monolayer cells 
were scratched using a pipette tip to generate a wound. Plates were then washed with 
medium and wounds were photographed using phase contrast microscopy with a Nikon 
Coolpix digital camera. Plates were then incubated in α-MEM supplemented with 1% 
(v/v) FBS for 20 hrs. Wounds were photographed again and wound closure was 
determined using Image J software. 
 
Live Cell Imaging- Cells were cultured in glass-bottom plates overnight and starved for 4 
hrs followed by visualization with high throughput microscopy for 1 hr on a Nikon TE 




2000-E microscope equipped with perfect focus system in a humid climate of 37°C and 
5% CO2. Subsequently, cells were treated with EGF or HGF and the exactly same fields 
were visualized for 1 hr. Movies were captured five minutes per frame with 20x 
objective. Cell speed was determined by tracking cell center and calculating the distance 
between two sequential frames. Cell dynamics were measured with cell surface area 
change between two sequent frames by homemade macro adopted in Image-Pro Plus 
(version 5.1, Media Cybernetics Inc., Silver Spring, MD). 
 
TIRF and FRAP- Total internal reflection fluorescence (TIRF) microscopy was 
performed on GFP-paxillin MTLn3 cells and GFP-S178A-paxillin in a climate control 
chamber. TIRF movies were captured on a Nikon TIRF microscope system (Eclipse TE 
2000-E, Nikon with automated stage) with framing every 5 minutes for 4 hrs using NIS-
elements AR software (Nikon). To determine the turnover of GFP-tagged paxillin in 
individual focal adhesions, fluorescence recovery after photobleaching (FRAP) was 
performed as follows:  photobleaching was applied to a small area covering a single focal 
adhesion for 1 s with laser intensity of 50 μW. Redistribution of fluorescence was 
monitored with 100 ms time intervals at 7.5μW starting directly after the bleach pulse. 
Approximately 20 focal adhesions (each in distinct cells) were averaged to generate one 
FRAP curve for a single experiment. All measurements were performed at 37 °C using a 
heating stage with feedback temperature control and the experiment was performed on at 
least three different days. Images were analyzed with Image software (Zeiss). The relative 
fluorescence intensity of individual focal adhesion was calculated at each time interval as 
follows: Irel(t) = (FAt / FA0), where FAt is the intensity of the focal adhesion at time point 
t after bleaching, FA0 is the average intensity of the focal adhesion before bleaching. The 
fluorescent curves were analyzed with non-linear regression analysis (GraphPad Prism 5).  
 
Gel Electrophoresis and Immunoblotting- Western blot analysis was performed as 
before (29). Cells were scraped in ice-cold TSE (10 mM Tris, 250 mM sucrose, 1 mM 
EGTA, pH 7.4) plus inhibitors (10 μg/ml aprotinin, 1 mM dithiothreitol, 10 μg/ml 
leupeptin, 50 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride). After 
sonication, protein levels were determined using the Bradford protein assay with IgG as a 
standard. Equal amounts (25 μg) of cellular lyses were separated on 7.5% polyacrylamide 
gels and transferred to PVDF membranes. Membranes were blocked in either 0.2% (w/v) 
casein in TBS-Tween20 (for phospho-state specific antibodies) or 5% (w/v) BSA in TBS-
T (for other primary antibodies) and probed with primary antibody overnight followed by 
sufficient washes and incubation with secondary antibodies. Alkaline phosphatase (AP)-
conjugated secondary antibodies for phospho-proteins were detected with the Western-
Star immunodetection system. For detection of horseradish peroxidase (HRP)-conjugated 
antibodies, ECL Plus reagent was used and followed by visualization on a Typhoon 
Imager 9400 (520nm, blue laser). 
 
Immunofluorescence- Cells were seeded on collagen coated glass coverslips. Cells were 
briefly washed in PBS, followed by fixation in 3.7% formaldehyde for 10 min at room 




temperature. After washing, coverslips were blocked in TBP (0.1% (w/v) Triton X-100, 
0.5% (w/v) BSA in PBS, pH 7.4). Incubation with primary antibodies diluted in TBP 
containing 0.05% (w/v) NaN3 was carried out overnight at 4°C. Primary antibodies were 
against paxillin. Coverslips were incubated with secondary antibodies conjugated to Cy5. 
After sufficient washing, coverslips were mounted on glass slides using Aqua 
Poly/Mount. Cells were visualized using a Bio-Rad Radiance 2100 MP confocal laser 
scanning system equipped with a Nikon Eclipse TE2000-U inverted fluorescence 
microscope and a 60X Nikon objective. 
Statistical Analysis- Student's t test was used to determine significant differences between 




Mutation of Paxillin Serine178 Inhibits MTLn3 Cell Proliferation and Wound Healing 
Capability and Attenuates Cell Attachment- Paxillin is implicated in EGF-stimulated cell 
migration of rat bladder tumor epithelial cells (NBT-II) through JNK-mediated 
phosphorylation at paxillin Ser178 (27). Firstly we determined the involvement of JNK in 
EGF-induced migration of MTLn3 mammary adenocarcinoma cells. Exposure to EGF 
caused a rapid onset of random cell migration in MTLn3 cells, which was inhibited by an 
inhibitor of JNK, SP600125, indicating the requirement for JNK in cell migration (Fig. 
1A). Next we determined the involvement of paxillin in this process. Treatment with EGF 
induced the transient phosphorylation of paxillin at Ser residue 178 in association with 
JNK activation. Importantly, this paxillin phosphorylation was dependent on JNK, since 
the inhibitor SP600125, prevented the phosphorylation at Ser178 (Fig. 1B). These data 
indicate that in MTLn3 cells EGF-induced phosphorylation of paxillin at Ser178 is 
mediated by JNK.  
 
To further investigate the role of paxillin Ser178 in cell migration and proliferation, we 
generated MTLn3 cell lines stably expressing either GFP-tagged wt-paxillin or mutant 
GFP-paxillin in which the serine residue 178 was replaced by alanine (further referred to 
as S178A-paxillin). Clones of MTLn3 cells stably expressing GFP-wt-paxillin or GFP-
S178A-paxillin were evaluated by flow cytometry (data not shown), western blotting and 
immunofluorescence (data not shown). Three wt-paxillin clones and three S178A-paxillin 
clones were selected for further experiments. Expression levels were equal in all three wt 
clones; one S178A clone had a lower expression level most likely due to reduced number 
of GFP-positive cells (Fig 2A). Expression levels of recombinant proteins remained stable 
for at least 8 passages (data not shown). Next, we determined the effect of S178A-paxillin 
expression on cell proliferation. S178A-paxillin expression significantly reduced the 
growth rate of MTLn3 cells (Fig.2B). This suggests that S178A-paxillin disturbs the 
essential cell proliferation signaling.  








Figure 1: EGF signaling induces JNK-paxillin 
involved cell migration. MTLn3 cells grown in 
collagen-coated glass-bottom plate were pretreated 
with or without JNK inhibitor SP600125 for 30min 
and stimulated with EGF. Live cell migration was 
visualized on Nikon Eclipse TE2000-E PFS 
microscope (Nikon). Cell migration speed was 
analyzed as described in Materials and Methods 
section (A). Monolayer cells were pretreated with 
SP600125 for 30 min and followed with indicated 
incubation of EGF for 0, 5, 10, 20, 30, 60 min. Cell 
lyses were collected and separated with SDS-PAGE, 











Given the prominent role of paxillin in focal adhesion formation and dynamics, we next 
examined the effect of S178A-paxillin expression on MTLn3 cell attachment and 
spreading. For this purpose cells were seeded on collagen-coated dishes and allowed to 
attach for 30, 60 90 and 120 minutes. Significantly less S178A-paxillin cells, compared to 
wt-paxillin cells, attached. Importantly, while most of wt-paxillin cells had already 
spread, most of the S178A-paxillin cells remained round and presented a smaller surface 
area even when they attached and spread (Fig. 2C). This indicates that Ser178 of paxillin 
is essential for efficient attachment and spreading of MTLn3 cells to collagen. Next we 
determined the effect of S178A-paxillin on cell migration in an artificial wound healing 
assay. The closure speed of artificial wounds was determined after 20 hrs (Fig. 3). While 
wt-paxillin cells had closed the wound by 83 %, in sharp contrast, S178A-paxillin cells 
had only closed 25% of the wound. In conclusion, these above results indicate that 
S178A-paxillin affects different aspects of cell adhesion and migration.  







Figure 2: Ser178 residue of paxillin regulates cell proliferation and attachment. 3 different colonies for 
wt and S178A cells were picked for further research. Cell lysates for each cell line were collected and 
analyzed for GFP-paxillin expression by western blotting (A). Equal amounts for each clone (3 wt-paxillin 
clones and 3 S178A-paxillin clones) were cultured for indicated time periods and cell proliferation was 
determined by cell counting (B). Cell adhesion assays were performed as described in Materials and 
Methods section for all the wt and S178A clones. Note that S178A-paxillin cells are defective in efficient 
cell spreading (right panel) (C). Data shown are results from three independent experiments (mean ± SD; 
n=3). 








Figure 3. GFP-S178A-paxillin 
reduces wound closure rate. 
The wound healing assay was 
performed as described in 
Materials and Methods. The 
wounds at indicated time points 
were photographed (Left). The 
length of wounds was measured 
in Image J and migration was 
expressed as the percentage of 




Reduced Dynamics of GFP-S178A-paxillin at Focal Adhesions- To investigate the 
mechanism of the inhibitory effect of S178A-paxillin on cell migration, next we 
determined the dynamics of S178A-paxillin at focal adhesions. First, we evaluated the 
localization of GFP-wt-paxillin and GFP-S178A-paxillin in MTLn3 cells. With normal 
confocal microscopy, clear localization at focal adhesion was difficult to determine, 
although both GFP-wt-paxillin and GFP-S178A-paxillin were present at membrane 
ruffles and co-localized with paxillin in the same staining pattern indicating spatial 
functionality of both wt and mutant GFP paxillin constructs (Fig. 4A). To discern 
localization at focal adhesions we used TIRF microscopy, which allowed the detection of 
GFP signal in cells at the focal plane where cells make direct contact with the coverslip. 
TIRF microscopy indicated that both wt-paxillin and S178A-paxillin were localized at 
focal adhesions (Fig. 4B), thus indicating that the localization of S178A-paxillin at focal 
adhesions does not disturb the formation of focal adhesions. Next we investigated the 
dynamics of wt-paxillin and S178A-paxillin at focal adhesions. For this purpose we 
performed fluorescence recovery after photobleaching (FRAP) experiment with GFP-wt-
paxillin and GFP-S178A-paxillin cells. Interestingly, GFP-S178A-paxillin cells showed 
the same recovery rate as GFP-wt-paxillin under control conditions. EGF stimulation 
increased the florescence recovery rate in GFP-wt-paxillin cells but not in GFP-S178A-
paxillin cells (Fig. 4C). Thus, Ser178 at least in part determines the turnover of paxillin at 
focal adhesions and this residue mutant disturbs the cell response to EGF. 
 
 







Figure 4: GFP-S178A-paxillin competitively co-localizes with endogenous paxillin at focal adhesion 
sites and decreases EGF-induced turnover of focal adhesions. GFP-wt-paxillin and mutant Ser178Ala 
cells were fixed for immunofluorescent assay and stained with mouse anti-paxillin antibody (A). A single 
frame from TIRF movies for GFP-wt-paxillin and mutant Ser178Ala cells (B). FRAP assay with GFP-wt-
paxillin cells and mutant Ser178Ala-paxillin cells. Cells were treated with or without EGF for 20 mins 
before FRAP (C). Data shown are representative results from three independent experiments.  
 
 
S178A-paxillin Inhibits Cell Motility in Serum Starved and EGF-Treated Conditions, 
but HGF Stimulates More Sufficiently- Next we investigated the effect of S178A on 
EGF-induced cell migration. Both wt-paxillin and S178A-paxillin cells were treated with 
EGF (10 nM) followed by the analysis of random cell migration. While wt-paxillin cells 
rapidly formed lamellipodia and became highly motile, this did not happen for S178A-
paxillin cells (movie not shown). Since S178A-paxillin acts as a dominant negative 
construct in these cells, S178A-paxillin would compete for the localization of endogenous 
paxillin at focal adhesions and we reasoned that endogenous paxillin should lose either 
the basal phosphorylation level of Ser178 and/or the capability of being phosphorylated 
by JNK at Ser178. Indeed, EGF stimulation hardly activated phosphorylation of 
endogenous paxillin; as expected GFP-S178A-paxillin in these cells was not 
phosphorylated at all. In wt-paxillin cells, both endogenous and GFP-wt-paxillin were 
phosphorylated at Ser178 after EGF treatment (Fig. 6 top).  







Figure 5: EGF and HGF induce cell 
migration and dynamic differently in 
GFP-wt-paxillin and mutant Ser178Ala 
cells. Random migration assay was done as 










Cell scattering is also induced by other growth factors, including hepatocyte growth 
factor/scatter factor (HGF) (30,31). HGF also induces activation of JNK in various cell 
types (32). We wondered whether HGF would be able to induce cell scatter in mutant 
cells. Treatment with HGF (5 ng/ml) induced cell migration in wt-paxillin cells. While 
S178A-paxillin did hardly migrate under serum starvation conditions, HGF stimulated 
cell migration better than EGF in S178A-paxillin cells (Fig. 5). These data indicate that, 
apparently, the cell migration machinery is functional in S178A-paxillin cells. 
Interestingly, in S178A-paxillin, HGF was capable of phosphorylating endogenous 
paxillin at Ser178 to a similar extent as in wt-paxillin cells; again S178A-paxillin was not 
phosphorylated after HGF treatment (Fig. 6 bottom). This suggests the phosphorylation of 
Ser178 is crucial for cell migration. 
 
S178A-paxillin MTLn3 Cells have Reduced EGF-induced Activation of AKT and ERK- 
Finally, we determined the possible mechanism by which S178A-paxillin affects EGF-
induced cell migration. Since EGFR signaling is regulated and trans-activated at focal 
adhesions by both integrins (33,34) and FAK (35-37), we reasoned that possibly S178A-
paxillin would disturb the downstream signaling of the EGFR. To investigate this, both 
wt-paxillin and S178A-paxillin cells were treated with EGF and downstream activation of 
both AKT and ERK was determined by western blotting. While EGF caused activation of 
AKT in wt-paxillin cells, proper AKT activation by EGF was inhibited in S178A-paxillin. 
Also ERK activation was slightly reduced in S178A-paxillin cells compared to wt-
paxillin cells after EGF treatment, albeit less significant than that for AKT (Fig. 7 top). 
We then evaluated whether S178A-paxillin cells responded normally to HGF. Indeed, 
HGF treatment resulted in similar levels of phosphorylated ERK in both wt-paxillin and 
S178A-paxillin cells (Fig. 7 bottom). While the activation of AKT was reduced in 
S178A-paxillin cells, the overall activity of AKT by HGF stimulation was higher, 
compared to EGF stimulation (compare Fig. 7 top and bottom panels). These data suggest 




that S178A-paxillin affects EGFR-mediated signaling and interferes with downstream 






Figure 6: GFP-wt-paxillin and mutant Ser178Ala cells display different activation of signal pathway 
to EGF and HGF. 90% confluent cells were starved for 4hrs and stimulated with EGF (10nM, top panels) 
or HGF (5ng/ml, lower panels) for 0, 5, 10, 20, 30, 60 mins. Cell lyses were collected and western blot 
assay were performed to probe with antibodies against pSer178 paxillin and paxillin as mentioned in 




           
The scaffold protein paxillin at focal adhesions regulates cell motility by regulating FA 
assembly and disassembly processes (3,17). In this study, we investigated the role of 
JNK-mediated phosphorylation of paxillin at Ser178 by generating cell lines stably 
expressing GFP-tagged paxillin in which the Ser178 residue was replaced by non-
phosphorylatable alanine. Using these cell lines we were able to demonstrate that: 1) 
Ser178 phosphorylation is essential for efficient cell migration; 2) Ser178 
phosphorylation determines the rate of cell proliferation; 3) Ser178 affects the efficiency 
of EGF-induced downstream signaling.  










Figure 7: MTLn3 mutant Ser178Ala cells display 
a delayed and deficient activation of p-AKT 
compared to wt-paxillin cells in response to EGF. 
90% confluent cells were starved for 4 hrs and 
stimulated with EGF (10 nM, top panels) or HGF (5 
ng/ml, lower panels) for 0, 5, 10, 20, 30 or 60 min. 
Cell lysates were collected and analyzed by western 






            
 
 
EGF is an important growth factor in the tumor metastasis process of MTLn3 cells (38). 
Our data indicate an important role for Ser178 of paxillin to control efficient EGF-
induced signaling. We have performed Affymetrix cDNA microarray analysis of GFP-
paxillin and GFP-S178A-paxillin (all clones depicted in Fig. 2). Interestingly, the 
preliminary data analysis indicate that the stable mutant S178A-paxillin cell lines express 
reduced levels of EGFR compared to wild type cell lines. Although further analysis of 
EGFR at the protein level is required, these data might explain both the reduced EGF-
induced activation of AKT and ERK, in association with reduced EGF-induced cell 
migration. Since EGFR signaling is crucial for tumor progression, more in vivo work 
concerning the role of paxillin Ser178 and EGFR expression in tumor formation and 
progression should be carried out. In addition to EGFR, the levels of some cytoskeleton-
associated proteins and matrix components were affected by S178A-paxillin expression, 
including secreted phosphoprotein 1 (fold change (mutant cells/wild type cells) =15), Rho 
GTPase activating protein 18 (FC=2), MMP3 (FC=6). These proteins may provide a clue 
for the cytoskeletal differences as well as the different capabilities in cell adhesion and 
migration observed in S178A-paxillin cells.   
 
We have showed that JNK mediates the phosphorylation of paxillin Ser178 after EGF 
treatment. JNK is also activated by cellular stress conditions such as oxidative stress or 
microtubule disruption. As indicated in chapter 4, the microtubule disrupting agent 
vincristine induces a drastic and sustained activation of JNK in MTLn3 cells, which is 
associated with the modification of paxillin by phosphorylation of Ser178 as well as by an 
alternative modification of paxillin resulting in a mobility shift by SDS-PAGE. 
Apparently, the JNK activation by growth factors does not cause the same mobility shift 
of paxillin (see appendix figure at the end of this chapter). This suggests a more complex 




regulation of paxillin by JNK, which may be dependent on either the transient JNK 
activation after growth factor treatment, or alternative stress signaling pathways that are 
activated by stress conditions, such as microtubule disruption. Future work should 
establish the role of both of these paxillin phosphorylation events under in vivo 
conditions, and the relevance to both cancer progression and the sensitivity towards 
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The comparison of paxillin modulation induced by vincristine (VCR) and EGF (shown is 
the immunoblot with paxillin antibody). Note the mobility shift of both GFP-tagged 
paxillin and endogenous paxillin by VCR but not by EGF. 
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The poor efficacy of breast cancer treatment is often a clinically intractable problem and 
the progressive stage of the disease is typically due to tumor metastasis formation. 
Primary tumors can be removed by surgery, chemotherapy and radiation therapies. 
However, small amount of remaining tumor cells in distant organs gain resistant 
capabilities and treatment of metastasis becomes more difficult. Therefore it is important 
to better understand the underlying metastasis process as well as the acquired drug 
resistance in breast cancer. 
 
Chemokines and receptors in tumor microenvironment provide survival and chemotaxis 
signaling to tumor cells and are also involved in tumor growth and progression via 
leukocyte recruitment at tumor site. Focal adhesions (FAs) link cells to extracellular 
matrix and function as integration sites of signaling by extracellular stimuli (e.g. soluble 
factors, mechanical force, etc). Growth-factor-activation and integrin-clustering-induced 
FA-mediated signaling regulates cytoskeleton reorganization, cell adhesion, migration, 
proliferation and survival. The studies described in this thesis aimed to explore the role of 
FA signaling and chemokine receptor signaling in diverse cell biological processes 
relevant to metastasis and drug resistance (e.g. cell migration, proliferation and survival), 
in the context of breast cancer metastasis and treatment. In this thesis, we investigated 
chemokine and growth factor signaling (i.e. CXCR3 ligands and EGF) as well as 
anticancer drug-induced cellular stress response signaling (i.e. doxorubicin and 
vincristine) in cell migration and survival. Briefly, we described an overview of 
chemokine and chemokine receptor profiles in MTLn3 cells and established the relevance 
of an autocrine loop of CXCR3-ligands in cell migration. We further investigated the role 
and mechanism of FAs in a drug resistant phenotype of breast cancer cells. Finally, we 
described how JNK-mediated modification of paxillin was involved in microtubule 
disrupting agents-induced cellular stress response, as well as growth factor-induced cell 
migration process. In this chapter, I intend to integrate these findings and indicate the 
opportunities for future research. 
 
Chemokine receptor signaling 
 
In chapter 2, the expression profile of chemokines and receptors in MTLn3 cells is 
described. Although we only described CXC ligands and receptors, our microarray data 
indicated that other CC chemokines and receptors were also present (data not shown). 
Recently, it is noted that CXCR3 ligands CXCL9, 10 and 11 are potentially neutral 
antagonists of CCR3 and CCR5 which counteract the responses by such inflammatory 
chemokines (1) and both of these receptors are present in our MTLn3 cells (data not 
shown). Although we cannot exclude that these ligands may stimulate CCR3 and CCR5 
in our model, knock down of CXCR3 with siRNA resulted in the reduced MTLn3 cell 
migration. This suggests that such an alternative activation by chemokine CXCL9, 10, 
and 11 is not biologically relevant in vitro. Aberrant expression of chemokines and 
receptors have often been found in diverse cancers, especially high expression of CXCR4 
in breast cancers has been described and studied in detail. We found higher expression of 




CXCR3 compared to CXCR4 in MTLn3, suggesting that CXCR3 might have stronger 
effect on tumor progression than CXCR4 in MTLn3. Moreover, the ligands of CXCR3 
are expressed in these cells allowing direct and efficient autocrine activation, while the 
CXCR4 ligand CXCL12 is not expressed in MTLn3 cells.  
 
We demonstrated the involvement of PI3K/AKT and MAPK/ERK in CXCR3-mediated 
cell motility and migration of MTLn3 cells. Signal transduction pathways derived from 
chemokine receptors are mainly investigated in the context of CXCR4 activation by 
CXCL12. The activation of downstream signaling events is mediated via G proteins, 
arrestin, PI3K, AKT, ERK and the transcription factors STAT and NF-κB (2). Chemokine 
receptors undergo dimerization after binding to ligands followed by conformational 
changes. Consequently, heterotrimeric G proteins are activated and the dissociation of Gi-
α and G-β/γ from receptor triggers the traditional G-protein mediated pathways: the 
exchange of GTP to GDP on Gα causes the activation of Src-Ras-ERK, and Gβγ triggers 
PI3K and PLC-PKC activation, followed by the formation of Cdc42-Rac-PAK complex 
and PKC-PYK2-FAK/Crk/p130Cas/paxillin complex. The latter complex is involved in 
actin cytoskeleton dynamics, cell polarity, cell adhesion and migration, and most likely, 
contributes to CXCR3 activation-mediated events (3-6). Another special pathway is 
related to the endocytosis and desensitization of chemokine receptor via receptor 
phosphorylation by G protein receptor kinases (GRKs) and binding of β-arrestin (7). 
Phosphorylation of the receptor by GRKs creates a binding site for arrestin and clathrin, 
resulting in receptor internalization and a shift to downstream cytoskeleton-related 
signaling. Arrestins also bind to microtubules, MAPK cascade components and non-
receptor tyrosine kinase Src and Yes (8). All these connections are indicative for a tight 
association of chemokine receptor signaling with actin and microtubule cytoskeleton 
reorganization, cell dynamic/migration and survival/proliferation. More in vitro study to 
quantify actin dynamics and FA turnover during CXCR3-mediated cell migration in 
MTLn3 and other breast cancer cells need to be performed. Moreover, it will be important 
to further dissect signaling pathways downstream of CXCR3 and how these signaling 
pathways are relevant to in vivo tumor progression. 
 
Considering the complexity of cancer types and cancer development, the large variety of 
chemokine/receptor, as well as the diversity of ligand-receptor binding, the exact 
mechanism and importance of chemokines and their receptors in cancer still remain 
largely unexplored. Future work should be focused on the role of CXCR3 and 
corresponding ligands in different in vitro and in vivo models. These may range from 3D 
cell culture models, zebra fish tumor implantation and metastasis models, and mouse 
tumor metastasis models, which have all been established in our lab. By using CXCR3-
specific inhibitors or shRNA-silencing techniques we should elucidate the exact role of 
CXCR3 signaling in tumor and metastasis formation. Moreover, since chemokines act 
together with growth factors in tumor microenvironment, the crosstalk and synergy of 
downstream signaling between CXCRs and growth factor signaling would be important 
to study.  





Focal adhesion signaling 
 
Focal adhesions (FAs) contain more than hundred of components. These so-called 
integrin adhesomes form a complex network with 690 interactions (9). FAK and paxillin 
are intrinsic components of the adhesome and they each have 30 or more interactions with 
other kinases, adaptor proteins, phosphatases and cytoskeletal proteins, indicating the 
significance of FAK and paxillin at FA sites. In chapter 3, we studied FAK-mediated 
signaling using gene expression microarray and discovered genes and pathways that were 
altered by the expression of a dominant negative acting FAK splice variant, FRNK. Some 
of these identified pathways are involved in cell growth, cytoskeleton organization, cell 
shape and motility. In chapter 4 and 5, we mainly investigated the role of paxillin in 
cytoskeleton reorganization, cell migration and proliferation/survival in stress response 
and growth factor stimulation conditions. We established an interaction between paxillin 
and JNK in stress signaling caused by microtubule disrupting agents. In chapter 5 the 
relationship between JNK and paxillin in tumor cell migration was established.  
 
FAK and Fra-1 in focal adhesion dynamics, cell migration and metastasis formation 
FAK and the transcription factor Fra-1 show increased expression in aggressive breast 
tumors than normal breast tissues (10, 11). In chapter 3, we have showed that FAK 
regulates Fra-1 expression, though it remains to be determined how FAK regulates Fra-1 
expression. It has been established that Fra-1 levels are controlled by both ERK and AKT 
activity (12). FAK can downstream activate ERK (see Introduction), but we did not 
observe a differential activation of ERK after FRNK expression in our model by western 
blot staining (data not shown). However, FRNK did affect AKT activation under cellular 
stress conditions after doxorubicin treatment (13), indicating a dysregulation of proper 
FAK-AKT linkage. It remains unclear whether FRNK disturbs FAK-AKT linkage under 
normal condition and therefore is responsible for Fra-1 expression in MTLn3 cells. Both 
FAK and Fra-1 are implicated in MTLn3 cell migration ((14) and chapter 3). In other 
cell types, Fra-1 regulates cell motility and migration through inactivating β-integrin and 
keeping Rho activity low via ROCK/Rho kinase (15), with the exact regulatory 
mechanism still unclear. Also in MTLn3 cells, Fra-1 knock down interfered with FA turn 
over and increased FA size. We did not observe any Fra-1 accumulation at FAs in 
MTLn3 cells. Given the role of Fra-1 as a transcription factor, we propose that the effects 
of Fra-1 knock down on cell migration are rather related to its transcriptional activity. 
Fra-1 possibly regulates the expression of proteins that either are part of the adhesome or 
regulate the activity of adhesome components. Interestingly, in this context, by using a 
cDNA adenoviral library, FosB (another AP-1 transcription factor Fos family member) 
was identified in a 3D EMT-related morphogenesis screen (Price and van de Water, 
personal communication, our lab). This suggests the potential involvement of Fra-1 in 3D 
environment to modulate EMT process. Indeed, Fra-1 is highly expressed in 
mesenchymal breast tumor cell lines, but not in epithelial-like breast tumor cells (16). 
Possibly there is a relationship between Fra-1 expression/activity, actin cytoskeletal 




network dynamics and FA turn over. More work should be done to define the exact role 
of Fra-1 in tumor cell survival and migration, and the consequences for metastasis 
formation and treatment in vivo. 
 
There is clear link between MAPK pathway and AP-1 activity, including the regulation of 
Fra-1. Both EGF and phorbol-12-myristate-13-acetate (PMA) increase the expression of 
Fra-1 in MTLn3 (data not shown). Also doxorubicin treatment causes Fra-1 accumulation 
in MTLn3 cells (data not shown). Since CXCR3 and CXCR4 activate ERK and AKT 
signaling (see above and chapter 2), CXCR3 or CXCR4 activation may potentially also 
affect the expression of Fra-1, and thereby, tumor cell migration. We have not studied this 
aspect so far. In addition, Fra-1 is accumulated and hyper-phosphorylated in DNA-
damage conditions via JNK and ERK (17). Based on the observations in chapter 4, we 
hypothesize that vincristine-induced activation of JNK in MTLn3 cells would potentially 
affect Fra-1 expression. This would raise the possibility that Fra-1 and/or other AP-1 
components are involved in microtubule disruption-induced FA stabilization and cell 
contractility. So far, we have not investigated into it.  
 
JNK signaling and focal adhesion regulation through paxillin 
JNK is normally activated by growth factors (i.e. EGF and HGF) or cytokines (i.e. 
TNFalpha or interleukin-1). Also cell injury causes JNK activation and continuous cell 
stress induces sustained activation of JNK. Active JNK translocates to the nuclear and 
induces phosphorylation of c-Jun and activates AP-1. Phosphorylated JNK also localizes 
at FAs after growth factor exposure or cellular stresses, including treatment with 
microtubule disrupting agents such as vincristine. There are various JNK substrates (18) 
including transcription factors which are typically functional in the nucleus, such as c-Jun, 
scaffold proteins which regulate cell movement (e.g., paxillin and some other microtubule 
associated proteins), and proteins that regulate cell survival (e.g. Bcl-2 localized at the 
mitochondria and ER). In this thesis, we focus on JNK-mediated phosphorylation of 
paxillin at Ser178 in the context of vincristine-induced cytoskeleton reorganization and 
growth factor-induced cell migration, which were studied in chapter 4 and 5 respectively.  
 
In chapter 4, we have found that the JNK-paxillin axis is upstream of ROCK/MLC-
dependent cell contractility induced by vincristine. JNK modulates LIM domain-
containing proteins, including LIMK. LIMK-cofilin signal pathway is responsible for 
actin polymerization and stress fiber formation (19). Therefore, there is a possibility that 
vincrisitine-induced actin stress fiber formation is mediated through JNK-LIMK-cofilin-
actin route. This needs further investigation. Although we mostly focused on JNK 
signaling, it is likely that many other kinases are involved in FA stabilization and cell 
contractility after microtubule disruption. Therefore, future emphasis should be placed on 
searching for other kinases involved in actin reorganization. Recently, a screening set up 
was developed in our lab to identify protein kinases and phosphatases that affect the 
formation of new FAs after treatment with another microtubule disrupting agent, 
nocodozole, as well as the FA turnover after washout of nocodozole. So far, the 




preliminary screen identified several other MAPKases that are involved in this process. 
Probably it will provide a general overview of signal network that mediates 
actin/microtubule cytoskeleton dynamics and/or FA turnover. Further research will be 
performed to establish the role of these kinases in tumor cell migration and metastasis 
process and/or susceptibility towards anticancer drugs.  
 
Breast cancer treatment 
 
Molecular targeted anticancer therapy of breast cancer can be beneficial to the efficiency 
of traditional radiotherapy, chemotherapy and hormonal therapy. Given to the implication 
of chemokine receptors and specific FA proteins in tumor development and progression, 
they are potentially therapeutic targets to improve current traditional clinical treatment 
regimens. Some inhibitors for specific receptors and (non)receptor tyrosine kinases, such 
as ErbB1, ErbB2 and Src, have been developed for cancer treatment (19-22). These 
kinases are also directly involved in FA turnover and modulation of these kinases may 
indirectly affect FA downstream signaling. Alternatively, novel anticancer therapy can be 
developed to target chemokine receptors and kinases that are central in FA regulation. 
Modulation of FA downstream signaling will ultimately benefit breast cancer therapy. 
Here I will describe the current status and future perspectives of CXCR3 antagonists and 
FAK inhibitors.  
 
CXCR3: a therapeutic target for breast cancer therapy? 
In chapter 2 we have showed that CXCR3 and CXCR4 are important in MTLn3 cell 
migration and invasion. Some antagonists and neutralizing antibodies for chemokine 
receptors have been developed for clinical trials by pharmaceutical companies, including 
CCR1, 2, 3, 5, CXCR1-4 (23). CXCR4 antagonist AMD3000 and other CXCR4 
antagonists were tested in various tumor metastases and HIV. They prevent CXCL12-
mediated cell chemotaxis, tumor formation and progression (24-26). A few CXCR3 
antagonists were also studied in breast cancer in vivo. CXCR3 antagonist AMG487 was 
tested in a murine breast cancer lung metastasis model (27). The systemic blockade and 
tumor-specific inhibition of CXCR3 with AMG487 significantly prevented tumor 
metastasis, but had no effect on local tumor growth and survival. This was consistent with 
another study using tumor specific antisense nucleotides against CXCR3 (28-30). 
Interestingly, the anti-metastatic effect of AMG487 was lost in natural killer (NK) cell-
depleted mice. This demonstrates that CXCR3-mediated tumor metastasis and formation 
require NK cells. Another selective CXCR3 antagonist NBI-74330 was tested in vitro and 
in vivo and it attenuates atherosclerotic plaque formation in LDL receptor-deficient mice 
(28, 31, 32). The effect of this inhibitor in cancer progression has never been investigated. 
Based on the above mentioned successful in vivo application, there is a great opportunity 
to compare effects of NBI-74330 and AMG487 and to substantiate the role of CXCR3 in 
breast cancer progression.  
 




It is important to note that chemokines not only act on tumor cells to stimulate 
proliferation and migration, but also execute immunostimulatory effects and contribute to 
tumor repression or progression (33). The CXC subgroup of chemokines is divided into 
ELR+ and ELR- chemokines, based on the presence and absence of glutamic acid-
leucine-arginine (ELR motif). The ELR+ chemokines are angiogenic and recruit tumor-
associated neutrophils and macrophages which favor tumor progression via secreting 
matrix degrading enzymes and growth factors. In contrast, the ELR- chemokines, like 
CXCL9, 10, 11, are angiostatic and recruit T lymphocytes and NK cells which are 
cytotoxic, and thereby suppress tumor development (34). However, the expression of 
CXCR3 in melanoma, colon and breast carcinoma seems to facilitate tumor metastasis 
formation to lymph nodes (28, 30, 35), suggesting that, like CXCR4, CXCR3 might have 
a special role of homing CXCR3-positive tumor cells to sites where IFN-γ-inducible 
chemokines, like CXCL9, 10, 11, are abundant. Since CXCR3 and its ligands have 
opposing roles in tumor development, a caution is required when CXCR3 antagonists are 
used as potential therapeutic targets and this might explain present failure of clinical trials 
(27). CXCR3 antagonists or chemokine CXCL9, 10, 11 neutralizing antibodies could be 
used as potential drugs to block the trafficking or self-survival and motile signaling in 
tumor cells. Future work should establish the role of chemokine CXCL9, 10, 11 and 
receptor CXCR3 in tumor metastasis in NK-depleted Fisher 334 rat and immune-deficient 
mice by using shRNA approaches to knock down receptor and ligands. 
 
FAK as an anticancer therapeutic target  
In chapter 3 we have demonstrated that FAK is essential in regulating the efficacy of 
doxorubicin in either primary breast tumors or lung metastases by using conditional 
FRNK expression. Over expression of FRNK sensitizes different tumor cell lines against 
anticancer drugs such as 5-fluoroucil, doxorubicin, vincristine (36). This supports FAK as 
a potential anticancer drug target. The modulation of FAK in vivo could be achieved by 
siRNA, specific inhibitors, or extrinsic introduction of dominant-negative mutants such as 
FRNK (37-39).  
 
FAK short interfering RNA (siRNA) shows high efficacy to downregulate FAK 
expression in vitro (40). Also, knock down of FAK in chapter 3 clearly deleted FAK 
protein expression. Inhibition of FAK with short hairpin RNAs (shRNAs) prevents FAK 
function in cell adhesion, migration and proliferation in mouse breast cancer cell line 4T1 
in vitro and suppresses tumor growth in heterotopic/orthotopic mice models in vivo (37). 
However, it may be difficult to deliver siRNA in vivo efficiently to tumor tissue because 
of rapid degradation of siRNA. Chemical approaches to modify siRNA stability as well as 
uptake in tumor cells can increase the efficacy of siRNA approaches to modulate FAK 
levels. So far, a modified polyethylenimine (PEI) gene carrier (41) and a neutral lipid 
liposome, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) (42) have been 
reported to introduce FAK siRNA successfully in vivo, which could be potentially 
utilized in breast cancer treatment and even modulated for breast tumor-selective target in 
the future.   





So far, several FAK selective or dual inhibitors including PF562271 and TAE226, have 
been tested in (pre)-clinical studies of different cancer types (43, 44). Disturbance of FAK 
activity and function have a synergistic effect with some traditional chemotherapeutics, as 
we demonstrated for FRNK expression. PF562271 has a dual effect on FAK and Pyk2 
with an IC50 in nano-molar scale in vitro. In vivo, maximal inhibition of FAK 
phosphorylation (78%) is obtained 1 hour after p.o. administration at 33 mg/kg dose in 
tumor-bearing mice and the inhibition ( >50% inhibition of  FAK phosphorylation ) lasts 
above 4 hours with a single dose (45). Furthermore, dose-dependent tumor growth 
inhibition and regression were observed in a broad range of human s.c. xenograft models, 
including prostate, breast, pancreatic, colon, lung and glioblastoma, with no observation 
of weight loss, morbidity or death (45). The inhibitory mechanisms of PF562271 in vivo 
rely on anoikis/apoptosis and reduction of micro-vascular density (45). TAE226 has been 
tested in other tumor models, for instance, glioma, ovarian and esophageal carcinoma 
(46-48). TAE226 inhibits phosphorylation of FAK and downstream signaling effectors 
AKT and ERK. It decreases cell proliferation, adhesion, migration and invasion in glioma 
cells (48). It also has significant action in ovarian carcinoma by inhibiting FAK 
phosphorylation at Y397 and pY861, as well as cell growth in a time and dose-dependent 
way. Moreover, it shows a synergistic effect on docetaxel-mediated cell growth inhibition,  
tumor burden reduction and prolonged survival in tumor-bearing mice (47). All these 
studies indicate the prospective application of FAK inhibitors in therapy combination. 
Future work will investigate whether the effect on tumor growth is dependent on intrinsic 
mechanisms of tumor cells or through anti-angiogenesis by inhibiting vascular endothelial 
cell migration. Moreover, it would be interesting to determine the combined effect of 
these inhibitors and traditional anticancer drug in breast cancer metastasis models in our 
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Breast cancer is the most common malignancy among women in the western world. The 
difficulties to treat breast cancer relate to breast cancer metastasis. Modulation of focal 
adhesion-mediated signaling can improve tumor resistance and benefit the therapeutic 
efficiency. This thesis focuses on focal adhesion signaling in various cell processes in 
breast cancer development. The long term goal is to discover an alterative way for breast 
tumor treatment through modulation of focal adhesion signaling. 
 
In the chapter 1, I introduce the different signaling pathways implicated in cell survival, 
proliferation, migration and point out a few effect factors which are involved in tumor 
development and might be therapeutic targets for tumor treatment. I mainly focus on the 
importance of chemokines and growth factor (receptors), MAPKase pathways, the 
transcription factor AP-1 and the PI3K/AKT signaling pathway in breast cancer. 
Moreover, I put emphasis on focal adhesion-related protein FAK and paxillin that are 
essential in focal adhesion turnover and signaling. These proteins are central in the rest of 
the thesis.  
 
Chemokines and receptors are important for regulation of tumor cell proliferation, 
migration and metastasis as well as the cellular compositions of the tumor 
microenvironment. Various chemokines and their receptors are expressed in different 
breast tumor stages and related to breast cancer progression. The roles of many receptor-
ligand pairs in this process remain unclear. In chapter 2, the role of chemokine receptor 
CXCR3 in cell motility and migration was examined in the rat mammary carcinoma cell 
line MTLn3. Firstly the expression profiling of chemokines CXCLs and chemokine 
receptor CXCRs were performed by microarray and validated with RT-PCR. CXCR3 and 
its ligands CXCL10 and CXCL11 were prominently expressed in MTLn3 cells compared 
with CXCR4. Secondly, the activation of CXCR3 and CXCR4 were measured with 
calcium influx assay to validate the functionality. CXCL11 enhanced random cell 
migration and stimulated chemotaxis-driven cell invasion. The activation of CXCR3 was 
associated with the activation of MAPKase/ERK and PI3K/AKT. Pharmacological 
inhibition of an upstream activator of ERK, MEK, with the inhibitor U0126, or 
phosphoinositide-3 kinase with LY294002, inhibited the CXCL11-induced MTLn3 cell 
invasion. The disruption of autocrine loop of CXCR3-respective ligands impaired cell 
migration associated with reduced protrusion formation. Together, these data suggests 
that autocrine CXCR3 activation is important for MTLn3 tumor cell migration and 
invasion and a potentially important drug target for breast cancer treatment.  
 
 FAK, the central player at FA sites, is involved in cell survival and migration. In chapter 
3, the FAK-mediated survival signaling was studied in rat breast cancer model in relation 
to the anticancer drug doxorubicin treatment. Conditional introduction of a dominant-
negative acting FAK splice variant, FAK-related non kinase (FRNK), competes for the 
localization of endogenous FAK at focal adhesions, and, thereby, disturbs FAK-mediated 




survival and migratory signaling at focal adhesions. FRNK expression does not 
significantly have inhibitory effect on cell proliferation or causes apoptosis in normal 
culture condition, however it sensitizes cell to doxorubicin treatment and inhibits cell 
spreading and migration to an artificial wound. Earlier work from our laboratory 
indicated that conditional FRNK expression inhibited primary breast cancer formation as 
well as the early steps of metastasis formation. FRNK expression did not inhibit 
outgrowth of macrometastasis. This allowed us to investigate the consequences of FRNK 
expression on the treatment with doxorubicin when metastases were already formed. 
FRNK expression sensitized both orthotopic MTLn3 cell breast tumors and experimental 
MTLn3 cell lung metastasis to doxorubicin. Gene expression profile and qRT-PCR 
indicated FRNK-expressing cells expressed less Fra-1 than non-expressing cells. Lastly, 
we validated the reduction of Fra-1 expression by FAK knock down with siRNA, as well. 
Fra-1 KD increased the focal adhesion formation and decreased the rate of its turnover. 
Moreover, Fra-1 KD sensitized MTLn3 cells to doxorubicin. Finally, overexpression of 
Fra-1 rescued doxorubicin-induced cell apoptosis in FRNK expressing cells. Our study 
provides a link between tyrosine kinase FAK and transcription factor Fra-1 whereby FAK 
signaling supports Fra-1 expression.    
 
FAs contain a variety of signaling molecules and adaptor proteins. We further 
investigated the focal adhesion associated adaptor protein paxillin in chapter 4 and 5. 
Paxillin regulates FA dynamic and it is involved in cell survival/proliferation and 
migration. In chapter 4 we investigated the mechanism by which paxillin regulated the 
cell morphological changes and F-actin cytoskeletal reorganization after microtubule 
cytoskeleton disruption by anticancer drugs vincristine. The microtubule disruption agent 
vincristine induced cell cycle arrest, contractile phenotype with bigger focal adhesions in 
association with F-actin stress fiber formation. This was accompanied with the activation 
of MAPK/JNK pathway before the onset of apoptosis, and active JNK localized at focal 
adhesion sites. Paxillin was modified to a much lower mobility on PAGE. Moreover, 
paxillin was phosphorylated at Ser178. Both modifications of paxillin after vincristine 
treatment were dependent on JNK activity since an inhibitor of JNK, SP600125 prevented 
these. Also, SP600125 inhibited cell rounding and cell contractility. siRNA-mediated 
knock down of paxillin itself did not affect cell apoptosis, but inhibited vincristine-
induced cell contractility and focal adhesion formation. The cell contractility was also 
inhibited by an inhibitor of ROCK, but this did not affect JNK activation and paxillin 
modification induced by vincristine treatment. Therefore, this study suggested a tight 
relationship between the vincristine-induced JNK activation, scaffold protein paxillin 
modification and regulation of focal adhesion dynamics and cell contractility.  
 
Paxillin has a crucial role in cell migration and proliferation. Different growth factors, 
including EGF and HGF, activate JNK. JNK can phosphorylate paxillin on Ser178. We 
studied the role of paxillin Ser178 residue in growth factor mediated cell migration of 
MTLn3 breast tumor cells in chapter 5. Firstly, EGF induced Ser178 phosphorylation in 
MTLn3 cells in a JNK-dependent manner. Moreover, EGF-induced cell migration was 




inhibited by SP600125, a specific inhibitor of JNK. The GFP-tagged Ser178Ala mutant 
of paxillin was expressed in MTLn3 cells; GFP-tagged wt-paxillin served as control. 
GFP-S178A paxillin inhibited MTLn3 cell attachment, cell migration and affected cell 
proliferation. Interestingly, the EGF-induced activation of PI3K/AKT and ERK signaling 
was reduced in S178A-paxillin cells compared to wt-paxillin cells. Thus, we propose that 
Ser178 of paxillin is important in the regulation of EGFR signaling, and thereby, may 
affect downstream signaling that typically facilitate cell migration and proliferation. 
Future studies should focus on the role of paxillin Ser178 in breast cancer growth, 
progression and metastasis formation in vivo.  
 
In chapter 6, I further discussed the results and findings in the previous research chapters 
in the context of the literature and the present work in our lab. I indicated the potential 















Borstkanker is een van de meest voorkomende kanker bij vrouwen in de Westerse wereld. 
Het probleem in de behandeling borstkanker is vooral het voorkomen en bestrijden van 
uitzaaiïngen (metastasen). Remming van de signaal transductie via focal adhesions kan de 
tumor resistentie verminderen en is daarom een veelbelovende manier om uitzaaiingen te 
voorkomen. Dit proefschrift behandelt de rol van focal adhesion signalering in 
verschillende cellulaire processen die belangrijk zijn voor metastasering van borstkanker. 
Het uiteindelijke doel is om een geschikte behandeling van borstkanker metastasering te 
ontdekken/ontwikkelen die gebaseerd is op het moduleren van focal adhesion signalering.  
 
In hoofdstuk 1 wordt een overzicht gegeven van de verschillende signaleringsroutes die 
een rol spelen bij cel overleving, proliferatie en migratie. Er worden tevens een aantal 
factoren uitgelicht die betrokken zijn bij tumor ontwikkeling en mogelijk interessant zijn 
als therapeutische target voor de behandeling van borstkanker. De focus ligt op de rol van 
chemokines en groeifactoren, MAPKase routes en de transcriptiefactor AP-1 alsook de 
PI3K/AKT signaleringsroutes in borstkanker. De focal adhesion-gerelateerde eiwitten 
FAK en paxillin, twee eiwitten die essentieel zijn voor focal adhesion turnover en 
signalering en centraal staan in dit proefschrift, worden uitvoerig behandeld. 
 
Chemokines en de corresponderende receptoren zijn belangrijk voor de regulering van 
tumorcel proliferatie en migratie en cellulaire samenstelling van de tumor micro-
omgeving alsook de vorming van metastasen. Verschillende chemokines en hun 
receptoren zijn geïmpliceerd in verschillende stadia van borstkanker. De expressie van 
sommige chemokines correleert met de progressie van borstkanker. De rol van 
verschillende receptor–ligand-paren zijn in dit proces nog niet volledig ontrafeld. In 
hoofdstuk 2 wordt de rol van de chemokine receptor CXCR3 in cel migratie in de 
borstkanker cellijn MTLn3 onderzocht. Allereerst werd het expressieprofiel van 
verschillende CXCL chemokines en de corresponderende  CXCR chemokine receptoren 
bepaald met behulp van microarrays als ook RT-PCR. Voornamelijk CXCR3 en de 
liganden CXCL10 and CXCL11 kwamen tot expressie in MTLn3 cellen. Vervolgens 
werd de activering van CXCR3 en CXCR4 met behulp van vrij calcium-influx analyse 
gemeten om de functionaliteit van deze receptoren in MTLn3 cellen te evalueren; beide 
receptoren zijn actief in MTLn3 cellen. Blootstelling van MTLn3 cellen aan CXCL11 
verhoogde de cel migratie en stimuleerde het chemotaxische-invasieve gedrag van deze 
tumorcellen. De activering van CXCR3 ging gepaard met de activering van MEK/ERK 
en PI3K/AKT signaal transductie routes. Farmacologische remming van een activator 
kinase van ERK, MEK, met de chemische remmer U0126, of remming van 
phosphoinositide-3 kinase (PI3K) met de remmer LY294002, verlaagde de CXCL11-
geïnduceerde MTLn3 celinvasiviteit significant. Downregulatie van de CXCR3 receptor 
met RNA-interferentie middels siRNA transfecties remde de celmigratie veroorzaakt door 
blootstelling aan CXCR3 liganden. Samenvattend suggereren deze data dat de autocriene 
CXCR3 activering zeer belangrijk is voor MTLn3 tumor celmigratie en –invasie. 




Blokkeren van de CXCR3 receptor zou daarom een potentieel belangrijke geneesmiddel 
target voor de behandeling van borstkanker progressie kunnen zijn. 
  
FAK speelt een centrale rol in de regulering van de dynamiek van focal adhesions. 
Tevens is FAK betrokken bij de signaal transductie vanuit focal adhesions om processen 
als cel overleving en cel migratie te ondersteunen. In hoofdstuk 3 wordt onze studie naar 
FAK-gemedieerde cel overleving in relatie tot antikanker therapie behandeld. 
Conditionele expressie van een dominant-negatieve variant van FAK, de FAK-
gerelateerde non kinase (FRNK), competeert voor de lokalisatie van endogeen FAK op 
focal adhesions. Het gevolg hiervan is dat de FAK-gemedieerde cel overleving en cel 
migratie signalering wordt verstoord. FRNK expressie heeft geen remmend effect op cel 
proliferatie en leidt niet tot apoptosis onder normale celkweek condities. Echter, FRNK 
expressie zorgt wel voor toename in gevoeligheid voor antikanker middelen zoals 
doxorubicin. In eerder onderzoek hebben we aangetoond dat conditionele expressie van 
FRNK zorgt voor een remming in de vorming van metastases; FRNK had hierbij geen 
effect op de uitgroei van macro-metastasen. Dit gaf ons de mogelijkheid om het effect 
van FRNK-expressie op de behandeling met doxorubicine te bestuderen nadat de 
metastasen al gevormd waren. Expressie van FRNK zorgde voor een toename in 
gevoeligheid van MTLn3 borsttumoren en experimentele MTLn3 metastasen voor 
behandeling met doxorubicin. Het gen expressieprofiel en de qRT-PCR data lieten zien 
dat cellen die FRNK tot expressie brachten minder Fra-1 mRNA tot expressie brachten 
dan FRNK-negatieve cellen. Hetzelfde werd gevonden na remming van FAK doormiddel 
van een siRNA-gemedieerde knock-down van FAK. Omgekeerd leidde een knock-down 
van Fra-1 niet tot een veranderde FAK expressie, maar wel tot een toename in de 
vorming en grootte van focal adhesions. Belangrijk was het feit dat een Fra-1 knock down 
in de MTLn3 cellen deze cellen gevoeliger maakte voor doxorubicin. Daarentegen 
maakte overexpressie van Fra-1 MTLn3 cellen die FRNK tot expressie brachten juist 
weer ongevoelig voor doxorubicin-geïnduceerde celdood. Onze studie toont aan dat er 
een relatie is tussen de signaal transductie gemedieerd door FAK en de expressie van de 
transcriptie factor Fra-1. Fra-1 op zijn beurt reguleert weer de gevoeligheid van cellen 
voor celdood.  
 
Focal adhesions bestaan uit verschillende signaleringsmoleculen en adapter proteïnen. In 
hoofstuk 4 en 5 wordt het focal adhesion eiwit paxillin verder bestudeerd. Paxillin 
reguleert de dynamiek van focal adhesions en daarmee de migratie van cellen; daarnaast 
is het ook van belang in de signaal transductie van cel overleving. In hoofdstuk 4 werd 
het mechanisme onderzocht hoe paxillin de morfologische veranderingen van de cel en de 
F-actin cytoskelet reorganisatie reguleert na beschadiging van het microtubuli cytoskelet 
na blootstelling met het cytostaticum vincristine. Zoals verwacht veroorzaakte vincristine 
een blokkade in de celcyclus. Daarnaast zorgde vincristine voor een verhoogde 
contractiliteit van de cellen gevolgd door opronding van de cellen. Dit ging  gepaard met 
grotere focal adhesions en vorming van zogenaamde F-actin cytoskelet stress fibers. 
Onder deze condities vond ook een activering plaats van de MAPK/JNK route waarbij 




actief JNK geassocieerd was met focal adhesions. Paxillin werd gefosforyleerd op serine 
residu 178 (Ser178), hetgeen voorkomen kon worden door een remmer van JNK 
(SP600125). SP600125 remde ook de contractiliteit en opronding van de cellen. Knock 
down van paxillin d.m.v. siRNA leidde niet tot apoptosis, maar inhibeerde vincristine-
geïnduceerde cel contractiliteit en de vorming van focal adhesions. Contractiliteit van de 
cellen werd ook geremd door een inhibitor van ROCK, maar deze beïnvloedde niet de 
activiteit van JNK alsook de phosphorylering van paxillin. Deze data suggereren een 
sterke samenhang tussen de JNK-activatie door vincristine, modificatie van het eiwit 
paxillin en de regulatie van focal adhesion dynamiek en cel contractiliteit. Deze 
gebeurtenissen kunnen van belang zijn voor het beter begrijpen van de mechanismen van 
werking van vincristine en suggereren dat paxillin of andere eiwitten betrokken bij de 
signaal transductie downstream van paxillin, een target kunnen zijn voor de behandeling 
van kanker.  
 
Zoals hierboven al genoemd speelt paxillin een cruciale rol in cel migratie en proliferatie. 
Verschillende groeifactoren, waaronder epidermaal groeifactor (EGF) en hepatocyte 
groeifactor (HGF), activeren JNK. JNK kan vervolgens paxillin fosforyleren op Ser178. 
In hoofdstuk 5 hebben we de rol van het paxillin Ser178 residu in groeifactor 
gemedieerde celmigratie van MTLn3 borst tumorcellen bestudeerd. EGF induceerde de 
fosforylering van paxillin Ser178 in MTLn3 cellen hetgeen afhankelijk was van de 
activiteit van JNK. De door EGF geïnduceerde cel migratie was ook afhankelijk van JNK 
activiteit, want een specifieke remmer van JNK (SP600125) voorkwam deze cel migratie. 
Vervolgens hebben we MTLn3 cellen gemaakt die een variant van paxillin tot expressie 
brachten die niet meer gefosforyleerd kan worden op Ser178: GPF-Ser178Ala-paxillin; 
GFP-gekoppelde wt-paxillin werd gebruikt voor het genereren van de controle cellijnen. 
Expressie van GFP-S178A-paxillin remde de hechting van MTLn3 cellen aan de 
extracellulaire matrix; tevens was de migratie van de MTLn3 cellen geremd. Normaal 
leidt activatie van de EGF-receptor tot de activering van de PI3K/AKT en MEK/ERK 
signaal transductie route. Expressie van GFP-S178A-paxillin, maar niet GFP-wt-paxillin, 
verlaagde deze door EGF blootstellling geïnduceerde activatie van PI3K/AKT en ERK 
signalering. We gaan ervan uit dat serine residu 178 van paxillin belangrijk is voor de 
regulatie van de intracellulaire signaal transductie na activatie van de EGFR receptor en 
dat via deze weg paxillin betrokken is bij de regulatie van EGF-geïnduceerde cel migratie 
en proliferatie. In vervolg onderzoek zou de nadruk moeten liggen op het bestuderen van 
de rol van de fosforylering van paxillin op Ser178 door JNK in ontwikkeling en 
progressie van borstkanker.  
 
In hoofdstuk 6 worden de resultaten en bevindingen van dit proefschrift in de context 
van recente literatuur en resultaten van onze onderzoeksgroep bediscussieerd. Daarbij 
komen de potentiële therapeutische targets en huidige therapeutische mogelijkheden aan 
bod en wordt visie voor toekomstig onderzoek besproken. 








List of abbreviations 
 
 
α-MEM    alpha-modified minimal essential  
AKT    protein kinase B (also abbreviated PKB) 
AMC    7-amino-4-methylcoumarin 
AP-1    activator protein 1 
ARF    ADP-ribosylation factor, a small GTP-binding protein  
ARP2/3   actin-related proteins2/3 
ASAP1   the Arf-GTPase-activating protein 1 
ATF    activating transcription factor 
BSA    bovin serum albumin 
CC (L/R)        C chemokine (ligand/receptor)  
Cdc42    cell division cycle 42 ,a GTP binding protein 
CDK    cyclin-dependent kinases 
Chk    checkpoint kinases 
c-MET   mesenchymal-epithelial transition factor 
CXC(L/R)   CXC chemokine (ligand/receptor) 
ECL    enhanced chemiluminescence 
ECM    extracellular matrix 
EGF(R)   epidermal growth factor (receptor) 
EMT    epithelial-mesenchymal transition 
ER    estrogen receptor 
ERK    extracellular signal-regulated kinase 
FA    focal adhesion  
FACS    fluorescence-activated cell sorting 
F-actin    filament-actin 
FAK    focal adhesion kinase 
FAT    focal adhesion targeting domain 
FERM    band 4.1, ezrin, radixin and moesin homology domain 
Fra-1(fosl-1)   fos related antigen-1(fos like-1) 
FRAP    fluorescence recovery after photobleaching 
GAP    GTPase activating proteins 
GFP    green fluorescent protein 
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GIT    G-protein-coupled receptor kinase interacting protein 
Grb2    growth factor receptor-bound protein 2 
GRAF GTPase activating protein for Rho associated with 
FAK 
GRK    G-protein receptor kinase 
GST    glutathione-S-transferase 
GTP    guanosine Triphosphate 
HE    haematoxylin and eosin 
HGF    hepatocyte growth factor 
ILK    integrin linked kinase 
I.P.    Intraperitoneal injection 
JNK    c-Jun N-terminal kinase 
KD    knock down 
KO    knock out 
LD    leucine-rich sequences 
LIMK    LIM-domain kinase 
MAPK    mitogen-activated protein kinase 
MDA    microtubule disrupting agents 
MDM2    murine double minute 2 (mdm2 oncogene) 
MLC    myosin light chain 
MLCK    myosin light chain kinase 
MMTV   mouse mammary tumor virus 
MMP    matrix metalloproteinases 
NF-kB nuclear factor kappa-light-chain-enhancer of activated 
B cells 
N-WASP   N-Wiskott Aldrich syndrome protein 
p130Cas   Crk-associated substrate 
PBS    phosphate buffered saline 
PI    propidium iodide 
PI3K    phosphoinositide-3 kinase 
PKB    protein kinases B 
PKL    paxillin kinase linker 
PLC    phospholipase C 
PPR    proline-rich regions 
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PTEN    phosphatase and tensin homolog 
PTP    protein tyrosine phosphatase 
Rac    Ras-related C3 botulinum toxin substrate 1 
Ras    Ras super family 
RhoA    Ras homolog gene family, member A 
ROCK    Rho-associated kinase 
qRT-PCR   quantitative real time- polymerase chain reaction  
SDS-PAGE sodium dodecyl sulfate - poly acrylamide gel 
electroforese 
SF     scatter factor 
SH    Src-homology domain 
siRNA    short interference RNA 
shRNA   short hairpin RNA 
SRE    serum response element 
PVDF    polyvinylideenfluoride 
TAM    tumor-associated macrophages 
TBP    0.05% Triton/0.5% BSA in PBS 
TIRF    total internal reflection fluorescence 
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